AUTHOR INDEX

(Page numbers marked with an asterisk refer to abstracts)

A

Aas, Knut A., and **Gardner, Frank H.** Survival of blood platelets labeled with chromium^{51} 1257

Abernathy, Robert S., and **Spink, Wesley W.** Studies with brucella endotoxin in humans: The significance of susceptibility to endotoxin in the pathogenesis of brucellosis 219

Abramson, David I., Kahn, Alan, Tuck, Samuel, Jr., Turman, George A., Rejal, Habib, and **Fleischer, Clara J.** Relationship between a range of tissue temperature and local oxygen uptake in the human forearm. I. Changes observed under resting conditions 1031

—, **Kahn, Alan, Rejal, Habib, Turman, George A., Tuck, Samuel, Jr.,** and **Fleischer, Clara J.** Relationship between a range of tissue temperature and local oxygen uptake in the human forearm. II. Changes observed after arterial occlusion, in the period of reactive hyperemia 1039

Abramson, Harry. See CHRISTENSEN, GRAY, ABRAMSON, KOBELT, BAER, and HELLEMS *884

Acton, F. S. See SEED, ACTON, and STUNKARD *930

Adam, Avinoam. See SZEINBERG, RAMOT, SHEBA, ADAM, HALBRECHT, RIKOVER, WISHNIEVSKY, and RABAU 1436

Adams, William S., Skoog, William A., and **Davis, Frances W.** An investigation of purine and pyrimidine excretion in normal and leukemic subjects utilizing ion exchange column and paper chromatographic techniques *875

Adelson, Edward. See VILLALOBOS, ADELSON, RILEY, and CROSBY 1

Agna, James W., Knowles, Harvey C., Jr., and **Alverson, Gabriele.** The mineral content of normal human bone 1357

Alexander, France. See DAUGHADAY, SALMON, and ALEXANDER *888

Alkjaersig, Norma. See SHERRY, LINDEMEYER, FLETCHER, and ALKJAERSIG *931

—. See FLETCHER, ALKJAERSIG, and SHERRY 1306

Alverson, Gabriele. See AGNA, KNOWLES, and ALVERSON 1357

Ambrus, Julian L. See BACK, AMBRUS, SIMPSON, and SHULMAN 864

Anderson, Helen M., and **Laragh, John H.** Renal excretion of potassium in normal and sodium depleted dogs 323

Anderson, Truman O. See JACKSON, DOWLING, and ANDERSON *904

Antkowiak, Dorothy E. See BOYLAN and ANTKOWIAK *879

Aprahamian, Arto H., Vanderveen, James L., Bunker, John P., Murphy, Anne P., and **Crawford, John D.** The effect of anesthetic agents on water diuresis *875

Arai, Y. See ELRICK, HLAD, WHIPPLE, and ARAI *891

Arias, Irwin M., Lowy, Bertram A., and **London, Irving M.** Studies of glucuronide synthesis and of glucuronyl transferase activity in liver and serum *875

Arnold, John, and **Pak, Charles.** Quantitative variations in the nucleohistone binding properties of human serum *876

Artom, C. See KING, BOYCE, LITTLE, and ARTOM 315

—. See BOYCE, KING, LITTLE, and ARTOM 1658

Ashenbrucker, Helen. See ATHENS, MAUER, ASHENBRUCKER, and CARTWRIGHT *876

Ashley, Charles A. See THOMAS, LOCHTE, JARETZKI, ASHLEY, and SAHLER *935

Athans, J. C. See ROSENBERG, ATHANS, BEHAR, and TISCH *926

Athens, John W., Mauer, Alvin M., Ashenbrucker, Helen, and **Cartwright, George E.** Leukokinetics as measured with radioactive diisopropylfluorophosphate (DF^{32}P) *876

Auditore, Joseph V. See HARTMANN, AUDITORE, and JACKSON 699

—. See HARTMANN, AUDITORE, and HOLLAND *900

Auerbach, Theresa. See FINE, MEISELAS, and AUERBACH 232

August, J. Thomas. See NELSON and AUGUST *919

—, **Nelson, Don H.,** and **Thorn, George W.** Response of normal subjects to large amounts of aldosterone 1549

Austen, Frank K., Rubini, Milton E., Meroney, William H., and **Wolff, J.** Salicylates and thyroid function. I. Depression of thyroid function 1131

—. See WOLFF and AUSTEN 1144

Axelrod, Julius. See SCHMID, AXELROD, HAMMAKER, and SWARM 1123

B

Back, Nathan, Ambrus, Julian L., Simpson, C. Lenore, and **Shulman, Sidney.** Study on the effect of streptokinase-activated plasmin (fibrinolysin) on clots in various stages of organization 864

Baer, Lesem J. See CHRISTENSEN, GRAY, ABRAMSON, KOBELT, BAER, and HELLEMS *884

Baker, Faith. See SMITH and BAKER *932

Baker, Orland. See CHAPMAN, BAKER, and MITCHELL *883

Baltch, Aldona, and **Bunn, Paul A.** Studies of the properdin system in normal humans, in infections and in malignant blood dyscrasias, using the phage technique for its measurement *876

Banks, Julia. See MARKS, JOHNSON, and BANKS *916

Barbero, Giulio. See KAYE, WILLIAMS, and BARBERO 752

Barnes, Benjamin A., Cope, Oliver, and **Harrison, Timothy.** Magnesium conservation in the human being on a low magnesium diet 430

Bartter, Frederic C. See SCHEDL and BARTTER *928

Bates, D. V. The measurement of the pulmonary diffusing capacity in the presence of lung disease 591

Bean, William B. See HODGES, OHLSON, and BEAN 1642

Bearn, A. G. See VESELL and BEARN 672

Beck, David. See EPSTEIN, BECK, RIVERA, LEVITIN, and CARONE *892

Bedell, George N., Wilson, William R., and **Seebohm, Paul M.** Pulmonary function in obese persons 1049

Beeken, Warren. See EBAUGH and BEEKEN *889
Behar, A. See ROSENBERG, ATHANS, BEHAR, and TISCH *926
Beierwaltes, William H. See BOLLET and BEIERWALTES *878
Benda, Clemens E. See BRONNER, BENDA, HARRIS, and KREPLICK 139
Bercu, Bernard A., Danforth, William H., Pund, Ernest E., Jr., and **Diettert, Gerald A.** Radioactive sodium for the measurement of myocardial blood flow *877
Bergenstal, Delbert M., and **Lipsett, Mortimer B.** The anabolic effect of sheep prolactin in man *877
Berger, Florence M. See IBER, NASSAU, PLOUGH, BERGER, MERONEY, and FREMONT-SMITH 1442
Berliner, Robert W. See DAVIDSON, LEVINSKY, and BERLINER 548
—. See LEVINSKY, DAVIDSON, and BERLINER *910
Berry, Edward R., and **Chanutin, Alfred.** Effect of blood storage conditions on the electrophoretic patterns of red cell hemolysates 974
Bessman, Alice N., and **Mirick, George S.** Blood ammonia levels following the ingestion of casein and whole blood 990
Betson, Yvonne. See DONOHUE, REIFF, HANSON, BETSON, and FINCH 1571
Beutler, Ernest, and **Blaisdell, Richard K.** Iron Enzymes in iron deficiency. II. Catalase in human erythrocytes 833
Bezman, A. See NAKAMURA, PICHETTE, BROITMAN, BEZMAN, ZAMCHECK, and VITALE *919
Bierman, Howard R., Marshall, G. June, Maekawa, Tadashi, Kelly, Keith H., and **Plante, Pauline.** Granulocytic activity of human plasma *877
Bing, R. J. See KAKO and BING 465
Birkenfeld, L. W., Leibman, J., O'Meara, M. P., and **Edelman, I. S.** Total exchangeable sodium, total exchangeable potassium, and total body water in edematous patients with cirrhosis of the liver and congestive heart failure 687
—. See LEIBMAN, BIRKENFELD, and EDELMAN *910
—. See EDELMAN, LEIBMAN, O'MEARA, and BIRKENFELD 1236
Blair, Alberta E. See WYNGAARDEN, BLAIR, and HILLEY 579
—. See LASTER and BLAIR *909
Blaisdell, Richard K. See BEUTLER and BLAISDELL 833
Blake, William D. "Low pressure" kidney and the water concentrating mechanism *878
Blakemore, William S. See COOPER, TOUCHSTONE, ROBERTS, BLAKEMORE, and ROSENTHAL 1524
Blankenhorn, David H., and **Braunstein, Herbert.** Carotenoids in man. III. The microscopic pattern of fluorescence in atheromas, and its relation to their growth 160
Blanquet, P., and **Tobias, C. A.** Hypothalamic irradiation in the rat *878
Block, Matthew. See CHAPMAN and BLOCK *883
Blount, S. Gilbert, Jr. See REEVES, GROVER, FILLEY, and BLOUNT *924
Bogdonoff, M. D. See COMBS, BRYANT, BOGDONOFF, and WARREN *885
Bollet, Alfred Jay. The measurement of tissue acid mucopolysaccharides 858
—, and **Beierwaltes, William H.** Acid mucopolysaccharide content of thyroid gland in thyroid disease and after thyrotropin *878
Bond, Victor P. See CRONKITE, FLIEDNER, RUBINI, BOND, and HUGHES *887
—. See JACKSON, SORENSEN, CRONKITE, and BOND *904
Bondurant, Stuart, Cohen, Sanford I., and **Silverman, Albert J.** A measurement of the effect of psychic stimulation on peripheral venous tone *879
Bongiovanni, Alfred M. See EBERLEIN and BONGIOVANNI *889
—, **Eberlein, Walter R.,** and **Caddell, Joan L.** Differences in metabolism of Reichstein's substance S in normal adults and children 1087
—. *In vitro* hydroxylation of steroids by whole adrenal homogenates of beef, normal man, and patients with the adrenogenital syndrome 1342
Bopp, Pierre. See GORLIN, BRACHFELD, BOPP, and MACLEOD *898
Borg, Donald, and **Cotzias, George C.** Manganese metabolism in man: Rapid exchange of Mn^{56} with tissue as demonstrated by blood clearance and liver uptake 1269
Borowsky, Benjamin A. See RECANT, BOROWSKY, and KESSNER *923
Bors, Ernest. See HEMINGWAY, BORS, and HOBBY 773
Boshell, Buris. See ROBIN, TRAVIS, JULIAN, CRUMP, and BOSHELL *925
Botti, Robert E. See RUBIN, WEISBERGER, BOTTI, and STORAASLI 1286
Boyce, W. H. See KING, BOYCE, LITTLE, and ARTOM 315
—, **King, J. S., Jr., Little, J. M.,** and **Artom, C.** Total nondialyzable solids (TNDS) in human urine. II. A method for reproducible fractionation 1658
Boyer, Samuel H., and **Chisholm, Arthur W.** Ventricular rate and response to L-epinephrine and levarterenol in experimental heart block: The influence of pentobarbital, hydrocortisone, and acid-base changes *879
Boylan, John W., and **Antkowiak, Dorothy E.** Saluretic effect of antidiuretic hormone (ADH) inhibition in the hydropenic state *879
Brachfeld, Norman. See GORLIN, BRACHFELD, BOPP, and MACLEOD *898
Bradley, Stanley E. See WHEELER, MELTZER, EPSTEIN, and BRADLEY *942
Bragdon, Joseph H., and **Gordon, Robert S., Jr.** Tissue distribution of C^{14} after the intravenous injection of labeled chylomicrons and unesterified fatty acids in the rat 574
Brandborg, Lloyd L. See RUBIN, BRANDBORG, PHELPS, and TAYLOR *927
Brandfonbrener, Martin. See FISHMAN, TURINO, BRANDFONBRENER, and HIMMELSTEIN *894
—. See FISHMAN, TURINO, BRANDFONBRENER, and HIMMELSTEIN 1071
Brandt, J. Leonard, Glaser, Warren, and **Jones, Audrey.** The uptake of isotopic magnesium in different portions of the heart *880
Branscome, William. See LEVITIN, BRANSCOME, and EPSTEIN 1667
Braude, Abraham I. See CAREY, BRAUDE, and ZALESKY 441
—, **Zalesky, Margaret,** and **Douglas, Herndon.** The mechanism of tolerance to fever *880
Braunstein, Herbert. See BLANKENHORN and BRAUNSTEIN 160
Braunwald, Eugene, Welch, G. H., Jr., and **Morrow, Andrew G.** The effects of acutely increased systemic

resistance on the left atrial pressure pulse: A method for the clinical detection of mitral insufficiency 35
Bricker, Neal S., Straffon, Ralph A., Mahoney, Edward P., and **Merrill, John P.** The functional capacity of the kidney denervated by autotransplantation in the dog 185
—, **Dewey, Richard R., Lubowitz, Herbert,** and **Stokes, James M.** The nature of the "defect" in concentrating and diluting mechanisms of the diseased kidney *881
Bridges, Thomas J., Clark, Kemp, and **Yahr, Melvin D.** Plethysmographic studies of the cerebral circulation: Evidence for cranial nerve vasomotor activity 763
Brin, Myron. See WOLFE, BRIN, and DAVIDSON 1476
Briscoe, William A., and **DuBois, Arthur B.** The relationship between airway resistance, airway conductance and lung volume in subjects of different age and body size 1279
Brodsky, William A., and **Kaim, John T.** Evidence for the presence of more than one mechanism of acid production in the kidney *881
Broitman, S. See NAKAMURA, PICHETTE, BROITMAN, BEZMAN, ZAMCHECK, and VITALE *919
Bronner, Felix, Benda, Clemens E., Harris, Robert S., and **Kreplick, Joseph.** Calcium metabolism in a case of gargoylism, studied with the aid of radiocalcium 139
Browder, Ann. See WALSER and BROWDER *940
Brown, Audrey K., and **Zuelzer, Wolf W.** Studies on the neonatal development of the glucuronide conjugating system 332
Brown, Ellen, Hopper, James, Jr., Sampson, John J., and **Mudrick, Charles.** The loss of fluid and protein from the blood during a systemic rise of venous pressure produced by repeated Valsalva maneuvers in man 1465
Brown, Rose H. See LYNN, WEBER, BROWN, WELCH, and MORRISON *915
Bruce, Robert A., Cobb, Leonard A., Katsura, Shigeaki, and **Morledge, John.** Comparative hemodynamic effects of isoproterenol and exercise (walking) in cardiac patients *881
Brust, Albert A. See WILBER and BRUST 476
—, **Howard, John M., Bryant, Milton,** and **Godwin, John.** Coarctation of the abdominal aorta with stenosis of the renal arteries and hypertension: Clinical and pathological study of two cases *882
Bryant, G. N. See COMBS, BRYANT, BOGDONOFF, and WARREN *885
Bryant, Milton. See BRUST, HOWARD, BRYANT, and GODWIN *882
Buchholz, Joachim H. See FINNERTY, BUCHHOLZ, and GUILLAUDEU 425
Bundy, Hallie F., and **Mehl, John W.** Trypsin inhibitors of human serum. I. Standardization, mechanism of reaction, and normal values 947
Bunker, John P. See APRAHAMIAN, VANDERVEEN, BUNKER, MURPHY, and CRAWFORD *875
Bunn, Paul A. See BALTCH and BUNN *876
Bunnell, Ivan L. See SHARP, GRIFFITH, BUNNELL, and GREENE 111
Burg, Maurice B., Papper, Solomon, and **Rosenbaum, Jack D.** Factors influencing the diuretic response to ingested water *882
Burrows, B. A. See SLINGERLAND, DELL, GRAHAM, TRAKAS, and BURROWS *932
Butterworth, C. E., Jr., Santini, Rafael, Jr., and **Perez-Santiago, Enrique.** The absorption of glycine and its conversion to serine in patients with sprue 20

C

Caddell, Joan L. See BONGIOVANNI, EBERLEIN, and CADDELL 1087
Cahan, Amos. See LEY, CAHAN, and MAYER *911
Calkins, Evan. See GILES and CALKINS 846
—, and **Cohen, Alan S.** Chemical composition of amyloid *882
Campbell, James A. See GRAETTINGER, MUENSTER, CHECCHIA, GRISSOM, and CAMPBELL 502
Carey, F. J., Braude, A. I., and **Zalesky, M.** Studies with radioactive endotoxin. III. The effect of tolerance on the distribution of radioactivity after intravenous injection of *Escherichia coli* endotoxin labeled with Cr^{51} 441
Carey, James B., Jr. The serum trihydroxy-dihydroxy bile acid ratio in liver and biliary tract disease 1494
Carleton, A. See MAZUR, GREEN, SAHA, and CARLETON 1809
Carone, Frank A. See EPSTEIN, BECK, RIVERA, LEVITIN, and CARONE *892
—. See EPSTEIN, RIVERA, and CARONE 1702
Carroll, Evelyn L. See PECHET, CARROLL, MITCHELL, and WEGNER *921
Carson, John C. See KUO and CARSON *908
Carter, John R., and **Warner, E. D.** Correction of defects in clotting accelerator activity by administration of methionine and vitamin K and of a new sulfhydryl-substituted methyl-naphthoquinone, vitamin K-S(II) 70
Carter, Norman W., Seldin, Donald W., and **Teng, H. C.** Renal and cellular responses to acute and chronic respiratory acidosis *883
Cartwright, George E. See ATHENS, MAUER, ASHENBRUCKER, and CARTWRIGHT *876
Castillo, Cesar. See CROSLEY, CASTILLO, FREEMAN, WHITE, and ROWE *887
—. See ROWE, CASTILLO, MAXWELL, FREEMAN, WHITE, and CRUMPTON *927
—. See MAXWELL, CASTILLO, WHITE, CRUMPTON, and ROWE 1413
Chanutin, Alfred. See BERRY and CHANUTIN 974
Chapman, Carleton B. See MITCHELL, SPROULE, and CHAPMAN 538
—, **Baker, Orland,** and **Mitchell, Jere H.** Left ventricular function at rest and during exercise *883
—. See MITCHELL, SPROULE, and CHAPMAN 1693
Chapman, Robert G., and **Block, Matthew.** Erythropoietic response to repeated phlebotomy with iron replacement in man *883
Checchia, Carlo S. See GRAETTINGER, MUENSTER, CHECCHIA, GRISSOM, and CAMPBELL 502
Cheng, Samuel, Pineda, Esteban, and **Stanley, Malcolm.** Serum cholesterol esters, cholesterol esterase and intestinal cholesterol exchange in patients with malignant obstructive jaundice *884
Chesley, Leon C., and **Tepper, Ira.** Some effects of magnesium loading upon renal excretion of magnesium and certain other electrolytes 1362
Chey, Woo Yoon. See LEEVY, ZINKE, CHEY, SNELL, and ENGLISH *910
Chisholm, Arthur W. See BOYER and CHISHOLM *879

Chobanian, Aram V. See HOLLANDER and CHOBANIAN *902
Christensen, Raymond C., Gray, Murray, Abramson, Harry, Kobelt, Carl, Baer, Lesem J., and **Hellems, Harper K.** The effects of aminophylline on the coronary and peripheral circulation in patients with emphysema *884
Clark, Kemp. See BRIDGES, CLARK, and YAHR 763
Clauss, R. H. See FRITTS, HARRIS, CLAUSS, ODELL, and COURNAND 99
Clough, W. L. See KASS, KAITZ, COTRAN, CLOUGH, and NICHOLS *906
Cobb, Leonard A. See BRUCE, COBB, KATSURA, and MORLEDGE *881
Cohen, Aaron A., Hemingway, Allan, and **Hemingway, Claire.** Displacement of nitrogen from normal human lungs during oxygen breathing 306
Cohen, Alan S. See CALKINS and COHEN *882
Cohen, Jonathan. See LOONEY, MALETSKOS, HELMICK, REARDON, COHEN, and GUILD *913
Cohen, Jules, Colwill, Jack M., Davis, Nancy, Kessler, William, Shepardson, Charles R., Reichsman, Franz, and **Engel, George L.** Effect of histamine on nocturnal gastric secretion during sleeping and waking states *884
Cohen, Sanford I. See BONDURANT, COHEN, and SILVERMAN *879
Colwill, Jack M. See COHEN, COLWILL, DAVIS, KESSLER, SHEPARDSON, REICHSMAN, and ENGEL *884
Combs, J. J., Jr., Bryant, G. N., Bogdonoff, M. D., and **Warren, J. V.** The effect of induced anxiety and hostility on cardiovascular functions *885
Condon, George P. See DANCIS, MONEY, CONDON, and LEVITZ 1373
Coniglio, J. G. See CROFFORD, CONIGLIO, MENG, and NEWMAN *886
Conn, Hadley L., Jr., and **Wood, John C.** Cation exchanges in the heart: Relation to the cardiac action potential *885
Cooper, David Y., Touchstone, Joseph C., Roberts, John M., Blakemore, William S., and **Rosenthal, Otto.** Steroid formation by adrenal tissue from hypertensives 1524
Cooperman, Jack M. See LUHBY, COOPERMAN, TELLER, and DONNENFELD *915
Cope, Oliver. See BARNES, COPE, and HARRISON 430
Cornwell, David G. See GITLIN, CORNWELL, NAKASATO, ONCLEY, HUGHES, and JANEWAY 172
Cotran, R. See KASS, KAITZ, COTRAN, CLOUGH, and NICHOLS *906
Cotzias, George C. See BORG and COTZIAS 1269
—, and **Greenough, James J.** The high specificity of the manganese pathway through the body 1298
Cournand, A. See FRITTS, HARRIS, CLAUSS, ODELL, and COURNAND 99
Cowsert, E. J., Younes, A. A., and **Morita, Y.** Determination of endogenous water production in renal failure based on measurement of oxygen consumption *886
Craig, James W., Miller, Max, Mackenzie, Malcolm S., and **Woodward, Hiram, Jr.** The influence of dietary carbohydrate deprivation on the metabolism on intravenously administered fructose and glucose in man 118
Cravioto, Joaquin. See GITLIN, CRAVIOTO, FRENK, MONTANO, GALVAN, GOMEZ, and JANEWAY 682
Crawford, John D. See APRAHAMIAN, VANDERVEEN, BUNKER, MURPHY, and CRAWFORD *875
—. See DRESCHER, TALBOT, MEARA, TERRY and CRAWFORD 1316
Crockett, Wayne A., and **Huff, Rex L.** Growth and form of leukemic white cells in cultures having varying amounts of the natural radioisotope of potassium *886
Crofford, O. B., Coniglio, J. G., Meng, H. C., and **Newman, E. V.** Demonstration of the specific metabolic defect in primary essential hyperlipemia with secondary diabetes *886
Cronkite, Eugene P., Fliedner, Theodor M., Rubini, Joseph R., Bond, Victor P., and **Hughes, Walter L.** Dynamics of proliferating cell systems of man studied with tritiated thymidine *887
—. See JACKSON, SORENSON, CRONKITE, and BOND *904
Crosby, William H. See VILLALOBOS, ADELSON, RILEY, and CROSBY 1
—. The capacity for bilirubin production as reflected by the concentration of plasma bilirubin *887
—. See LANGE, CROSBY, DONOHUE, FINCH, GIBSON, MCMANUS, and STRUMIA 1485
Crosley, Archer P., Jr., Castillo, Cesar, Freeman, D. Joseph, White, Douglas H., Jr., and **Rowe, George G.** The acute effects of carbonic anhydrase inhibitors on systemic hemodynamics *887
Crump, Charles H. See GARDNER, ROBIN, TRAVIS, JULIAN, and CRUMP *895
—. See ROBIN, TRAVIS, JULIAN, CRUMP, and BOSHELL *925
—. See ROBIN, WHALEY, CRUMP, and TRAVIS 981
Crumpton, Charles W. See ROWE, CASTILLO, MAXWELL, FREEMAN, WHITE, and CRUMPTON *927
—. See MAXWELL, CASTILLO, WHITE, CRUMPTON, and ROWE 1413
Cummings, Martin M., and **Hudgins, Paul C.** Chemical constituents of pine pollen and their possible relationship to sarcoidosis *888

D

Damast, Barbara. See WEST, DAMAST, and PEARSON 341
Dancis, Joseph, and **Shafran, Manya.** The origin of plasma proteins in the guinea pig fetus 1093
—, **Money, William L., Condon, George P.,** and **Levitz, Mortimer.** The relative transfer of estrogens and their glucuronides across the placenta in the guinea pig 1373
Danforth, William H. See BERCU, DANFORTH, PUND, and DIETTERT *877
Daughaday, William H. Binding of corticosteroids by plasma proteins. III. The binding of corticosteroid and related hormones by human plasma and plasma protein fractions as measured by equilibrium dialysis 511
—. Binding of corticosteroids by plasma proteins. IV. The electrophoretic demonstration of corticosteroid binding globulin 519
—, **Salmon, William D., Jr.,** and **Alexander, France.** The measurement of serum sulfation factor as an index of somatotropin activity in man *888
Dautrebande, Lucien. See DUBOIS and DAUTREBANDE 1746

Davidson, Charles S. See WOLFE, BRIN, and DAVIDSON 1476
Davidson, Douglas G. See ORLOFF, WAGNER, and DAVIDSON 458
—, **Levinsky, Norman G.,** and **Berliner, Robert W.** Maintenance of potassium excretion despite reduction of glomerular filtration during sodium diuresis 548
—. See LEVINSKY, DAVIDSON, and BERLINER *910
Davis, Francis W. See ADAMS, SKOOG, and DAVIS *875
Davis, J. H. See ECKEL, POST, and DAVIS *890
Davis, James O., Kliman, Bernard, Yankopoulos, Nicholas A., and **Peterson, Ralph E.** Increased aldosterone secretion following acute constriction of the inferior vena cava 1783
Davis, Nancy. See COHEN, COLWILL, DAVIS, KESSLER, SHEPARDSON, REICHSMAN, and ENGEL *884
Davis, William D. See REICHMAN, DAVIS, STORAASLI, and GORLIN 1848
Davison, Selvan, and **Wisham, Lawrence H.** The clearance of Na^{24} from the normal and osteoarthritic knee joint and the response to intra-arterial Priscoline® 389
Deadrick, Ruth Edwards. See LANCHANTIN and DEADRICK 1736
Deiss, William P., and **Holmes, Leila B.** Hexosamines of seromucoid 51
Dell, E. S. See SLINGERLAND, DELL, GRAHAM, TRAKAS, and BURROWS *932
Dempsey, Eleanor F. See HENNEMAN, WALLACH, and DEMPSEY *901
Dennis, Warren H., and **Telfer, James D.** Changes in the impedance locus diagram of swine skin produced by thermal injury *888
Dewey, Priscilla A. See TEREPKA, TORIBARA, and DEWEY 87
Dewey, Richard R. See BRICKER, DEWEY, LUBOWITZ, and STOKES *881
Didisheim, Paul. See LEWIS, WALTERS, DIDISHEIM, and MERCHANT 1323
Diettert, Gerald A. See BERCU, DANFORTH, PUND, and DIETTERT *877
Dohan, J. Lawrence. See LASAGNA, LATIES, and DOHAN 533
Donald, William D., Winkler, Charles H., and **Hare, Kendrick.** Investigations on the mechanism of the leukopenic response to Shigella endotoxin 1100
Donnenfeld, Alvin M. See LUHBY, COOPERMAN, TELLER, and DONNENFELD *915
Donohue, Dennis M. See LANGE, CROSBY, DONOHUE, FINCH, GIBSON, MCMANUS, and STRUMIA 1485
—, **Gabrio, Beverly W.,** and **Finch, Clement A.** Quantitative measurement of hematopoietic cells of the marrow 1564
—, **Reiff, Robert H., Hanson, Mary Lu, Betson, Yvonne,** and **Finch, Clement A.** Quantitative measurement of the erythrocytic and granulocytic cells of the marrow and blood 1571
Doscherholmen, Alfred, and **Hagen, Paul S.** Delay of absorption of radiolabeled cyanocobalamin in the intestinal wall in the presence of intrinsic factor *888
Douglas, Herndon. See BRAUDE, ZALESKY, and DOUGLAS *880
Dowling, Harry F. See JACKSON, DOWLING, and ANDERSON *904
Dreiling, David A., Rosenthal, William S., and **Janowitz, Henry D.** Regulation of the serum amylase: The effects of alterations in carbohydrate metabolism in normals, diabetics and some patients with liver disease *889
Drescher, Alexander N., Talbot, Nathan B., Meara, Patricia A., Terry, Mary, and **Crawford, John D.** A study of the effects of excessive potassium intake upon body potassium stores 1316
DuBois, Arthur B. See BRISCOE and DUBOIS 1279
—, and **Dautrebande, Lucien.** Acute effects of breathing inert dust particles and of carbachol aerosol on the mechanical characteristics of the lungs in man. Changes in response after inhaling sympathomimetic aerosols 1746
Duggan, Kathleen C. See FALOON, FISHER, and DUGGAN *893

E

Ebaugh, Franklin G., Jr., and **Beeken, Warren.** The chemical quantitation of the daily fecal hemoglobin excretion in normals and patients with bleeding alimentary canal lesions *889
Eberlein, Walter R., and **Bongiovanni, Alfred M.** Steroid metabolism in the "salt-losing" form of congenital adrenal hyperplasia *889
—. See MCCRORY and EBERLEIN *917
—. See BONGIOVANNI, EBERLEIN, and CADDELL 1087
Eckel, R. E., Post, R. S., and **Davis, J. H.** The effect of *in vivo* dialysis upon muscle composition in uremia *890
Eckstein, John W. See WOOD and ECKSTEIN 41
—, and **Hamilton, William K.** The effect of hyperventilation on effective right atrial pressure in man *890
—, **Hamilton, William K.,** and **McCammond, John M.** Pressure-volume changes in the forearm veins of man during hyperventilation 956
—, and **Hamilton, William K.** Changes in transmural central venous pressure in man during hyperventilation 1537
Eddleman, E. E., Jr. Avoidable errors in selection of patients for mitral valvulotomy *890
Edelman, I. S. See BIRKENFELD, LEIBMAN, O'MEARA, and EDELMAN 687
—. See LEIBMAN, BIRKENFELD, and EDELMAN *910
—, **Leibman, J., O'Meara, M. P.,** and **Birkenfeld, L. W.** Interrelations between serum sodium concentration, serum osmolarity and total exchangeable sodium, total exchangeable potassium and total body water 1236
Edwards, John Robert. See GRANT, MACDONALD, EDWARDS, STACEY, and STUECK 1166
Egdahl, Richard H., and **Melby, James C.** Induced tolerance of dogs to endotoxin: Correlation of febrile response and adrenal function *891
Eidinoff, Maxwell L., Knoll, Joseph E., Marano, Benjamin J., Kvamme, Elling, Rosenfeld, Robert S., and **Hellman, Leon.** Cholesterol biosynthesis. Studies related to the metabolic role of squalene 655
Eilers, William. See TOBIAN, MARTIN, and EILERS *935
Eisenberg, E., Fraser, T. Russell, and **Gordon, G. S.** Rates of osteogenesis measured by nonradioactive

strontium in subjects with normal and decreased skeletal mass *891
Elrick, H. See HUFFMAN, HLAD, WHIPPLE, and ELRICK 369
—, **Hlad, C. J., Jr., Whipple, N. E.,** and **Arai, Y.** The influence of blood glucose on renal clearance of phosphorus in diabetic patients *891
Engbring, Norman H., and **Engstrom, William W.** Further studies on the effects of estrogen and testosterone on the circulating thyroid hormone *892
Engel, Frank L. See WHITE and ENGEL *942
—. See MCPHERSON, WERK, MYERS, and ENGEL 1379
—. See WHITE and ENGEL 1556
Engel, George L. See COHEN, COLWILL, DAVIS, KESSLER, SHEPARDSON, REICHSMAN, and ENGEL *884
Engle, Ralph L., Jr., Woods, Kenneth R., and **Pert, James H.** Studies on the phylogenesis of gamma globulins and plasma cells *892
English, Arthur. See LEEVY, ZINKE, CHEY, SNELL, and ENGLISH *910
Engstrom, William W. See ENGBRING and ENGSTROM *892
Epstein, Franklin H., Beck, David, Rivera, Manuel J., Levitin, Howard, and **Carone, Frank A.** Selective inhibition of renal concentrating ability by experimental hypercalcemia *892
—. See LEVITIN, BRANSCOME, and EPSTEIN 1667
—, **Rivera, Manuel J.,** and **Carone, Frank A.** The effect of hypercalcemia induced by calciferol upon renal concentrating ability 1702
Epstein, Robert M. See WHEELER, MELTZER, EPSTEIN, and BRADLEY *942
Estep, Herschel. See LIDDLE, ISLAND, ESTEP, and TOMKINS *912
Evans, Iuean E. See PROUT and EVANS *922

F

Faenza, Louis J. See TISHKOFF, MCFARLAND, and FAENZA *935
Fagan, Violet M. See SIPERSTEIN and FAGAN 1185
—. See SIPERSTEIN and FAGAN 1196
Fahey, John L., McCoy, Patricia F., and **Goulian, Mehran.** Chromatography of serum proteins in normal and pathologic sera: The distribution of protein-bound carbohydrate and cholesterol, siderophilin, thyroxin-binding protein, B_{12}-binding protein, alkaline and acid phosphatases, radioiodinated albumin and myeloma proteins 272
—, **McCoy, Patricia F.,** and **Horbett, Ann P.** Chromatographic characterization of the serum protein changes in pathologic sera *893
Falbriard, Adrien. See SCHWARTZ, FALBRIARD, and RELMAN 744
—. See SCHWARTZ, FALBRIARD, and LEMIEUX *929
Faloon, William W., Fisher, Curtis J., and **Duggan, Kathleen C.** Occurrence of a sprue-like syndrome during neomycin therapy *893
Farr, Richard Studley. The febrile response upon injection of bovine albumin into previously sensitized rabbits *894
Federman, Daniel D., Robbins, Jacob, and **Rall, J. E.** Effects of methyl testosterone on thyroid function, thyroxine metabolism, and thyroxine-binding protein 1024
Fellers, Francis X. See SCHWARTZ, FELLERS, KNAPP, and YAFFE *929
Figueroa, William G. See TUTTLE and FIGUEROA *937
Filley, Giles F. See REEVES, GROVER, FILLEY, and BLOUNT *923
Finch, Clement A. See LANGE, CROSBY, DONOHUE, FINCH, GIBSON, MCMANUS, and STRUMIA 1485
—. See DONOHUE, GABRIO, and FINCH 1564
—. See DONOHUE, REIFF, HANSON, BETSON, and FINCH 1571
Fine, Daniel, Meiselas, Leonard E., and **Auerbach, Theresa.** The effect of acute hypovolemia on the release of "aldosterone" and on the renal excretion of sodium 232
Finnerty, Frank A., Jr., Buchholz, Joachim H., and **Guillaudeu, Robert L.** The blood volumes and plasma protein during levarterenol-induced hypertension 425
Fisher, Curtis J. See FALOON, FISHER, and DUGGAN *893
Fishman, Alfred P., Turino, Gerard M., Brandfonbrener, Martin, and **Himmelstein, Aaron.** The pulmonary collateral blood flow in man *894
—, **Turino, G. M., Brandfonbrener, M.,** and **Himmelstein, A.** The "effective" pulmonary collateral blood flow in man 1071
Fishman, Robert A., Ransohoff, Joseph, and **Osserman, Elliott F.** Factors influencing the concentration gradient of protein in cerebrospinal fluid 1419
Flack, Agnes. See PLOTKIN, KOPROWSKI, HUMMELER, FLACK, and STOKES *921
Fleischer, Clara J. See ABRAMSON, KAHN, TUCK, TURMAN, REJAL, and FLEISCHER 1031
—. See ABRAMSON, KAHN, REJAL, TURMAN, TUCK, and FLEISCHER 1039
Fletcher, Anthony P. See SHERRY, LINDEMEYER, FLETCHER, and ALKJAERSIG *931
—, **Alkjaersig, Norma,** and **Sherry, Sol.** The clearance of heterologous protein from the circulation of normal and immunized man 1306
Fliedner, Theodor M. See CRONKITE, FLIEDNER, RUBINI, BOND, and HUGHES *887
Foley, Joseph. See SEGAL and FOLEY 719
Folli, Giuseppe. See POLLAK, FOLLI, PIRANI, REID, and MUEHRCKE *921
Frame, Elizabeth G. The levels of individual free amino acids in the plasma of normal man at various intervals after a high protein meal 1710
Frank, C. W., Jordan, A., Kiefhaber, F., and **Zinn, M.** Some responses of the pulmonary and systemic circulations of man to acute alterations of the alveolar carbon dioxide tension *894
Franklin, William. The effect of smoking on pulmonary function in a working adult population *895
Frantz, Ivan D., Jr. See TUNA, RECKERS, and FRANTZ 1153
Fraser, T. Russell. See EISENBERG, FRASER, and GORDON *891
Frayser, Regina. See HICKAM and FRAYSER 567
—. See ROSS, FRAYSER, and HICKAM *926
Frazell, E. L. See HELLMAN, FRAZELL, and ROSENFELD *900
Fredrickson, Donald S., McCollester, Duncan L., and **Ono, Katsuto.** The role of unesterified fatty acid transport in chylomicron metabolism 1333

—, and **Gordon, Robert S., Jr.** The metabolism of albumin bound C^{14}-labeled unesterified fatty acids in normal human subjects 1504
Freeman, D. Joseph. See CROSLEY, CASTILLO, FREEMAN, WHITE, and ROWE *887
—. See ROWE, CASTILLO, MAXWELL, FREEMAN, WHITE, and CRUMPTON *927
Freiman, David G. See WESSLER, MING, GUREWICH, and FREIMAN *941
Freinkel, Norbert, and **Goodner, Charles J.** The metabolism of insulin by human placental tissue *895
—. See INGBAR and FREINKEL 1603
Freis, Edward D., and **Schnaper, Harold W.** The effects of a variety of hemodynamic changes on the rapid and slow components of the circulation in the human forearm 838
Fremont-Smith, Kenneth. See IBER, NASSAU, PLOUGH, BERGER, MERONEY, and FREMONT-SMITH 1442
Frenk, Silvestre. See GITLIN, CRAVIOTO, FRENK, MONTANO, GALVAN, GOMEZ, and JANEWAY 682
Friedman, Meyer. See ST. GEORGE, FRIEDMAN, and ISHIDA 836
Friend, Dale G. See ZILELI, HAMLIN, REUTTER, and FRIEND 409
Fritts, H. W., Jr., Harris, P., Clauss, R. H., Odell, J. E., and **Cournand, A.** The effect of acetylcholine on the human pulmonary circulation under normal and hypoxic conditions 99
Froesch, E. Rudolph, Winegrad, Albert I., Renold, Albert E., and **Thorn, George W.** Mechanism of the glucosuria produced by the administration of steroids with glucocorticoid activity 524

G

Gabrilove, J. L. Effect of acetazolamide (Diamox®) on thyroid function *895
Gabrio, Beverly W. See DONOHUE, GABRIO, and FINCH 1564
Gabuzda, George J. See WEBSTER and GABUZDA 414
Gallagher, T. F., Kappas, Attallah, Hellman, Leon, Lipsett, M. B., Pearson, O. H., and **West, C. D.** Adrenocortical hyperfunction in "idiopathic" hirsutism and the Stein-Leventhal syndrome 794
—. See KAPPAS and GALLAGHER *905
Galvan, Rafael Ramos. See GITLIN, CRAVIOTO, FRENK, MONTANO, GALVAN, GOMEZ, and JANEWAY 682
Gardner, Frank H., Robin, Eugene D., Travis, David M., Julian, Desmond G., and **Crump, Charles H.** Some pathophysiological aspects of paroxysmal nocturnal hemoglobinuria *895
—. See AAS and GARDNER 1257
Gawronska, Eva. See NASRALLA, GAWRONSKA, and HSIA 1403
Geller, Herman M. See REDEKER, GELLER, and REYNOLDS 606
—. See REYNOLDS, REDEKER, and GELLER *925
Gibson, John G., II. See LANGE, CROSBY, DONOHUE, FINCH, GIBSON, MCMANUS, and STRUMIA 1485
Gilbertsen, A. Sigrid. The contrasting ratios and significance of the tetrapyrryl (bilirubinoid) and dipyrryl ("fuscin") compounds of the feces, in certain anemias *896
Giles, Robert B., Jr., and **Calkins, Evan.** The relationship of serum hexosamine, globulins, and antibodies to experimental amyloidosis 846
—, **Michael, Myra,** and **Smith, Joe Ed.** The relationship of serum hexosamine elevations to immunological reactions *896
Gilkey, Caroline. See HEYMANN, NASH, GILKEY, and LEWIS 808
Giordano, Carmelo. See MERRILL, GUINAND-BALDO, and GIORDANO *917
Gitlin, David, Cornwell, David G., Nakasato, Doris, Oncley, J. L., Hughes, Walter L., Jr., and **Janeway, Charles A.** Studies on the metabolism of plasma proteins in the nephrotic syndrome. II. The lipoproteins 172
—, **Cravioto, Joaquin, Frenk, Silvestre, Montano, Evangelina L., Galvan, Rafael Ramos, Gomez, Federico,** and **Janeway, Charles A.** Albumin metabolism in children with protein malnutrition 682
—, **Klinenberg, James R.,** and **Hughes, Walter L.** The site of catabolism of plasma albumin *897
Glaser, Warren. See BRANDT, GLASER, and JONES *880
Glenchur, Harry, Haglund, Roger V., Hall, Wendell H., and **Wilcox, Robert H.** Urinary bacteriological studies from patients with inlying catheters *897
Gobbi, Franco, and **Stefanini, Mario.** Therapeutic attempts with cephalin fraction of bovine brain in thrombocytopenia and classical hemophilia *897
Godwin, John. See BRUST, HOWARD, BRYANT, and GODWIN *882
Gold, Norman I., Singleton, Elaine, Macfarlane, David A., and **Moore, Francis D.** Quantitative determination of the urinary cortisol metabolites, "tetrahydro F," "allo-tetrahydro F" and "tetrahydro E": Effects of adrenocorticotropin and complex trauma in the human 813
Goldgraber, Moshe B. Granulomatous lesions—An expression of the hypersensitive state *898
Goldman, Arthur G. See GROSSMAN, MINES, GOLDMAN, and WOLFMAN *899
Goldstein, Madeline. See HIATT, GOLDSTEIN, and TABOR 829
Goldstein Robert. See NITZBERG, GOLDSTEIN, and PEYMAN *920
Golub, James R. See WÉGRIA, MUELHEIMS, GOLUB, JREISSATY, and NAKANO 471
Gomez, Federico. See GITLIN, CRAVIOTO, FRENK, MONTANO, GALVAN, GOMEZ, and JANEWAY 682
Good, R. A. See KELLY, GOOD, and VARCO *906
Goodman, DeWitt S. The interaction of human erythrocytes with sodium palmitate 1729
Goodner, Charles J. See FREINKEL and GOODNER *895
Gordon, Edwin E. See TROEN and GORDON 1516
Gordon, G. S. See EISENBERG, FRASER, and GORDON *891
Gordon, Robert S., Jr. See BRAGDON and GORDON 574
—. See FREDRICKSON and GORDON 1504
Gorlin, Richard, Brachfeld, Norman, Bopp, Pierre, and **MacLeod, Colin.** Physiological diagnosis of disordered coronary circulation *898
—. See REICHMAN, DAVIS, STORAASLI, and GORLIN 1848
Gottschalk, Carl W., Mylle, Margaret, Winters, Robert W., and **Welt, Louis G.** Micropuncture study of the osmolality of renal tubular fluid in potassium-depleted rats *898
Goulian, Mehran. See FAHEY, MCCOY, and GOULIAN 272

Graettinger, John S., Muenster, Joseph J., Checchia, Carlo S., Grissom, Robert L., and **Campbell, James A.** A correlation of clinical and hemodynamic studies in patients with hypothyroidism 502
Graham, D. E. See SLINGERLAND, DELL, GRAHAM, TRAKAS, and BURROWS *932
Grant, Joseph L., MacDonald, Alastair, Edwards, John Robert, Stacey, Richard R., and **Stueck, George H., Jr.** Red cell changes in chronic pulmonary insufficiency 1166
Grape, Birger. See TYLER and GRAPE *937
Gray, Murray. See CHRISTENSEN, GRAY, ABRAMSON, KOBELT, BAER, and HELLEMS *884
Green, S. See MAZUR, GREEN, SAHA, and CARLETON 1809
Greene, David G. See SHARP, GRIFFITH, BUNNELL, and GREENE 111
Greenough, James J. See COTZIAS and GREENOUGH 1298
Greisman, Sheldon E., and **Wisseman, Charles L., Jr.** Cardiovascular dysfunction during rickettsial toxemia *898
Gribetz, Donald. See LEVITT, HALPERN, POLIMEROS, SWEET, and GRIBETZ 294
Griffith, Geraint T. See SHARP, GRIFFITH, BUNNELL, and GREENE 111
Griggs, Robert C., Weisman, Russell, Jr., and **Harris, John W.** *In vivo* demonstration of splenic "conditioning" in hereditary spherocytosis—Alterations in osmotic and mechanical fragility related to erythrocyte aging and splenic sequestration *899
Griscom, John. See RAMSEY, GRISCOM, and SNELL *923
Grissom, Robert L. See GRAETTINGER, MUENSTER, CHECCHIA, GRISSOM, and CAMPBELL 502
Grob, David, and **Harvey, John C.** Effects in man of the anticholinesterase compound sarin (isopropyl methyl phosphonofluoridate) 350
Gross, Ruth T., Hurwitz, Ruth E., and **Marks, Paul A.** An hereditary enzymatic defect in erythocyte metabolism: Glucose-6-phosphate dehydrogenase deficiency 1176
Grossman, Jacob, Mines, Martin F., Goldman, Arthur G., and **Wolfman, Morris.** Effects of calcium on urine concentrating ability *899
Grover, Robert F. See REEVES, GROVER, FILLEY, and BLOUNT *923
Guild, Warren R. See LOONEY, MALETSKOS, HELMICK, REARDON, COHEN, and GUILD *913
Guillaudeu, Robert L. See FINNERTY, BUCHHOLZ, and GUILLAUDEU 425
Guinand-Baldo, Alberto. See MERRILL, GUINAND-BALDO, and GIORDANO *917
Gurewich, Victor. See WESSLER, MING, GUREWICH, and FREIMAN *941
Gurney, Clifford W. Erythropoietin in fractionated and unfractionated plasma *900

H

Hackel, Donald B. See KLEINERMAN, SANCETTA, and HACKEL 285
Hagen, Paul S. See DOSCHERHOLMEN and HAGEN *888
Haglund, Roger V. See GLENCHUR, HAGLUND, HALL, and WILCOX *897
Halbrecht, Izhak. See SZEINBERG, RAMOT, SHEBA, ADAM, HALBRECHT, RIKOVER, WISHNIEVSKY, and RABAU 1436
Halden, E. Richard. See SPROULE, HALDEN, and MILLER 486
Hall, Wendell H. See GLENCHUR, HAGLUND, HALL, and WILCOX *897
Halpern, Mark H. See LEVITT, HALPERN, POLIMEROS, SWEET, and GRIBETZ 294
Hamerman, David, and **Schuster, Hilda.** Hyaluronate in normal human synovial fluid 57
Hamilton, William K. See ECKSTEIN and HAMILTON *890
—. See ECKSTEIN, HAMILTON, and MCCAMMOND 956
—. See ECKSTEIN and HAMILTON 1537
Hamlin, James T., III. See ZILELI, HAMLIN, REUTTER, and FRIEND 409
Hammaker, Lydia. See SCHMID, AXELROD, HAMMAKER, and SWARM 1123
Hanson, Mary Lu. See DONOHUE, REIFF, HANSON, BETSON, and FINCH 1571
Hare, Kendrick. See DONALD, WINKLER, and HARE 1100
Harris, Jean. See VAUGHAN and HARRIS *939
Harris, John W. See GRIGGS, WEISMAN, and HARRIS *899
Harris, P. See FRITTS, HARRIS, CLAUSS, ODELL, and COURNAND 99
Harris, Robert S. See BRONNER, BENDA, HARRIS, and KREPLICK 139
Harrison, Timothy. See BARNES, COPE, and HARRISON 430
Hartmann, Robert C., Auditore, Joseph V., and **Jackson, Dudley P.** Studies on thrombocytosis. I. Hyperkalemia due to release of potassium from platelets during coagulation 699
—, **Auditore, Joseph V.,** and **Holland, William C.** Erythrocytic acetylcholinesterase defect in paroxysmal nocturnal hemoglobinuria *900
Harvey, John C. See GROB and HARVEY 350
Hecht, Hans H., Patel, Dali J., and **Lange, Ramon L.** On the diagnosis of functional coarctation *900
Hellems, Harper K. See CHRISTENSEN, GRAY, ABRAMSON, KOBELT, BAER, and HELLEMS *884
Hellman, Leon. See EIDINOFF, KNOLL, MARANO, KVAMME, ROSENFELD, and HELLMAN 655
—. See GALLAGHER, KAPPAS, HELLMAN, LIPSETT, PEARSON, and WEST 794
—, **Frazell, E. L.,** and **Rosenfeld, R. S.** Direct measurement of cholesterol absorption via the thoracic duct in man *900
Helmick, Marie. See LOONEY, MALETSKOS, HELMICK, REARDON, COHEN, and GUILD *913
Hemingway, Allan. See COHEN, HEMINGWAY, and HEMINGWAY 306
—, **Bors, Ernest,** and **Hobby, Richard P.** An investigation of the pulmonary function of paraplegics 773
Hemingway, Claire. See COHEN, HEMINGWAY, and HEMINGWAY 306
Henneman, Dorothy H., and **Vandam, Leroy D.** Effect of ether anesthesia on human skeletal muscle metabolism *901
Henneman, Philip H., Wallach, Stanley, and **Dempsey, Eleanor F.** The metabolic defect responsible for uric acid renal stone formation *901

Hennes, Allen R. See SHREEVE and HENNES 1006
Herbert, Victor. Studies of the mechanism of the effect of hog intrinsic factor concentrate on the uptake of vitamin B_{12} by rat liver slices 646
—. Mechanism of intrinsic factor action in the isolated rat small intestine *901
Heymann, Walter, Nash, Gerald, Gilkey, Caroline, and **Lewis, Mildred.** Studies on the causal role of hypoalbuminemia in experimental nephrotic hyperlipemia 808
Hiatt, Howard H. Studies of ribose metabolism. III. The pathway of ribose carbon conversion to glucose in man 651
—, **Goldstein, Madeline,** and **Tabor, Herbert.** Urinary excretion of formiminoglutamic acid by human subjects after antifolic acid therapy 829
—. Pathways of ribose synthesis in normal and pentosuric human subjects *902
—. Studies of ribose metabolism. V. Factors influencing *in vivo* ribose synthesis in the rat 1453
—. Studies of ribose metabolism. VI. Pathways of ribose synthesis in man 1461
Hickam, John B., and **Frayser, Regina.** A comparative study of intrapulmonary gas mixing and functional residual capacity in pulmonary emphysema, using helium and nitrogen as the test gases 567
—. See ROSS, FRAYSER, and HICKAM *926
Hilley, Linnelle. See WYNGAARDEN, BLAIR, and HILLEY 579
Himmelstein, Aaron. See FISHMAN, TURINO, BRANDFONBRENER, and HIMMELSTEIN *894
—. See FISHMAN, TURINO, BRANDFONBRENER, and HIMMELSTEIN 1071
Hlad, C. J., Jr. See HUFFMAN, HLAD, WHIPPLE, and ELRICK 369
—. See ELRICK, HLAD, WHIPPLE, and ARAI *891
Hobby, Richard P. See HEMINGWAY, BORS, and HOBBY 773
Hodes, H. L. See SWEET, LEVITT, and HODES 65
Hodges, Robert E., Ohlson, Margaret A., and **Bean, William B.** Pantothenic acid deficiency in man 1642
Hogancamp, Charles. See NOLTING, MACK, LUTHY, KIRSCH, and HOGANCAMP *921
Holland, William C. See HARTMANN, AUDITORE, and HOLLAND *900
Hollander, William, and **Chobanian, Aram V.** The mode of action of chlorothiazide and mercurial diuretics as antihypertensive agents *902
Hollenberg, C. H. See RABEN and HOLLENBERG *922
Holmes, Leila B. See DEISS and HOLMES 51
Hook, Edward W., and **Wagner, Robert R.** Cross resistance to cerebral typhoid infection and influenza virus neurotoxicity *903
Hopper, James, Jr. See BROWN, HOPPER, SAMPSON, and MUDRICK 1465
Horbett, Ann P. See FAHEY, MCCOY, and HORBETT *893
Howard, John M. See BRUST, HOWARD, BRYANT, and GODWIN *882
Hsia, David Yi-Yung. See NASRALLA, GAWRONSKA, and HSIA 1403
Huckabee, William E. Relationships of pyruvate and lactate during anaerobic metabolism. I. Effects of infusion of pyruvate or glucose and of hyperventilation 244
—. Relationships of pyruvate and lactate during anaerobic metabolism. II. Exercise and formation of O_2-debt 255
—. Relationships of pyruvate and lactate during anaerobic metabolism. III. Effect of breathing low-oxygen gases 264
—. Adequacy of renal oxygenation in essential hypertension *903
—, and **Judson, Walter E.** The role of anaerobic metabolism in the performance of mild muscular work. I. Relationship to oxygen consumption and cardiac output, and the effect of congestive heart failure 1577
—. The role of anaerobic metabolism in the performance of mild muscular work. II. The effect of asymptomatic heart disease 1593
Hudgins, Paul C. See CUMMINGS and HUDGINS *888
Huff, Rex L. See CROCKETT and HUFF *886
Huffman, E. R., Hlad, C. J., Jr., Whipple, N. E., and **Elrick, H.** The influence of blood glucose on the renal clearance of phosphate 369
Hughes, Walter L., Jr. See GITLIN, CORNWELL, NAKASATO, ONCLEY, HUGHES, and JANEWAY 172
—. See CRONKITE, FLIEDNER, RUBINI, BOND, and HUGHES *887
—. See GITLIN, KLINENBERG, and HUGHES *897
Hummeler, Klaus. See PLOTKIN, KOPROWSKI, HUMMELER, FLACK, and STOKES *921
Hurwitz, Ruth E. See GROSS, HURWITZ, and MARKS 1176

I

Iber, Frank L., Nassau, Kurt, Plough, Irvin C., Berger, Florence M., Meroney, William H., and **Fremont-Smith, Kenneth.** The use of radioiodinated albumin in metabolic studies. The effects of the level of dietary protein and L-triiodothyronine on the catabolism of radioiodinated human serum albumin 1442
Ingbar, Sidney H. Pre-albumin, a new thyroxine-binding protein of human plasma: Its isolation and physiologic activity in normal and abnormal states *903
—, and **Freinkel, Norbert.** Studies of thyroid function and the peripheral metabolism of I^{131}-labeled thyroxine in patients with treated Graves' disease 1603
Ishida, Tadashi. See ST. GEORGE, FRIEDMAN, and ISHIDA 836
Island, Donald. See LIDDLE, ISLAND, ESTEP, and TOMKINS *912
Isselbacher, Kurt J. The demonstration of bilirubin sulfate in bile *904

J

Jackson, Dudley P. See HARTMANN, AUDITORE, and JACKSON 699
—, **Sorensen, Dale K., Cronkite, Eugene P.,** and **Bond, Victor P.** Comparison of the effectiveness of transfusions of fresh and lyophilized platelets in controlling bleeding due to thrombocytopenia *904
Jackson, George Gee, Dowling, Harry F., and **Anderson, Truman O.** Common cold neutralization by human immune globulin *904
Jaffé, Ernst R., Vanderhoff, Grace A., Lowy, Bertram A., and **London, Irving M.** The relationship of the age of rabbit erythrocytes to the effects of inosine on their osmotic resistance 1293
Jandl, James H. Sequestration of reticulocytes and o. abnormal red cells by filtration at low pressures *905

—, and **Tomlinson, Ann S.** The destruction of red cells by antibodies in man. II. Pyrogenic, leukocytic and dermal responses to immune hemolysis 1202
Janecek, Jeanette. See TOBIAN, THOMPSON, TWEDT, and JANECEK 660
Janeway, Charles A. See GITLIN, CORNWELL, NAKASATO, ONCLEY, HUGHES, and JANEWAY 172
—. See GITLIN, CRAVIOTO, FRENK, MONTANO, GALVAN, GOMEZ, and JANEWAY 682
Janowitz, Henry D. See DREILING, ROSENTHAL, and JANOWITZ *889
Jaretzki, Alfred, III. See THOMAS, LOCHTE, JARETZKI, ASHLEY, and SAHLER *935
Johnson, Alan J., and **McCarty, W. Ross.** The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase *905
Johnson, Anne B. See MARKS, JOHNSON, and BANKS *916
—. See MARKS and JOHNSON 1542
Jones, Audrey. See BRANDT, GLASER, and JONES *880
Jordan, A. See FRANK, JORDAN, KIEFHABER, and ZINN *894
Josephson, Aaron M., and **Lisker, Ruben.** Demonstration of a circulating anticoagulant in plasma thromboplastin antecedent deficiency 148
Jreissaty, Robert. See WÉGRIA, MUELHEIMS, GOLUB, JREISSATY, and NAKANO 471
Judson, Walter E. See HUCKABEE and JUDSON 1577
Julian, Desmond G. See GARDNER, ROBIN, TRAVIS, JULIAN, and CRUMP *895
—. See ROBIN, TRAVIS, JULIAN, CRUMP, and BOSHELL *925

K

Kahn, Alan. See ABRAMSON, KAHN, TUCK, TURMAN, REJAL, and FLEISCHER 1031
—. See ABRAMSON, KAHN, REJAL, TURMAN, TUCK, and FLEISCHER 1039
Kaim, John T. See BRODSKY and KAIM *881
Kaitz, A. L. See KASS, KAITZ, COTRAN, CLOUGH, and NICHOLS *906
Kako, K., and **Bing, R. J.** Contractility of actomyosin bands prepared from normal and failing human hearts 465
Kappas, Attallah. See GALLAGHER, KAPPAS, HELLMAN, LIPSETT, PEARSON, and WEST 794
—, and **Gallagher, T. F.** Genetic and intrauterine influences on steroid hormone production in man *905
Kass, E. H., Kaitz, A .L., Cotran, R., Clough, W. L., and **Nichols, R. L.** Asymptomatic bacteriuria and pyelonephritis of pregnancy *906
Katsura, Shigeaki. See BRUCE, COBB, KATSURA, and MORLEDGE *881
Kaye, Robert, Williams, Margaret L., and **Barbero, Giulio.** Comparative study of glucose and fructose metabolism in infants with reference to utilization and to the accumulation of glycolytic intermediates 752
Kellermeyer, Robert W. See SCHRIER and KELLERMEYER *928
Kelly, John J., Jr. See MURRAY and KELLY *918
Kelly, Keith H. See BIERMAN, MARSHALL, MAEKAWA, KELLY, and PLANTE *877
Kelly, W. D., Good, R. A., and **Varco, R. L.** Anergy and the response to homografts in Hodgkin's Disease *906
Kerby, Grace P. The distribution of acid mucopolysaccharides in Cohn fractions of human plasma proteins 678
—. The effect of inflammation on the hexuronate-containing polysaccharides of human plasma 962
Kessler, William. See COHEN, COLWILL, DAVIS, KESSLER, SHEPARDSON, REICHSMAN, and ENGEL *884
Kessner, David M. See RECANT, BOROWSKY, and KESSNER *923
Kiefhaber, F. See FRANK, JORDAN, KIEFHABER, and ZINN *894
King, J. S., Jr., Boyce, W. H., Little, J. M., and **Artom, C.** Total nondialyzable solids (TNDS) in human urine. I. The amount and composition of TNDS from normal subjects 315
—. See BOYCE, KING, LITTLE, and ARTOM 1658
Kipnis, David M., and **Noall, Matthew M.** Stimulation of amino acid penetration into mammalian skeletal muscle by insulin *906
Kirklin, John W. See SWAN, SAVARD, and KIRKLIN *934
Kirsch, Morton. See NOLTING, MACK, LUTHY, KIRSCH, and HOGANCAMP *921
Kistner, Sten A. See MOSCHIDES, STEFANINI, MAGALINI, and KISTNER 127
Kleeman, Charles R., Rockney, Robert E., and **Maxwell, Morton H.** The effect of parathyroid extract (PTE) on the renal clearance of diffusible calcium *907
—, **Maxwell, Morton H.,** and **Rockney, Robert E.** Mechanisms of impaired water excretion in adrenal and pituitary insufficiency. I. The role of altered glomerular filtration rate and solute excretion 1799
Kleinerman, Jerome, Sancetta, Salvatore M., and **Hackel, Donald B.** Effects of high spinal anesthesia on cerebral circulation and metabolism in man 285
Kliman, Bernard. See DAVIS, KLIMAN, YANKOPOULOS, and PETERSON 1783
Klinenenberg, James R. See GITLIN, KLINENBERG, and HUGHES *897
Kobelt, Carl. See CHRISTENSEN, GRAY, ABRAMSON, KOBELT, BAER, and HELLEMS *884
Knapp, John. See SCHWARTZ, FELLERS, KNAPP, and YAFFE *929
Knight, Vernon. See WHITE and KNIGHT *942
Knoll, Joseph E. See EIDINOFF, KNOLL, MARANO, KVAMME, ROSENFELD, and HELLMAN 655
Knowles, Harvey C., Jr. See AGNA, KNOWLES, and ALVERSON 1357
Komisaruk, Richard. See LEWIS, LIN, NOE, and KOMISARUK 1061
Koprowski, Hilary. See PLOTKIN, KOPROWSKI, HUMMELER, FLACK, and STOKES *921
Krantz, Kermit E. See SIMS and KRANTZ 1764
Kreplick, Joseph. See BRONNER, BENDA, HARRIS, and KREPLICK 139
Kuhns, William J. Immediate wheal hypersensitivity. I. The diphtheria system as a model in studying the nature of reagins *907
Kunin, Calvin M., and **Rees, Searle.** Persistence of antibiotics in blood of patients with acute tubular necrosis and uremia *908
Kuo, Peter T., and **Carson, John C.** Dietary fats and blood lipids *908
Kvamme, Elling. See EIDINOFF, KNOLL, MARANO, KVAMME, ROSENFELD, and HELLMAN 655

L

Lalezari, Parviz, and **Spaet, Theodore H.** Studies on the genetics of leukocyte antigens *908

Lanchantin, Gerard F., and **Deadrick, Ruth Edwards.** Serum protein changes in thermal trauma. I. Electrophoretic analysis at pH 8.6 1736

Lange, Kurt, Wasserman, Edward, Slobody, Lawrence B., and **Wenk, Eugene J.** Seven year follow-up of one type of prolonged intermittent steroid therapy in nephrosis *908

Lange, Ramon L. See HECHT, PATEL, and LANGE *900

Lange, Robert D., Crosby, William H., Donohue, Dennis M., Finch, Clement A., Gibson, John G., II, McManus, Thomas J., and **Strumia, Max M.** Effect of inosine on red cell preservation 1485

Laragh, John H. See ANDERSON and LARAGH 323

Lasagna, Louis, Laties, Victor G., and **Dohan, J. Lawrence.** Further studies on the "pharmacology" of placebo administration 533

Lasley, David A. See OPPENHEIMER, WISE, and LASLEY 380

Lassen, Niels A. See LILIENFIELD, LASSEN, and ROSE *912

Laster, Leonard, and **Blair, Alberta.** Uric acid riboside phosphorylase in human tissue—Inhibition by colchicine, and other properties *909

Lathem, Willoughby. Reappraisal of renal hemoglobin excretion: The differential transport of free and protein-bound hemoglobin *909

Laties, Victor G. See LASAGNA, LATIES, and DOHAN 533

Lawrence, Walter, Jr. See MYERS and LAWRENCE *918

Leaf, Alexander. See MAFFLY and LEAF *916

Leahy, Robert H. See YU, LOVEJOY, SCHREINER, WALTHER, LEAHY, and STANFIELD *944

Leevy, Carroll M., Zinke, Myra R., Chey, Woo Yoon, Snell, Junius, and **English, Arthur.** Observations on hepatic metabolism of oxytetracycline in man *910

Leibman, J. See BIRKENFELD, LEIBMAN, O'MEARA, and EDELMAN 687

—, **Birkenfeld, L. W.,** and **Edelman, I. S.** The dependence of plasma potassium concentration on plasma osmolarity, blood pH, and body composition *910

—. See EDELMAN, LEIBMAN, O'MEARA, and BIRKENFELD 1236

Lemieux, Guy. See SCHWARTZ, FALBRIARD, and LEMIEUX *929

Levinsky, Norman G. See DAVIDSON, LEVINSKY, and BERLINER 548

—, **Davidson, Douglas G.,** and **Berliner, Robert W.** Effects of reduced glomerular filtration on urine concentration in the presence of antidiuretic hormone *910

Levitin, Howard. See EPSTEIN, BECK, RIVERA, LEVITIN, and CARONE *892

—, **Branscome, William,** and **Epstein, Franklin H.** The pathogenesis of hypochloremia in respiratory acidosis 1667

Levitt, Marvin F. See SWEET, LEVITT, and HODES 65

—, **Halpern, Mark H., Polimeros, Demetra P., Sweet, Avron Y.,** and **Gribetz, Donald.** The effect of abrupt changes in plasma calcium concentrations on renal function and electrolyte excretion in man and monkey 294

—, **Levy, Marshall S.,** and **Polimeros, Demetra.** Effect of a reduction in filtered load on solute and water excretion in hydropenic man *911

Levitz, Mortimer. See DANCIS, MONEY, CONDON, and LEVITZ 1373

Levy, Marshall S. See LEVITT, LEVY, and POLIMEROS *911

Levy, Robert I., Weiner, I. M., and **Mudge, Gilbert H.** The effects of acid-base balance on the diuresis produced by organic and inorganic mercurials 1016

Lewis, Arthur. See LOSPALLUTO, LEWIS, and ZIFF *913

Lewis, Benjamin M., Lin, Tai-Hon, Noe, Frances E., and **Komisaruk, Richard.** The measurement of pulmonary capillary blood volume and pulmonary membrane diffusing capacity in normal subjects; the effects of exercise and position 1061

Lewis, Jessica H., and **Merchant, William R.** The probable identity of glass factor with Hageman factor *911

—, **Walters, Denny, Didisheim, Paul,** and **Merchant, William R.** Application of continuous flow electrophoresis to the study of the blood coagulation proteins and the fibrinolytic enzyme system. I. Normal human materials 1323

Lewis, Mildred. See HEYMANN, NASH, GILKEY, and LEWIS 808

Ley, Allyn B., Cahan, Amos, and **Mayer, Klaus.** A circulating antibody directed against penicillin *911

Liddle, Grant W., Island, Donald, Estep, Herschel, and **Tomkins, Gordon M.** Modification of adrenal steroid patterns in man by means of an inhibitor of 11 beta-hydroxylase *912

Lilienfield, Lawrence S., Lassen, Niels A., and **Rose, John C.** Diverse distribution of red cells and plasma albumin in anatomical regions of the kidney *912

—, and **Rose, John C.** Effect of blood pressure alterations on intrarenal red cell-plasma separation 1106

Lin, Tai-Hon. See LEWIS, LIN, NOE, and KOMISARUK 1061

Lindemeyer, Robert I. See SHERRY, LINDEMEYER, FLETCHER, and ALKJAERSIG *931

Linman, James W. The hemopoietic effect of butyl alcohol *913

Lipkin, Martin, and **Sleisenger, Marvin H.** Studies of visceral pain: Measurements of stimulus intensity and duration associated with the onset of pain in esophagus, ileum and colon 28

Lipsett, M. B. See GALLAGHER, KAPPAS, HELLMAN, LIPSETT, PEARSON, and WEST 794

—. See BERGENSTAL and LIPSETT *877

—, and **Pearson, Olof H.** Sodium depletion in adrenalectomized humans 1394

Lisker, Ruben. See JOSEPHSON and LISKER 148

Little, J. M. See KING, BOYCE, LITTLE, and ARTOM 315

—. See BOYCE, KING, LITTLE, and ARTOM 1658

Lochte, Harry L., Jr. See DONNALL and LOCHTE 166

—. See THOMAS, LOCHTE, JARETZKI, ASHLEY, and SAHLER *935

London, Irving M. See Arias, Lowy, and London *875

—. See JAFFÉ, VANDERHOFF, LOWY, and LONDON 1293

Looney, W. B., Maletskos, C. J., Helmick, Marie, Reardon, John, Cohen, Jonathan, and **Guild, Warren R.** A study of the dynamics of strontium and calcium metabolism and radioelement removal *913

Lospalluto, Joseph, Lewis, Arthur, and **Ziff, Morris.** Isolation of the rheumatoid factor *913
Louria, Donald B. Penicillin treatment of experimental infections produced by penicillin-resistant staphylococci *914
Lovejoy, Frank W., Jr. See YU, NYE, LOVEJOY, SCHREINER, and YIM 194
—. Pressure-volume relationships of the lung in patients with cardiorespiratory diseases *914
—. See YU, LOVEJOY, SCHREINER, WALTHER, LEAHY, and STANFIELD *944
Lowder, John A. See WINTERS, LOWDER, and ORDWAY 640
Lowy, Bertram A. See ARIAS, LOWY, and LONDON *875
—. See JAFFÉ, VANDERHOFF, LOWY, and LONDON 1293
Lubowitz, Herbert. See BRICKER, DEWEY, LUBOWITZ, and STOKES *881
Ludwig, George D. Urinary excretion of indoles causing false-positive Watson-Schwartz tests for porphobilinogen *914
Luhby, A. Leonard, Cooperman, Jack M., Teller, David N., and **Donnenfeld, Alvin M.** Excretion of formiminoglutamic acid in folic acid deficiency states *915
Luthy, Ernst. See NOLTING, MACK, LUTHY, KIRSCH, and HOGANCAMP *921
Lynn, William S., Weber, Carl, Brown, Rose H., Welch, Margaret, and **Morrison, Ashton B.** Observations on the physiologic changes accompanying hyperlipemia in rabbits *915
Lyons, Harold A. See TING and LYONS *935

Mc

McCammond, John M. See ECKSTEIN, HAMILTON, and MCCAMMOND 956
McCarty, W. Ross. See JOHNSON and MCCARTY *905
McCollester, Duncan L. See FREDRICKSON, MCCOLLESTER, and ONO 1333
McCoy, Patricia F. See FAHEY, MCCOY, and GOULIAN 272
—. See FAHEY, MCCOY, and HORBETT *893
McCrory, Wallace W., and **Eberlein, Walter R.** The nature of the sodium diuresis produced by an "aldosterone antagonist," spirolactone *917
McFarland, William. See TISHKOFF, MCFARLAND, and FAENZA *935
McGee, H. L. See ROTHSCHILD, SCHREIBER, ORATZ, and MCGEE 1229
McManus, Thomas J. See LANGE, CROSBY, DONOHUE, FINCH, GIBSON, MCMANUS, and STRUMIA 1485
McPherson, Harry T., Werk, Emile E., Jr., Myers, Jack D., and **Engel, Frank L.** Studies on ketone metabolism in man. II. The effect of glucose, insulin, cortisone and hypoglycemia on splanchnic ketone production 1379

M

MacDonald, Alastair. See GRANT, MACDONALD, EDWARDS, STACEY, and STUECK 1166
Macfarlane, David A. See GOLD, SINGLETON, MACFARLANE, and MOORE 813
MacLeod, Colin. See GORLIN, BRACHFELD, BOPP, and MACLEOD *898
Mack, Robert. See NOLTING, MACK, LUTHY, KIRSCH, and HOGANCAMP *921
Mackenzie, Malcolm S. See CRAIG, MILLER, MACKENZIE, and WOODWARD 118
MacNair, Margaret B. See SCHMID and MACNAIR 708
Madison, Leonard L. See UNGER and MADISON 627
—, and **Unger, Roger H.** The physiologic significance of the secretion of endogenous insulin into the portal circulation. I. Comparison of the effects of glucagon-free insulin administered via the portal vein and via a peripheral vein on the magnitude of hypoglycemia and peripheral glucose utilization 631
—, and **Seldin, Donald W.** Ammonia excretion and renal enzymatic adaptation in human subjects, as disclosed by administration of precursor amino acids 1615
Maekawa, Tadashi. See BIERMAN, MARSHALL, MAEKAWA, KELLY, and PLANTE *877
Maffly, LeRoy H., and **Leaf, Alexander.** The intracellular osmolarity of mammalian tissues *916
Magalini, Sergio I. See MOSCHIDES, STEFANINI, MAGALINI, and KISTNER 127
Mahoney, Edward P. See BRICKER, STRAFFON, MAHONEY, and MERRILL 185
Maletskos, C. J. See LOONEY, MALETSKOS, HELMICK, REARDON, COHEN, and GUILD *913
Manis, James G. See SCHACHTER and MANIS 800
Manning, Elizabeth L. See MULLER, MANNING, and RIONDEL *918
Manso, Carlos, and **Wroblewski, Felix.** Glutathione reductase activity in blood and body fluids 214
—. See WROBLEWSKI, MOORE, MANSO, and SUGUIRA *943
Marano, Benjamin J. See EIDINOFF, KNOLL, MARANO, KVAMME, ROSENFELD, and HELLMAN 655
Marcus, Aaron J., and **Spaet, Theodore H.** Platelet phosphatides: Their separation, identification, and clotting activity 1836
Marks, Paul A., Johnson, Anne B., and **Banks, Julia.** Adenosine triphosphate generation in relation to the pathway of glucose utilization in human erythrocytes *916
—. See GROSS, HURWITZ, and MARKS 1176
—, and **Johnson, Anne B.** Relationship between the age of human erythrocytes and their osmotic resistance: A basis for separating young and old erythrocytes 1542
Marshall, Hiram W. See SWAN, MARSHALL, and WOOD 202
Marshall, June. See BIERMAN, MARSHALL, MAEKAWA, KELLY, and PLANTE *877
Marshall, R. A comparison of methods of measuring the diffusing capacity of the lungs for carbon monoxide. Investigation by fractional analysis of the alveolar air 394
Martin, Stephen. See TOBIN, MARTIN, and EILERS *935
Massie, Ralph W. Relationship between red cell and plasma volume during recovery from pernicious anemia and megaloblastic anemia of folic acid deficiency *916
Mauer, Alvin M. See ATHENS, MAUER, ASHENBRUCKER, and CARTWRIGHT *876
Maxwell, George M. See ROWE, CASTILLO, MAXWELL, FREEMAN, WHITE, and CRUMPTON *927

—, **Castillo, Cesar A., White, Douglas H., Jr., Crumpton, Charles W.,** and **Rowe, George G.** Induced tachycardia: Its effect upon the coronary hemodynamics, myocardial metabolism and cardiac efficiency of the intact dog 1413
Maxwell, Morton H. See KLEEMAN, ROCKNEY, and MAXWELL *907
—. See KLEEMAN, MAXWELL, and ROCKNEY 1799
Mayer, Klaus. See LEY, CAHAN, and MAYER *911
Mazur, A., Green, S., Saha, A., and **Carleton, A.** Mechanism of release of ferritin iron *in vivo* by xanthine oxidase 1809
Meara, Patricia A. See DRESCHER, TALBOT, MEARA, TERRY, and CRAWFORD 1316
Mehl, John W. See BUNDY and MEHL 947
Meiselas, Leonard E. See FINE, MEISELAS, and AUERBACH 232
Melby, James C. See EGDAHL and MELBY *891
—, and **Spink, Wesley W.** Comparative studies on adrenal cortical function and cortisol metabolism in healthy adults and in patients with shock due to infection 1791
Meltzer, Jay I. See WHEELER, MELTZER, EPSTEIN, and BRADLEY *942
Meng, H. C. See CROFFORD, CONIGLIO, MENG, and NEWMAN *886
Merchant, William R. See LEWIS and MERCHANT *911
—. See LEWIS, WALTERS, DIDISHEIM, and MERCHANT 1323
Meroney, William H. See AUSTEN, RUBINI, MERONEY, and WOLFF 1131
—. See IBER, NASSAU, PLOUGH, BERGER, MERONEY, and FREMONT-SMITH 1442
Merrill, John P. See BRICKER, STRAFFON, MAHONEY, and MERRILL 185
—, **Guinand-Baldo, Alberto,** and **Giordano, Carmelo.** A mechanism of renal hypertension in the human *917
Michael, Myra. See GILES, MICHAEL, and SMITH *896
Miller, Aaron. The *in vitro* binding of cobalt^{60} labeled vitamin B_{12} by normal and leukemic sera 556
—, and **Sullivan, John F.** Increased binding of vitamin B_{12} by serum mucoproteins in chronic myelogenous leukemia *917
Miller, Max. See CRAIG, MILLER, MACKENZIE, and WOODWARD 118
Miller, William F. See SPROULE, HALDEN, and MILLER 486
Mines, Martin F. See GROSSMAN, MINES, GOLDMAN, and WOLFMAN *899
Ming, Si-Chun. See WESSLER, MING, GUREWICH, and FREIMAN *941
Mirick, George S. See BESSMAN and MIRICK 990
Mitchell, Jere H., Sproule, Brian J., and **Chapman, Carleton B.** The physiological meaning of the maximal oxygen intake test 538
—. See CHAPMAN, BAKER, and MITCHELL *883
—, **Sproule, Brian J.,** and **Chapman, Carleton B.** Factors influencing respiration during heavy exercise 1693
Mitchell, Mary. See PECHET, CARROLL, MITCHELL, and WEGNER *921
Money, William L. See DANCIS, MONEY, CONDON, and LEVITZ 1373
Montano, Evangelina L. See GITLIN, CRAVIOTO, FRENK, MONTANO, GALVAN, GOMEZ, and JANEWAY 682
Moore, Alice E. See WROBLEWSKI, MOORE, MANSO, and SUGUIRA *943
Moore, Francis D. See GOLD, SINGLETON, MACFARLANE, and MOORE 813
Morell, Anatol G. See STERNLIEB, MORELL, and SCHEINBERG *934
Morita, Y. See COWSERT, YOUNES, and MORITA *886
Morledge, John. See BRUCE, COBB, KATSURA, and MORLEDGE *881
Morrison, Ashton B. See LYNN, WEBER, BROWN, WELCH, and MORRISON *915
Morrow, Andrew G. See BRAUNWALD, WELCH, and MORROW 35
Moschides, Elly, Stefanini, Mario, Magalini, Sergio I., and **Kistner, Sten A.** Content and composition of the mucoprotein fraction of human serum (seromucoid) in disease, with special reference to hematologic disorders 127
Mudge, Gilbert H. See LEVY, WEINER, and MUDGE 1016
Mudrick, Charles. See BROWN, HOPPER, SAMPSON, and MUDRICK 1465
Muehrcke, Robert C. See POLLAK, FOLLI, PIRANI, REID, and MUEHRCKE *922
Muelheims, Gerhard. See WÉGRIA, MUELHEIMS, GOLUB, JREISSATY, and NAKANO 471
Muenster, Joseph J. See GRAETTINGER, MUENSTER, CHECCHIA, GRISSOM, and CAMPBELL 502
Muirhead, E. E., and **Stirman, J. A.** Hemolysis in uremia: Prevention of intracorpuscular defect by renal tissue *918
Muller, Alex F., Manning, Elizabeth L., and **Riondel, Anne M.** The effect of potassium depletion and repletion on aldosterone excretion *918
Murphy, Anne P. See APRAHAMIAN, VANDERVEEN, BUNKER, MURPHY, and CRAWFORD *875
Murray, John F., and **Kelly, John J., Jr.** The relation of thyroidal hormone level to epinephrine response *918
Myers, Jack D. See MCPHERSON, WERK, MYERS, and ENGEL 1379
Myers, W. P. Laird, and **Lawrence, Walter, Jr.** Studies on the influence of cortisone on serum calcium homeostasis *919
Mylle, Margaret. See GOTTSCHALK, MYLLE, WINTERS, and WELT *898

N

Nakamura, M., Pichette, P., Broitman, S., Bezman, A., Zamcheck, N., and **Vitale, J.** The demonstration of a succinoxidase inhibitor in gastrointestinal mucosa *919
Nakano, Jiro. See WÉGRIA, MUELHEIMS, GOLUB, JREISSATY, and NAKANO 471
Nakasato, Doris. See GITLIN, CORNWELL, NAKASATO, ONCLEY, HUGHES, and JANEWAY 172
Nash, Gerald. See HEYMANN, NASH, GILKEY, and LEWIS 808
Nasralla, Maridee, Gawronska, Eva, and **Hsia, David Yi-Yung.** Studies on the relation between serum and spinal fluid bilirubin during early infancy 1403
Nassau, Kurt. See IBER, NASSAU, PLOUGH, BERGER, MERONEY, and FREMONT-SMITH 1442
Nathan, David G. See WARREN and NATHAN. 1724

Nelson, Don H., and **August, J. Thomas.** Failure of aldosterone to maintain sodium retention in normal subjects and Addisonian patients *919
—. See AUGUST, NELSON, and THORN 1549
Nelson, James H. See ROBBINS and NELSON 153
Newman, E. V. See CROFFORD, CONIGLIO, MENG, and NEWMAN *886
Nichols, George, Jr., and **Nichols, Nancy.** The effect of parathyroidectomy on the availability of bone sodium *920
—. Serial changes in tissue carbon dioxide content during acute respiratory acidosis 1111
—. See NICHOLS and NICHOLS 1676
Nichols, Nancy. See NICHOLS and NICHOLS *920
—, and **Nichols, George, Jr.** The effect of alloxan diabetes and acidosis on the mineral and water content of bone 1676
Nichols, R. L. See KASS, KAITZ, COTRAN, CLOUGH, and NICHOLS *906
Niederman, James C. Experimental inapparent poliomyelitis: Factors involved in reinfection of humans with attenuated poliovirus *920
Nitzberg, Saul, Goldstein, Robert, and **Peyman, Michael A.** Blood coagulation and blood lipids *920
Noall, Matthew M. See KIPNIS and NOALL *906
Noe, Frances E. See LEWIS, LIN, NOE, and KOMISARUK 1061
Nolting, David, Mack, Robert, Luthy, Ernst, Kirsch, Morton, and **Hogancamp, Charles.** Measurement of coronary blood flow and myocardial ribidium uptake with Rb^{86} *921
Noyes, Howard E. See SANFORD and NOYES 1425
Nye, R. E., Jr. See YU, NYE, LOVEJOY, SCHREINER, and YIM 194

O

Odell, J. E. See FRITTS, HARRIS, CLAUSS, ODELL, and COURNAND 99
Ohlson, Margaret A. See HODGES, OHLSON, and BEAN 1642
O'Meara, M. P. See BIRKENFELD, LEIBMAN, O'MEARA, and EDELMAN 687
—. See EDELMAN, LEIBMAN, O'MEARA, and BIRKENFELD 1236
Oncley, J. L. See GITLIN, CORNWELL, NAKASATO, ONCLEY, HUGHES, and JANEWAY 172
Ono, Katsuto. See FREDRICKSON, MCCOLLESTER, and ONO 1333
Oppenheimer, Jack H., Wise, Henry M., and **Lasley, David A.** The role of the thyroid gland in experimental traumatic shock 380
Oratz, M. See ROTHSCHILD, SCHREIBER, ORATZ, and MCGEE 1229
Ordway, Nelson K. See WINTERS, LOWDER, and ORDWAY 640
Orloff, Jack, Wagner, Henry N., Jr., and **Davidson, Douglas G.** The effect of variations in solute excretion and vasopressin dosage on the excretion of water in the dog 458
Osserman, Elliott F. See FISHMAN, RANSOHOFF, and OSSERMAN 1419

P

Pak, Charles. See ARNOLD and PAK *876
Papper, Solomon. See BURG, PAPPER, and ROSENBAUM *882
—. See RANDALL and PAPPER *923
—. See RANDALL and PAPPER 1628
Patel, Dali J. See HECHT, PATEL, and LANGE *900
Paul, William M. See SHEPPARD, TURNER, and PAUL *931
Payne, Rose, and **Rolfs, Mary R.** Fetomaternal leukocyte incompatibility 1756
Pearson, Olof H. See WEST, DAMAST, and PEARSON 341
—. See GALLAGHER, KAPPAS, HELLMAN, LIPSETT, PEARSON, and WEST 794
—. See LIPSETT and PEARSON 1394
Pechet, Maurice M., Carroll, Evelyn L., Mitchell, Mary, and **Wegner, Mary Jo.** Studies of the activities of steroid hormones on electrolyte balance and the constituents of protoplasm: The effects of 16 alpha-hydroxylation of 21-carbon steroids *921
Perez-Santiago, Enrique. See BUTTERWORTH, SANTINI, and PEREZ-SANTIAGO 20
Pert, James H. See ENGLE, WOODS, and PERT *892
Peterson, Ralph E. The influence of the thyroid on adrenal cortical function 736
—. See DAVIS, KLIMAN, YANKOPOULOS, and PETERSON 1783
Peyman, Michael A. See NITZBERG, GOLDSTEIN, and PEYMAN *920
Phelps, Patricia C. See RUBIN, BRANDBORG, PHELPS, and TAYLOR *927
Phillips, Louise Lang, and **Skrodelis, Valija.** The fibrinolytic enzyme system in normal, hemorrhagic and disease states 965
Pichette, P. See NAKAMURA, PICHETTE, BROITMAN, BEZMAN, ZAMCHECK, and VITALE *919
Pineda, Esteban. See CHENG, PINEDA, and STANLEY *884
Pirani, Conrad L. See POLLAK, FOLLI, PIRANI, REID, and MUEHRCKE *922
Plante, Pauline. See BIERMAN, MARSHALL, MAEKAWA, KELLY, and PLANTE *877
Plotkin, Stanley A., Koprowski, Hilary, Hummeler, Klaus, Flack, Agnes, and **Stokes, Joseph, Jr.** Clinical trials of five strains of orally administered attenuated polio virus *921
Plough, Irvin C. See IBER, NASSAU, PLOUGH, BERGER, MERONEY, and FREMONT-SMITH 1442
Polimeros, Demetra P. See LEVITT, HALPERN, POLIMEROS, SWEET, and GRIBETZ 294
—. See LEVITT, LEVY, and POLIMEROS *911
Pollak, Victor E., Folli, Giuseppe, Pirani, Conrad L., Reid, Ross T. W., and **Muehrcke, Robert C.** On the electronmicroscopic recognition and clinical cure of lipoid nephrosis in adults *922
Post, R. S. See ECKEL, POST, and DAVIS *890
Prince, James. See SCHERER, PRINCE, and ST. GEME *928
Prout, Thaddeus E., and **Evans, Iuean E.** Determination of the rate of insulin destruction *in vivo* *922
Pund, Ernest E., Jr. See BERCU, DANFORTH, PUND, and DIETTERT *877

R

Rabau, Ervin. See SZEINBERG, RAMOT, SHEBA, ADAM, HALBRECHT, RIKOVER, WISHNIEVSKY, and RABAU 1436
Raben, M. S., and **Hollenberg, C. H.** Effect of growth hormone on plasma fatty acids *922
Rall, David P. See STABENAU, WARREN, and RALL *933
Rall, J. E. See FEDERMAN, ROBBINS, and RALL 1024

Ramot, Bracha. See SZEINBERG, RAMOT, SHEBA, ADAM, HALBRECHT, RIKOVER, WISHNIEVSKY, and RABAU 1436

Ramsey, Lloyd H., Griscom, John, and **Snell, James.** Ventilatory response to CO_2 in patients with congestive heart failure *923

Randall, Russell E., Jr., and **Papper, Solomon.** The effect of isotonic expansion of the extracellular fluid volume on the natriuretic response to infusions of saline in postoperative patients *923

—, and **Papper, Solomon.** Mechanism of postoperative limitation in sodium excretion: The role of extracellular fluid volume and of adrenal cortical activity 1628

Ransohoff, Joseph. See FISHMAN, RANSOHOFF, and OSSERMAN 1419

Rapoport, Abraham. See STREETEN, RAPOPORT, and WILSON *934

Ratnoff, Oscar D. An enzyme in plasma inactivating Hageman factor *923

Reardon, John. See LOONZY, MALETSKOS, HELMICK, REARDON, COHEN, and GUILD *913

Recant, Lillian, Borowsky, Benjamin A., and **Kessner, David M.** Aminonucleoside glomerulonephritis: Morphologic and metabolic studies *924

Reckers, Lois. See TUNA, RECKERS, and FRANTZ 1153

Redeker, Alan G., Geller, Herman M., and **Reynolds, Telfer B.** Hepatic wedge pressure, blood flow, vascular resistance and oxygen consumption in cirrhosis before and after end-to-side portacaval shunt 606

—. See REYNOLDS, REDEKER, and GELLER *925

Reed, Claude F. See TROUP and REED *937

Rees, Searle. See KUNIN and SEARLE *908

Reeves, John T., Grover, Robert F., Filley, Giles F., and **Blount, S. Gilbert, Jr.** The circulatory dynamics in pulmonary emphysema during treadmill exercise *923

Reichman, Stanley, Davis, William D., Storaasli, John P., and **Gorlin, Richard.** Measurement of hepatic blood flow by indicator dilution techniques 1848

Reichsman, Franz. See COHEN, COLWILL, DAVIS, KESSLER, SHEPARDSON, REICHSMAN, and ENGEL *884

Reid, Ross T. W. See POLLAK, FOLLI, PIRANI, REID, and MUEHRCKE *922

Reiff, Robert H. See DONOHUE, REIFF, HANSON, BETSON, and FINCH 1571

Rejal, Habib. See ABRAMSON, KAHN, TUCK, TURMAN, REJAL, and FLEISCHER 1031

—. See ABRAMSON, KAHN, REJAL, TURMAN, TUCK, and FLEISCHER 1039

Relman, Arnold S. See SCHWARTZ, FALBRIARD, and RELMAN 744

—, **Stewart, William K.,** and **Schwartz, William B.** A study of the adjustments to sodium- and water-retaining hormones in normal subjects *924

Renold, Albert E. See FROESCH, WINEGRAD, RENOLD, and THORN 524

—. See WINEGRAD, SHAW, and RENOLD *943

Reutter, Fritz W. See ZILELI, HAMLIN, REUTTER, and FRIEND 409

Reynolds, Telfer B. See REDEKER, GELLER, and REYNOLDS 606

—, **Redeker, Alan G.,** and **Geller, Herman, M.** Changes in wedged hepatic venous pressure and hepatic blood flow accompanying clinical improvement in cirrhosis *925

Rikover, Mosheh. See SZEINBERG, RAMOT, SHEBA, ADAM, HALBRECHT, RIKOVER, WISHNIEVSKY, and RABAU 1436

Riley, Philip A., Jr. See VILLALOBOS, ADELSON, RILEY, and CROSBY 1

Riondel, Anne M. See MULLER, MANNING, and RIONDEL *918

Rivera, Manuel J. See EPSTEIN, BECK, RIVERA, LEVITIN, and CARONE *892

—. See EPSTEIN, RIVERA, and CARONE 1702

Robbins, Jacob, and **Nelson, James H.** Thyroxine-binding by serum protein in pregnancy and in the newborn 153

—. See FEDERMAN, ROBBINS, and RALL 1024

Roberts, John M. See COOPER, TOUCHSTONE, ROBERTS, BLAKEMORE, and ROSENTHAL 1524

Robertson, Mary C. See ROSE, ROBERTSON, and SCHWARTZ *926

Robin, Eugene D. See GARDNER, ROBIN, TRAVIS, JULIAN, and CRUMP *895

—, **Travis, David M., Julian, Desmond G., Crump, Charles H.,** and **Boshell, Buris.** Blood sugar regulation during sleep in normal and diabetic subjects *925

—, **Whaley, Robert D., Crump, Charles H.,** and **Travis, David M.** Alveolar gas tensions, pulmonary ventilation and blood pH during physiologic sleep in normal subjects 981

Rockney, Robert E. See KLEEMAN, ROCKNEY, and MAXWELL *907

—. See KLEEMAN, MAXWELL, and ROCKNEY 1799

Rolf, Doris. See WHITE and ROLF 8

Rolfs, Mary R. See PAYNE and ROLFS 1756

Rose, Herbert G., Robertson, Mary C., and **Schwartz, Theodore B.** Hormonal influences on intracellular proteolytic enzyme activity *926

Rose, John C. See LILIENFIELD, LASSEN, and ROSE *912

—. See LILIENFIELD and ROSE 1106

Rosenbaum, Jack D. See BURG, PAPPER, and ROSENBAUM *882

Rosenberg, I. N., Athans, J. C., Behar, A., and **Tisch, C. B.** Thiocyanate-dischargeable iodide in the dog thyroid gland *926

Rosenfeld, Robert S. See EIDINOFF, KNOLL, MARANO, KVAMME, ROSENFELD, and HELLMAN 655

—. See HELLMAN, FRAZELL, and ROSENFELD *900

Rosenthal, Otto. See COOPER, TOUCHSTONE, ROBERTS, BLAKEMORE, and ROSENTHAL 1524

Rosenthal, William S. See DREILING, ROSENTHAL, and JANOWITZ *889

Ross, Joseph C., Frayser, Regina, and **Hickam, John B.** A study of the means by which exercise increases the pulmonary diffusing capacity for carbon monoxide *926

Rothschild, M. A., Schreiber, S. S., Oratz, M., and **McGee, H. L.** The effect of adrenocortical hormones on albumin metabolism studied with albumin-I^{131} 1229

Rowe, George G. See CROSLEY, CASTILLO, FREEMAN, WHITE, and ROWE *887

—, **Castillo, Cesar A., Maxwell, George M., Freeman, D. J., White, Douglas H.,** and **Crumpton, Charles W.** Systemic and coronary hemodynamics in normal men and women *927

—. See MAXWELL, CASTILLO, WHITE, CRUMPTON, and ROWE 1413

Rowe, Wallace P. Chronic salivary gland virus infection in children *927
Rubin, Cyrus E., Brandborg, Lloyd L., Phelps, Patricia C., and **Taylor, Hawley C., Jr.** Intestinal similarities between celiac disease and idiopathic sprue *927
Rubin, David, Weisberger, Austin S., Botti, Robert E., and **Storaasli, John P.** Changes in iron metabolism in early chloramphenicol toxicity 1286
Rubini, Joseph R. See CRONKITE, FLIEDNER, RUBINI, BOND, and HUGHES *887
Rubini, Milton E. See AUSTEN, RUBINI, MERONEY, and WOLFF 1131

S

Saha, A. See MAZUR, GREEN, SAHA, and CARLETON 1809
Sahler, Otto D. See THOMAS, LOCHTE, JARETSKI, ASHLEY, and SAHLER *935
St. Geme, Joseph. See SCHERER, PRINCE, and ST. GEME *928
St. George, Shirley, Friedman, Meyer, and **Ishida, Tadashi.** The renal excretion of digoxin in the normal young subject 836
Salmon, William D., Jr. See DAUGHADAY, SALMON, and ALEXANDER *888
Sampson, John J. See BROWN, HOPPER, SAMPSON, and MUDRICK 1465
Sancetta, Salvatore M. See KLEINERMAN, SANCETTA, and HACKEL 285
—. See TRAKS and SANCETTA *936
Sandberg, Avery A., and **Slaunwhite, W. Roy, Jr.** Transcortin: A corticosteroid-binding plasma protein *928
Sanford, Jay P., and **Noyes, Howard E.** Studies on the absorption of *Escherichia coli* endotoxin from the gastrointestinal tract of dogs in the pathogenesis of "irreversible" hemorrhagic shock 1425
Santini, Rafael, Jr. See BUTTERWORTH, SANTINI, and PEREZ-SANTIAGO 20
Savard, Roger M. See SWAN, SAVARD, and KIRKLIN *934
Schachter, David, and **Manis, James G.** Salicylate and salicyl conjugates: Fluorimetric estimation, biosynthesis and renal excretion in man 800
Schedl, Harold P., and **Bartter, Frederic C.** An explanation for and experimental correction of the abnormal water retention in cirrhosis *928
Scheinberg, I. Herbert. See STERNLIEB, MORELL, and SCHEINBERG *934
Scherer, William F., Prince, James, and **St. Geme, Joseph.** ECHO-9 virus exanthema *928
Schloerb, Paul R. The management of uremia by perfusion of an isolated jejunal segment: With observations of the dynamics of water and electrolyte exchange in the human jejunum 1818
Schmid, K., and **MacNair, Margaret B.** Characterization of the proteins of certain postmortem human synovial fluids 708
Schmid, Rudi, Axelrod, Julius, Hammaker, Lydia, and **Swarm, Richard L.** Congenital jaundice in rats, due to a defect in glucuronide formation 1123
Schnaper, Harold W. See FREIS and SCHNAPER 838
Schreiber, S. S. See ROTHSCHILD, SCHREIBER, ORATZ, and McGEE 1229
Schreiner, Bernard F. See YU, NYE, LOVEJOY, SCHREINER, and YIM 194
—. See YU, LOVEJOY, SCHREINER, WALTHER, LEAHY, and STANFIELD *944
Schrier, Stanley L., and **Kellermeyer, Robert W.** Compensatory mechanisms in primaquine-sensitive erythrocytes *928
Schuster, Hilda. See HAMERMAN and SCHUSTER 57
Schwartz, Robert, Fellers, Francis X., Knapp, John, and **Yaffe, Sumner.** The renal response to acetazolamide (Diamox®) during the metabolic acidosis of salicylate intoxication *929
Schwartz, Theodore B. See ROSE, ROBERTSON, and SCHWARTZ *926
Schwartz, William B., Falbriard, Adrien, and **Relman, Arnold S.** An analysis of bicarbonate reabsorption during partial inhibition of carbonic anhydrase 744
—. See RELMAN, STEWART, and SCHWARTZ *924
—, **Falbriard, Adrien,** and **Lemieux, Guy.** The kinetics of renal bicarbonate reabsorption during acute respiratory acidosis *929
Seebohm, Paul M. See BEDELL, WILSON, and SEEBOHM 1049
Seed, J. C., Acton, F. S., and **Stunkard, A. J.** A model for the appraisal of glucose metabolism *930
Segal, Stanton, and **Foley, Joseph.** The metabolism of D-ribose in man 719
—, and **Topper, Yale J.** The biosynthesis and metabolism of L-fucose in man *930
Seldin, Donald W. See CARTER, SELDIN, and TENG *883
—. See MADISON and SELDIN 1615
Shafran, Manya. See DANCIS and SHAFRAN 1093
Shafrir, Eleazar. Partition of unesterified fatty acids in normal and nephrotic syndrome serum and its effect on serum electrophoretic pattern 1775
Shapiro, Alvin P. Relationship of hypertension and renal impairment to experimental chronic pyelonephritis in rats *930
Sharp, John Turner, Griffith, Geraint T., Bunnell, Ivan L., and **Greene, David G.** Ventilatory mechanics in pulmonary edema in man 111
Shaw, Walter N. See WINEGRAD, SHAW, and RENOLD *943
Sheba, Chaim. See SZEINBERG, RAMOT, SHEBA, ADAM, HALBRECHT, RIKOVER, WISHNIEVSKY, and RABAU 1436
Shelokov, Alexis. Hemadsorption in the diagnosis and study of viral infections *931
Shepardson, Charles R. See COHEN, COLWILL, DAVIS, KESSLER, SHEPARDSON, REICHSMAN, and ENGEL *884
Sheppard, Robert H., Turner, V. Marilyn, and **Paul, William M.** A study of the transplacental transfer of thyroid hormones in sheep *931
Sherry, Sol, Lindemeyer, Robert I., Fletcher, Anthony P., and **Alkjaersig, Norma.** The appearance of a fibrinolysin activator in the blood of patients with enhanced fibrinolytic activity *931
—. See FLETCHER, ALKJAERSIG, and SHERRY 1306
Shipp, Joseph C. Inhibition of water reabsorption in the intact perfused renal tubule by ouabain and dinitrophenol: Evidence for active sodium transport *932
Shreeve, Walton W. Pathways of carbohydrate formation in man. I. Isotope distribution in glucose from nondiabetic subjects 999
—, and **Hennes, Allen R.** Pathways of carbohydrate formation in man. II. The effect of diabetes and glucocorticoid administration on isotope distribution in glucose from subjects given 1-C^{14}-acetate 1006

Shulman, Sidney. See BACK, AMBRUS, SIMPSON, and SHULMAN 864
Silberman, Harold R. See WYNGAARDEN and SILBERMAN *944
Silverman, Albert J. See BONDURANT, COHEN, and SILVERMAN *879
Simpson, C. Lenore. See BACK, AMBRUS, SIMPSON, and SHULMAN 864
Sims, Ethan A. H., and **Krantz, Kermit E.** Serial studies of renal function during pregnancy and the puerperium in normal women 1764
Singleton, Elaine. See GOLD, SINGLETON, MACFARLANE, and MOORE 813
Siperstein, Marvin D. See WILSON and SIPERSTEIN *943
—, and **Fagan, Violet M.** Studies on the relationship between glucose oxidation and intermediary metabolism. I. The influence of glycolysis on the synthesis of cholesterol and fatty acid in normal liver 1185
—, and **Fagan, Violet M.** Studies on the relationship between glucose oxidation and intermediary metabolism. II. The role of glucose oxidation in lipogenesis in diabetic rat liver 1196
Skom, Joseph H., and **Talmage, David W.** Nonprecipitating insulin antibodies 783
—, and **Talmage, David W.** The role of nonprecipitating insulin antibodies in diabetes 787
Skoog, William A. See ADAMS, SKOOG, and DAVIS *875
Skrodelis, Valija. See PHILLIPS and SKRODELIS 965
Slaunwhite, W. Roy, Jr. See SANDBERG and SLAUNWHITE *928
—. See SOKAL and SLAUNWHITE *933
Sleisenger, Marvin H. See LIPKIN and SLEISENGER 28
Slingerland, D. W., Dell, E. S., Graham, D. E., Trakas, A. P., and **Burrows, B. A.** Thyroid secretion of nonthyroxine iodine *932
Slobody, Lawrence B. See LANGE, WASSERMAN, SLOBODY, and WENK *908
Sloviter, Henry A. Effects of the intravenous administration of glycerol solutions to animals and man 619
Smith, Joe Ed. See GILES, MICHAEL, and SMITH *896
Smith, Lloyd H., Jr., and **Baker, Faith.** Pyrimidine metabolism in man: The biosynthesis of orotic acid *932
Snell, James. See RAMSEY, GRISCOM, and SNELL *923
Snell, Junius. See LEEVY, ZINKE, CHEY, SNELL, and ENGLISH *910
Sokal, Joseph E., and **Slaunwhite, W. Roy, Jr.** Metabolism of cortisone by malignant prostatic tissue *933
Sorensen, Dale K. See JACKSON, SORENSEN, CRONKITE, and BOND *904
Southam, Chester M. Studies of properdin in cancer patients *933
Spaet, Theodore H. See LALEZARI and SPAET *908
—. See MARCUS and SPAET 1836
Spink, Wesley W. See ABERNATHY and SPINK 219
—. See MELBY and SPINK 1791
Sproule, Brian J., Halden, E. Richard, and **Miller, William F.** A study of cardiopulmonary alterations in patients with sickle cell disease and its variants 486
—. See MITCHELL, SPROULE, and CHAPMAN 538
—. See MITCHELL, SPROULE, and CHAPMAN 1693
Stabenau, James, Warren, Kenneth S, and **Rall, David P.** The role of pH gradients in the distribution of ammonia between blood and cerebrospinal fluid (CSF), brain, and muscle *933
Stacey, Richard R. See GRANT, MACDONALD, EDWARDS, STACEY, and STUECK 1166
Stanfield, C. Alpheus. See YU, LOVEJOY, SCHREINER, WALTHER, LEAHY, and STANFIELD *944
Stanley, Malcolm. See CHENG, PINEDA, and STANLEY *884
Stefanini, Mario. See MOSCHIDES, STEFANINI, MAGALINI, and KISTNER 127
—. See GOBBI and STEFANINI *897
Sterling, Kenneth. Radiothyroxine turnover studies in thyroid disease after therapy 1348
Sternlieb, Irmin, Morell, Anatol G., and **Scheinberg, I. Herbert.** The effect of intravenously administered ceruloplasmin on copper absorption in a patient with Wilson's disease *934
Stewart, William K. See RELMAN, STEWART, and SCHWARTZ *924
Stirman, J. A. See MUIRHEAD and STIRMAN *918
Stokes, James M. See BRICKER, DEWEY, LUBOWITZ, and STOKES *881
Stokes, Joseph, Jr. See PLOTKIN, KOPROWSKI, HUMMELER, FLACK, and STOKES *921
Storaasli, John P. See RUBIN, WEISBERGER, BOTTI, and STORAASLI 1286
—. See REICHMAN, DAVIS, STORAASLI, and GORLIN 1848
Straffon, Ralph A. See BRICKER, STRAFFON, MAHONEY, and MERRILL 185
Streeten, David H. P., Rapoport, Abraham, and **Wilson, William S.** The existence of a large, slowly-exchangeable pool of body sodium *934
Strumia, Max M. See LANGE, CROSBY, DONOHUE, FINCH, GIBSON, MCMANUS, and STRUMIA 1485
Stueck, George H., Jr. See GRANT, MACDONALD, EDWARDS, STACEY, and STUECK 1166
Stunkard, A. J. See SEED, ACTON, and STUNKARD *930
Suguira, Kanematsu. See WROBLEWSKI, MOORE, MANSO, and SUGUIRA *943
Sullivan, John F. See MILLER and SULLIVAN *917
Swan, H. J. C., Marshall, Hiram W., and **Wood, Earl H.** The effect of exercise in the supine position on pulmonary vascular dynamics in patients with left-to-right shunts 202
—, **Savard, Roger M.,** and **Kirklin, John W.** Relation of size of ventricular septal defects to circulatory dynamics *934
Swarm, Richard L. See SCHMID, AXELROD, HAMMAKER, and SWARM 1123
Sweet, Avron Y., Levitt, M. F., and **Hodes, H. L.** The effect of desoxycorticosterone acetate on water and electrolyte distribution 65
—. See LEVITT, HALPERN, POLIMEROS, SWEET, and GRIBETZ 294
Szeinberg, Aryeh, Ramot, Bracha, Sheba, Chaim, Adam, Avinoam, Halbrecht, Izhak, Rikover, Mosheh, Wishnievsky, Shlomoh, and **Rabau, Ervin.** Glutathione metabolism in cord and newborn infant blood 1436

T

Tabor, Herbert, and **Wyngarden, Lillian.** A method for the determination of formiminoglutamic acid in urine 824

—. See HIATT, GOLDSTEIN, and TABOR 829
Talbot, Nathan B. See DRESCHER, TALBOT, MEARA, TERRY, and CRAWFORD 1316
Talmage, David W. See SKOM and TALMAGE 783
—. See SKOM and TALMAGE 787
Taylor, Hawley C., Jr. See RUBIN, BRANDBORG, PHELPS, and TAYLOR *927
Telfer, James D. See DENNIS and TELFER *888
Teller, David N. See LUHBY, COOPERMAN, TELLER, and DONNENFELD *915
Teng, H. C. See CARTER, SELDIN, and TENG *883
Tenney, S. Marsh. See VALTIN and TENNEY *938
Tepper, Ira. See CHESLEY and TEPPER 1362
Terepka, A. Raymond, Toribara, T. Y., and **Dewey, Priscilla A.** The ultrafiltrable calcium of human serum. II. Variations in disease states and under experimental conditions 87
Terry, Mary. See DRESCHER, TALBOT, MEARA, TERRY, and CRAWFORD 1316
Thomas, E. Donnall, and **Lochte, Harry L., Jr.** Studies on the biochemical defect of pernicious anemia. I. *In vitro* observations on oxygen consumption, heme synthesis and deoxyribonucleic acid synthesis by pernicious anemia bone marrow 166
—, **Lochte, Harry L., Jr., Jaretzki, Alfred, III, Ashley, Charles A.,** and **Sahler, Otto D.** Homografts of bone marrow in dogs after lethal total-body radiation *935
Thompson, Janet. See TOBIAN, THOMPSON, TWEDT, and JANECEK 660
Thorn, George W. See FROESCH, WINEGRAD, RENOLD, and THORN 524
—. See AUGUST, NELSON, and THORN 1549
Ting, Er Yi, and **Lyons, Harold A.** The relaxation pressure-volume diagram in pulmonary disease *935
Tisch, C. B. See ROSENBERG, ATHANS, BEHAR, and TISCH *926
Tishkoff, Garson H., McFarland, William, and **Faenza, Louis J.** Urinary excretion of delta-aminolevulinic acid in various hematological disorders *935
Tobian, Louis, Thompson, Janet, Twedt, Robert, and **Janecek, Jeanette.** The granulation of juxtaglomerular cells in renal hypertension, desoxycorticosterone and postdesoxycorticosterone hypertension, adrenal regeneration hypertension, and adrenal insufficiency 660
—, **Martin, Stephen,** and **Eilers, William.** The effect of pH on norepinephrine-induced contractions of arterial smooth muscle *936
Tobias, C. A. See BLANQUET and TOBIAS *878
Tomkins, Gordon M. See LIDDLE, ISLAND, ESTEP, and TOMKINS *912
Tomlinson, Ann S. See JANDL and TOMLINSON 1202
Topper, Yale J. See SEGAL and TOPPER *930
Toribara, T. Y. See TEREPKA, TORIBARA, and DEWEY 87
Touchstone, Joseph C. See COOPER, TOUCHSTONE, ROBERTS, BLAKEMORE, and ROSENTHAL 1524
Trakas, A. P. See SLINGERLAND, DELL, GRAHAM, TRAKAS, and BURROWS *932
Traks, Elmerice, and **Sancetta, Salvatore M.** Effects of "dry" heat exposure on splanchnic flow and resistance in man *936
Travis, David M. See GARDNER, ROBIN, TRAVIS, JULIAN, and CRUMP *895
—. See ROBIN, TRAVIS, JULIAN, CRUMP, and BOSHELL *925
—. See ROBIN, WHALEY, CRUMP, and TRAVIS 981
Troen, Philip. Production of free and conjugated corticosteroids by perfused human placentas *936
—, and **Gordon, Edwin E.** Perfusion studies of the human placenta. I. Effect of estradiol and human chorionic gonadotropin on citric acid metabolism 1516
Troup, Stanley B., and **Reed, Claude F.** Platelet thromboplastic factor: Its chemical nature, *in vitro* activity, and the identification of similar thromboplastic substances in red blood cells *937
Tuck, Samuel, Jr. See ABRAMSON, KAHN, TUCK, TURMAN, REJAL, and FLEISCHER 1031
—. See ABRAMSON, KAHN, REJAL, TURMAN, TUCK, and FLEISCHER 1039
Tuna, Naip, Reckers, Lois, and **Frantz, Ivan D., Jr.** The fatty acids of total lipids and cholesterol esters from normal plasma and atheromatous plaques 1153
Turino, Gerard M. See FISHMAN, TURINO, BRANDFONBRENER, and HIMMELSTEIN *894
—. See FISHMAN, TURINO, BRANDFONBRENER, and HIMMELSTEIN 1071
Turman, George A. See ABRAMSON, KAHN, TUCK, TURMAN, REJAL, and FLEISCHER 1031
—. See ABRAMSON, KAHN, REJAL, TURMAN, TUCK, and FLEISCHER 1039
Turner, V. Marilyn. See SHEPPARD, TURNER, and PAUL *931
Tuttle, Stewart G., and **Figueroa, William G.** Hypercalciuria associated with reduction in corticoid therapy after prolonged administration of prednisone and after bilateral adrenalectomy for Cushing's syndrome *937
Twedt, Robert. See TOBIAN, THOMPSON, TWEDT, and JANECEK 660
Tyler, John M., and **Grape, Birger.** The use of a patient-cycled respirator to evaluate mechanical and central factors in the hypercapnia of emphysema *937

U

Uhr, Jonathan W. Specific desensitization of the delayed hypersensitive state *938
Unger, Roger H., and **Madison, Leonard L.** Comparison of response to intravenously administered sodium tolbutamide in mild diabetic and nondiabetic subjects 627
—. See MADISON and UNGER 631

V

Valtin, Heinz, and **Tenney, S. Marsh.** Respiratory adaptations in induced hyperthyroidism *938
Vandam, Leroy D. See HENNEMAN and VANDAM *901
Vanderhoff, Grace A. See JAFFÉ, VANDERHOFF, LOWY, and LONDON 1293
Vanderveen, James L. See APRAHAMIAN, VANDERVEEN, BUNKER, MURPHY, and CRAWFORD *875
Vandiviere, H. M. Significance of virulence and viability as related to quantitative immunogenic properties of several antituberculosis vaccines *939
Varco, R. L. See KELLY, GOOD, and VARCO *906
Vaughan, John H., and **Harris, Jean.** The rheumatoid factor in rheumatoid arthritis *939

Vesell, Elliot S., and **Bearn, A. G.** Observations on the heterogeneity of malic and lactic dehydrogenase in human serum and red blood cells 672
Vignos, Paul J., Jr. A biochemical study of certain skeletal muscle constituents in human muscular dystrophy *939
Villalobos, Tulio J., Adelson, Edward, Riley, Philip A., Jr., and **Crosby, William H.** A cause of the thrombocytopenia and leukopenia that occur in dogs during deep hypothermia 1
Vitale, J. See NAKAMURA, PICHETTE, BROITMAN, BEZMAN, ZAMCHECK, and VITALE *919

W

Wagner, Henry N., Jr. See ORLOFF, WAGNER, and DAVIDSON 458
Wagner, Robert R. See HOOK and WAGNER *903
Wallach, Stanley. See HENNEMAN, WALLACH, and DEMPSEY *901
Walser, Mackenzie, and **Browder, Ann.** Effect of sulfate on physical state and renal excretion of divalent cations *940
Walters, Denny. See LEWIS, WALTERS, DIDISHEIM, and MERCHANT 1323
Walther, Heinz. See YU, LOVEJOY, SCHREINER, WALTHER, LEAHY, and STANFIELD *944
Warner, E. D. See CARTER and WARNER 70
Warren, J. V. See COMBS, BRYANT, BOGDONOFF, and WARREN *885
Warren, Kenneth S. The differential toxicity of ammonium salts 497
—. See STABENAU, WARREN, and RALL *933
—, and **Nathan, David G.** The passage of ammonia across the blood-brain-barrier and its relation to blood pH 1724
Wasserman, Edward. See LANGE, WASSERMAN, SLOBODY, and WENK *908
Weber, Carl. See LYNN, WEBER, BROWN, WELCH, and MORRISON *915
Webster, Leslie T., Jr., and **Gabuzda, George J.** Ammonium uptake by the extremities and brain in hepatic coma 414
Wedgewood, Ralph J. A new bactericidal system in normal serum and plasma *940
Wegner, Mary Jo. See PECHET, CARROLL, MITCHELL, and WEGNER *921
Wégria, René, Muelheims, Gerhard, Golub, James R., Jreissaty, Robert, and **Nakano, Jiro.** Effect of aortic insufficiency on arterial blood pressure, coronary blood flow and cardiac oxygen consumption 471
Weil, Max H. Morphologic changes in dogs following the production of shock with endotoxin and their comparison to the morphologic changes occurring during shock associated with bacteremia in patients *940
Weiner, I. M. See LEVY, WEINER, and MUDGE 1016
Weisberger, Austin S. Some antileukemic effects of a sulfhydryl inactivator derived from the active principle of garlic (allium sativum) *941
—. See RUBIN, WEISBERGER, BOTTI, and STORAASLI 1286
Weisman, Russell, Jr. See GRIGGS, WEISMAN, and HARRIS *899
Welch, G. H., Jr. See BRAUNWALD, WELCH, and MORROW 35
Welch, Margaret. See LYNN, WEBER, BROWN, WELCH, and MORRISON *915
Weller, John M. Tissue electrolytes in hypertension due to excess sodium chloride administration *941
Welt, Louis G. See GOTTSCHALK, MYLLE, WINTERS, and WELT *898
Wenk, Eugene J. See LANGE, WASSERMAN, SLOBODY, and WENK *908
Werk, Emile E., Jr. See MCPHERSON, WERK, MYERS, and ENGEL 1379
Wessler, Stanford, Ming, Si-Chun, Gurewich, Victor, and **Freiman, David G.** Studies on the nature and incidence of Buerger's disease *941
West, Charles D., Damast, Barbara, and **Pearson, O. H.** Adrenal estrogens in patients with metastatic breast cancer 341
—. See GALLAGHER, KAPPAS, HELLMAN, LIPSETT, PEARSON, and WEST 794
Whaley, Robert D. See ROBIN, WHALEY, CRUMP, and TRAVIS 981
Wheeler, Henry O., Meltzer, Jay I., Epstein, Robert M., and **Bradley, Stanley E.** Hepatic storage and biliary transport of bromsulfalein in dog and man *942
Whipple, N. E. See HUFFMAN, HLAD, WHIPPLE, and ELRICK 369
—. See ELRICK, HLAD, WHIPPLE, and ARAI *891
White, Arthur C., and **Knight, Vernon.** Inhibition of mycobacteriophage propagation by fresh serum *942
White, Douglas H., Jr. See CROSLEY, CASTILLO, FREEMAN, WHITE, and ROWE *887
—. See ROWE, CASTILLO, MAXWELL, FREEMAN, WHITE, and CRUMPTON *927
—. See MAXWELL, CASTILLO, WHITE, CRUMPTON, and ROWE 1413
White, H. L., and **Rolf, Doris.** Comparison of various procedures for determining sucrose and inulin space in the dog 8
White, J. Earle, and **Engel, Frank L.** The influence of adrenocorticotrophic hormone (ACTH) on the release of nonesterified fatty acids from rat adipose tissue *in vitro* *942
—, and **Engel, Frank L.** Lipolytic action of corticotropin on rat adipose tissue *in vitro* 1556
Wilber, Joseph, A., and **Brust, Albert A.** The circulatory and metabolic effects in man of histamine, Mecholyl®, tetraethylammonium and atropine in the presence of circulating epinephrine and nor-epinephrine 476
Wilcox, Robert H. See GLENCHUR, HAGLUND, HALL, and WILCOX *897
Williams, Margaret L. See KAYE, WILLIAMS, and BARBERO 752
Wilson, Jean D., and **Siperstein, Marvin D.** The mechanism of the protein-sparing effect of glucose *943
Wilson, William R. See BEDELL, WILSON, and SEEBOHM 1049
Wilson, William S. See STREETEN, RAPOPORT, and WILSON *934
Winegrad, Albert I. See FROESCH, WINEGRAD, RENOLD, and THORN 524
—, **Shaw, Walter N.,** and **Renold, Albert E.** Depression by growth hormone of the phosphogluconate oxidative pathway in adipose tissue *943
Winkler, Charles H. See DONALD, WINKLER, and HARE 1100

Winters, Robert W., Lowder, John A., and **Ordway, Nelson K.** Observations on carbon dioxide tension during recovery from metabolic acidosis 640
—. See GOTTSCHALK, MYLLE, WINTERS, and WELT *898
Wise, Henry M. See OPPENHEIMER, WISE, and LASLEY 380
Wisham, Lawrence H. See DAVISON and WISHAM 389
Wishnievsky, Shlomoh. See SZEINBERG, RAMOT, SHEBA, ADAM, HALBRECHT, RIKOVER, WISHNIEVSKY, and RABAU 1436
Wisseman, Charles L., Jr. See GREISMAN and WISSEMAN *898
Wolfe, Stanley, J., Brin, Myron, and **Davidson, Charles S.** The effect of thiamine deficiency on human erythrocyte metabolism 1476
Wolff, J. See AUSTEN, RUBINI, MERONEY, and WOLFF 1131
—, and **Austen, Frank K.** Salicylates and thyroid function. II. The effect on the thyroid-pituitary interrelation 1144
Wolfman, Morris. See GROSSMAN, MINES, GOLDMAN, and WOLFMAN *899
Wood, Earl H. See SWAN, MARSHALL, and WOOD 202
Wood, J. Edwin, and **Eckstein, John W.** A tandem forearm plethysmograph for study of acute responses of the peripheral veins of man: The effect of environmental and local temperature change, and the effect of pooling blood in the extremities 41
Wood, John C. See CONN and WOOD *885
Woods, James W. Susceptibility of rats with hormonal hypertension to experimental pyelonephritis 1686
Woods, Kenneth R. See ENGLE, WOODS, and PERT *892
Woodward, Hiram, Jr. See CRAIG, MILLER, MACKENZIE, and WOODWARD 118
Wrobléwski, Felix. See MANSO and WROBLÉWSKI 214
—, **Moore, Alice E., Manso, Carlos,** and **Suguira, Kanematsu.** Mechanisms of body fluid enzyme alterations in the absence of tissue necrosis *943
Wyngaarden, James B., Blair, Alberta E., and **Hilley, Linnelle.** On the mechanism of overproduction of uric acid in patients with primary gout 579
—, and **Silberman, Harold R.** On the regulation of purine nucleotide synthesis and uric acid production in gout *944
Wyngarden, Lillian. See TABOR and WYNGARDEN 824

Y

Yaffe, Sumner. See SCHWARTZ, FELLERS, KNAPP, and YAFFE *929
Yahr, Melvin D. See BRIDGES, CLARK, and YAHR 763
Yankopoulos, Nicholas A. See DAVIS, KLIMAN, YANKOPOULOS, and PETERSON 1783
Yim, Bernard J. B. See YU, NYE, LOVEJOY, SCHREINER, and YIM 194
Younes, A. A. See COWSERT, YOUNES, and MORITA *886
Yu, Paul N., Nye, R. E., Jr., Lovejoy, Frank W., Jr., Schreiner, Bernard F., and **Yim, Bernard J. B.** Studies of pulmonary hypertension. IX. The effects of intravenous hexamethonium on pulmonary circulation in patients with mitral stenosis 194
—, **Lovejoy, Frank W., Jr., Schreiner, Bernard F., Walther, Heinz, Leahy, Robert H.,** and **Stanfield, C. Alpheus.** Circulatory dynamics of aortic stenosis *944

Z

Zalesky, M. See CAREY, BRAUDE, and ZALESKY 441
—. See BRAUDE, ZALESKY, and DOUGLAS *880
Zamcheck, N. See NAKAMURA, PICHETTE, BROITMAN, BEZMAN, ZAMCHECK, and VITALE *919
Zierler, Kenneth L. Hyperpolarization of muscle membrane by insulin *944
Ziff, Morris. See LOSPALLUTO, LEWIS, and ZIFF *913
Zileli, M. Seref, Hamlin, James T., III, Reutter, Fritz W., and **Friend, Dale G.** Evaluation of catechol amine levels in renal insufficiency 409
Zinke, Myra R. See LEEVY, ZINKE, CHEY, SNELL, and ENGLISH *910
Zinn, M. See FRANK, JORDAN, KIEFHABER, and ZINN *894
Zuelzer, Wolf W. See BROWN and ZUELZER 332

SUBJECT INDEX

(Page numbers marked with an asterisk refer to abstracts)

A

Acetate
ammonium, toxicity of, 497–501
and hyaluronate precipitation, 59–63
radiolabeled in diabetic glucose study, 1006–1014, 1196–1201
Acetazolamide
and acidosis
metabolic, 744–750, 929*
respiratory, 883*
and bicarbonate excretion, 745–748
and blood ammonium-nitrogen concentrations, 417
and carbonic anhydrase, 883*, 895*
and potassium excretion, 552, 553
and thyroid function, 895*
Acetyl-CoA, and fatty acid synthesis, 1192
Acetylcholine
in paroxysmal nocturnal hemoglobinuria, 900*
and pulmonary circulation in hypoxia, 99–108
Acetylphenylhydrazine, and glutathione, 1438–1440
and red cell alteration, 1213
Acidity, titrable of urine
in respiratory acidosis, 883*
and sodium diuresis, 917*
Acidosis
and acetazolamide, 744–750, 883*, 929*
and ammonia distribution, 933*, 1726
diabetic, 640–644
and bone electrolyte concentration, 1679–1685
and epinephrine responsiveness, 879*
and fructose, 760, 761
and glucose, 760–761, 1006–1008, 1013–1014
in hypoxia, 252
and lactate, 760, 1586
and levarterenol responsiveness, 879*
and mercurial diuresis, 1016–1022
and plasma carbon dioxide, 252, 640–644, 1111–1121
and plasma electrolytes, 1678–1685
and potassium exchange for hydrogen, 329, 330
and renal chloride losses, 1671–1674
respiratory, 879*, 881*, 883*
carbonic anhydrase in, 930*
and cerebral bicarbonate, 1118–1121
hypochloremia in, 1667–1675
and renal bicarbonate reabsorption, 929*, 930*
of sleep, 896*, 988
serum sodium and potassium in, 1250
uremic, 640–644
Acromegaly
osteoporosis and calcium uptake, 891*
and serum sulfation factor, 888*
ACTH. *See* Adrenocorticotropic hormone
Actomyosin, and contractibility of heart bands, 465–469
Addison's disease. *See* Adrenal gland, insufficiency
Adenine
conversion to uric acid, 583–587
excretion, in leukemia, 875*
Adenocarcinoma, prostatic and cortisone, 933*
Adenosine
diphosphate, in ribose conversion to glucose, 652
and plasma iron, 1812–1814
triphosphate, 652
and aminonucleoside glomerulonephritis, 924*
and blood storage, inosine, 1485–1492
and glucose, 916*, 1191, 1440
in glucuronide formation, 875*
and hexokinase activity, 1440
inhibition by purine compounds, 944*
and phosphate energy transfer, 940*
protein-sparing effect, 943*
Adenylic acid, plasma iron response to, 1812–1814
Adrenalectomy
and estrogen excretion, 347
juxtaglomerular indices, 665, 666, 669
and leukocyte response to Shigella toxin, 1102–1104
and steroid formation in hypertension, 1525, 1535
Adrenal gland
cortex
and ACTH, 342, 889*
and albumin metabolism, 1229–1234
in aldosterone secretion, 1786–1788
and castration, 348
in congenital hyperplasia, 889*
cortisol secretion by, 741, 820
and endotoxin, 891*, 1428
enzymatic systems in adrenogenital syndrome, 1342–1347
and estrogen excretion, 347, 348
function in shock due to infection, 1791–1797
and hirsutism, 794–798
in hyperkalemia, 1321
and juxtaglomerular granulation, 665, 667–670
and 17-ketosteroids excretion, 741, 1087
and postoperative sodium excretion, 1631, 1638
and renal function in pregnancy, 1772
steroid formation by, in hypertension, 516, 1524–1535
and stress, 820
and thyroid hormone, 736–742
hyperfunction
calcium, phosphorus and nitrogen exchanges, 937*
in hirsute women, 798
tubular glucose reabsorption, 528
insufficiency, 239–241, 665, 688, 689, 1238
and cortisol, 912*, 1631, 1638
and pernicious anemia, 916*, 917*
and renal electrolytes, 921*, 923*, 1631, 1637
medulla
bilirubin crystals, in jaundice, 1127
salicylate uptake, 1148
weight, 1533
and diastolic blood pressure, 1535
Adrenocorticotropic hormone
and adipose tissue fatty acid, 942*, 1556–1562
and aldosterone release, 240, 241
blood ammonium-nitrogen concentrations, 417
and bone marrow homografts, 935*
and brucella endotoxin effects, 226, 227
and congenital adrenal hyperplasia, 889*
and cortisol formation in hypertension, 1532
eosinopenic response to in pantothenic acid deficiency, 1653
and estrogen production, 342–349
excretion, and SU-4885, 912*
and formiminoglutamic acid excretion, 830
genetic and intrauterine influences on production, 905*
and glucose reabsorption, 530
lipolytic action of, 1556–1562
in nephrotic syndrome, 909*
and plasma cortisol, in infection shock, 1793–1795
and ribose synthesis, 1458
and steroid formation by adrenal tissue, 1529–1532
and urinary cortisol metabolites in stress, 813–822
Afibrinogenemia, in pregnancy, 965–972
Agammaglobulinemia, serum protein changes in, 893*
Age
and acid mucopolysaccharide content of dermis, 860
and adrenal cortex function, 795, 1525, 1526
and airway resistance, 1279–1285
and albumin half-life in malnutrition, 683
and anaerobic metabolism, 1595, 1596
and ammonium uptake, 415–418
in anemia, 1179, 1181
and arteriosclerosis, 392

Age (*cont'd*)
of atheromas, and fluorescence, 164
and calcium metabolism in gargoylism, 145
and capillary blood volume, 1064–1069
and cardiopulmonary changes in sickle cell disease, 488, 489
and cerebrospinal fluid, 1420
of clots, and effect of plasmin, 864–870
of erythrocytes, 899*
and inosine, 1293–1296
and osmotic resistance, 1542–1547
and glucuronide conjugation, 333–339
and glutathione stability, 1438, 1439
and hemodynamics, 286, 927*
and hypertension, 1526
pulmonary, 203, 204
and insulin antibodies, 788, 791
and lipoprotein metabolism, 172–184
and lung
diffusion capacity, 540, 542, 569, 570, 598, 600, 603, 1064–1069
volume, 1279–1285, 1051, 1054
and protein
malnutrition, 682–686
in spinal fluid, 1407, 1408
and radiothyroxine turnover studies after therapy, 1351, 1352
and salivary gland virus infection, 927*
and sulfation factor, 888*
and urinary steroids, 1089–1091
of xanthine oxidase and activity, 1814

Agglutination
of erythrocytes, 905*
and antibody destruction, 1216, 1217, 1225–1226
leukocytes, 1216, 1217
in identical twins, 908*
in pregnancy, 1757
and penicillin exposure, 912*

Alanine
plasma concentration, 1712–1723
and urinary excretion, 1618
of nondialyzable solids, 318, 320

Albumin
antinatriuretic effects, 236, 237, 241
and central venous pressure, 926*
cerebrospinal fluid concentration, 1419–1424
cortisol binding by, 519–523
extravascular space, 1233
in kidney, 1110
febrile response to injection, 894*
and globulin ratio, 713
after blood and casein ingestion, 991–997
in hypovolemia, postphlebotomy, 236–238, 241
and isoprophyl methyl phosphonofluoridate (sarin), 362
and lipoprotein ratios, of fatty acids, 1775–1782
metabolism, 682–686
and adrenocortical hormones, 1229–1234
and dietary protein, 1443–1451
and triiodothyronine, 1448, 1449 1451
and methionine, placental transfer, 1095
plasma concentration. *See* Plasma, albumin
and protein intake, 1445–1451
malnutrition, 682–686
serum concentration. *See* Serum, albumin
in synovial fluid, postmortem, 711–717
synthesis, 1231, 1233
and thyroxine, 154, 157
vitamin B_{12} binding capacity, 557–566

Alcohol
batyl, hemopoietic effect of, 913*
and cerebral blood flow, 763–771
and anesthesia, 286–288
and endotoxin response, 223
and portacaval shunt, 615–617
and thiamine deficiency, 1480
and uric acid production, 580

Aldosterone
antagonist, spirolactone, 917*
and blood pH, 1550
and corticosterone binding, 514, 517
and cortisol binding, 513, 890*
and electrolytes, 1551
postphlebotomy, 239
secretion
after caval constriction, 1783–1790
after dextran, 1786
in hypovolemia, 236–241
and sodium excretion, 920*, 1549–1554, 1637, 1638
urinary excretion, 238–241, 918*
and congenital adrenal hyperplasia, 889*, 890*

Alkaline phosphatase. *See* Phosphatase, alkaline

Alkalosis
and ammonia
tissue uptake, 1727
toxicity, 500
and bicarbonate concentration, 252, 1021
in diabetes, 640–644
extracellular, and DCA, 68, 69
hypokalemic, 917*
and ACTH, 342
metabolic, 1017–1019
and gastric disorder, 1653
respiratory, 933*
and hepatic coma syndrome, 500
and lactic dehydrogenase, 252
serum sodium concentration, 1250, 1251
and spirolactone, 917*
and urinary excretion after amino acid, 1623

Allergy
and antituberculosis vaccines, 939*
and diphtheria antitoxin, 907

Allicin, and sulfhydryl compounds, 941*

Aluminum powder breathing, 1750, 1752

Alveolus
carbon dioxide tension during sleep, 982–984
diffusing capacity, 394–407
of helium and nitrogen, 567–573
in lung disease, 591–604
nitrogen clearance, 569, 570
and oxygen breathing, 306–313
in pulmonary edema, 114–116

American Society for Clinical Investigation
proceedings of fiftieth annual meeting, 872, 873
papers presented, 874*–945*

Amino acids
See also under specific names
plasma
and dietary protein uptake, 1712–1717
in sprue, 21–26
in protein synthesis, 943*
fetal, transfer from mother, 1094
and insulin, 906*
in uremia, 890*
and urinary excretion, 1615–1626
of glucuronic acid, 1125
nondialyzable solids, 318, 320

α-Amino-n-butyric acid
muscle penetration, 906*
plasma concentration, 1714

o-Aminophenyl glucosiduronic acid, formation in jaundice, 1124, 1125

Aminophyllin
compliance and resistance changes after, 114
in emphysema, and cardiac output, 884*
and water excretion, in adrenal and pituitary insufficiency, 1799–1808

Ammonium
bicarbonate, 1725–1727
blood concentration. *See* Blood, ammonium concentration
blood-brain-barrier passage and blood pH, 1724–1728
chloride, 1725–1727
ammonium excretion after, 1617–1626
and carbon dioxide tension, 643
in diabetes, 1679
electrolyte excretion after, 297–300
potentiation of mercurials, 1021
excretion, 1617–1626
and acetazolamide, 929*
after amino acid, 1624–1626
after calcium gluconate, 298, 299
after carbon dioxide breathing, 1669–1672
after neomycin, 893*
and renal enzymatic adaptation, 1615–1626
in respiratory acidosis, 883*
and spirolactone, 917*
and uric acid stones, 901*
hydroxide, 1726, 1727
metabolism, 910*
in hepatic disease, 414–423
sulfate fractionation of plasma, 151
toxicity of salts of, 497–501

Amylase
blood concentration and carbohydrate utilization, 889*

Amyloidosis
amyloid composition, 882*, 883*
antibody, globulin, and hexosamine in, 846–857
serum and seromucoid hexosamines, 53, 55
Anasarca
in nephrotic children, 183
and thiamine deficiency, 1480
Anastomosis
in mitral stenosis and hexamethonium, 200
portacaval
hepatic hemodynamics in, 608, 609
and spider angiomata, 617
Δ^4-Androstene-3,17-dione
absorbance in sulfuric acid, 1343
Δ^4-Androstene-11β-ol-3,17-dione
and steroid formation, 1535
Androsterone
and corticosterone binding, 514, 517
production of, 905*
in hirsutism, 795–798
Anemia
aplastic, and chloramphenicol toxicity, 1286–1292
blood transfusions for, 77–81
Cooley's, 936*
formiminoglutamic acid excretion in, 830, 915*
hemolytic, 883*, 936*
and erythrocyte glucose-6-phosphate, 1176–1183
and hyperkalemia, 701
mucoprotein fractions in, 129
"primaquine-type" drug-induced, 928*
hypochromic and hemorrhagic diathesis, 81
hypoplastic, 936*
hyporegenerative, 896*
iron deficiency, 129, 216, 833–835
macrocytic, of pregnancy, 915*
megaloblastic, 896*, 915*
folic acid deficiency, 916*, 917*
pernicious, 129, 916, 917*, 936*
pernicious, 129, 916*, 917*, 936*
bone marrow, *in vitro* studies, 166–171
sickle cell, cardiopulmonary alteration, 486–494
in uremia, 918*
urobilinogen and mesobilifuscin ratio in, 896*
Anesthesia
antidiuretic effect, 875*
and cardiac output, 899*
and cerebral blood flow, 285–292
pressure responses to stimuli, 763–770
and glomerular filtration in kidney transplant, 187, 188, 192
and hypotension, 289–292
and lactic acid concentrations, 901*
and muscle metabolism, 901*
and postoperative sodium excretion, 1629
Angina pectoris, and coronary circulation, 898*
spider, and portacaval anastomosis, 617
Anorexia, and isopropyl methyl phosphonofluoridate (sarin), 353, 354
Anoxemia, and spinal anesthesia, 289–292
Antibiotics
See also specific antibiotics
in necrosis and uremia, 908*
resistance to prophylactic, 897*
Antibody
in amyloidosis, 846–857
and antigen, 854, 855, 1220
and biological properties of reagin, 907*
and endotoxin uptake, 455–457
erythrocyte destruction by, 1202–1226
and insulin, 783–785, 895*
precipitable to bovine plasma albumin, 896*
in pregnancy, 1757–1759
production, 892*
and delayed skin reactivity, 938*
transplacental exchange of, 895*
serum, 455–457, 854–857
streptokinase, assay for, 1314, 1315
Antigen
in amyloidosis, 849, 850, 854, 855
in erythrocyte sequestration, 1220
leukocyte
heredity factors, 908*, 1758–1762
nonbacterial, and fever, 894*
plasma clearance, rates of, 1306–1314
Antihemophilic factor, 1323–1330
and thromboplastin antecedent deficiency, 148, 151
Antithrombin, 1323–1330
and heparin cofactor, 1328, 1329
Antitoxin, diphtheria
in allergy, 907*
in synovial fluid, 711
Aorta
acid mucopolysaccharide content, 858, 861
atherosclerosis, 162, 163
coarctation, 882*, 900*
platelet count and hypothermia, 2–6
pressure in, 471–475
and left atrial pulse pressure, 35–39
and tetraethylammonium, after norepinephrine, 484
Aortic valve
insufficiency, 471–475
and mitral regurgitation, 38
stenosis, circulatory dynamics of, 944*
Arabinose, and insulin, 732, 824
Arachidonic acid, 1155
Arginine
intake, and plasma concentration, 1712–1714, 1717
renal response to, 318, 320, 458–463
Arterenol. *See* Norepinephrine
Arteriosclerosis
cerebral, 288, 1238
and degenerative joint disease, 392
and hypertension, 1688–1692
gouty, 909*
and plasma polysaccharides, 962–964
rheumatoid
gamma globulin factor, 913*
rheumatoid factor in, 939*
seromucoid galactosamine-glucosamine ratio, 53
synovial fluid, hyaluronate concentration, 63
Ascites
ammonia concentration in, 991–997
and nitrogen ratios, 416–418
in nephrotic children, 183
and serum albumin, 925*
tumor, and ribose excretion, 1458, 1459
Asian influenza, properdin concentration in, 877*
Asparagine, and ammonium excretion, 1618
Aspartic acid
intake, and plasma concentration, 1712–1717
urinary excretion, 318, 320
after ammonium chloride, 1619
Asthma
and pulmonary diffusion, 598, 601
in obesity, 1054
Atherosclerosis
of Buerger's disease, 941*, 942*
lesions, localization, 161–165
plaques, cholesterol esters and fatty acids in, 1153–1164
Atrium
pressure
and acetylcholine, 105
and mitral stenosis, 38, 39
and norepinephrine, 37–39
septal defect, in left-to-right shunt, 203, 204
Atropine
and isopropyl methyl phosphonofluoridate (sarin), 355, 356, 367
pressure effects, 482–484
and norepinephrine, 476
Autotransplantation. *See* Transplant
Azotemia
and amyloidosis, 855
and chloramphenicol toxicity, 1289–1292
edematous, seromucoid hexosamines, 54
prerenal, and blood ammonia, 996
in pyelonephritis, and hypertension, 930*
and serum calcium, ultrafiltrable, 96

B

Barbital, and cortisol binding, 520–523
Barbiturate
anesthetic effects, 1432
and cerebral hemodynamics, 286
and thiamine deficiency, 1480
Bacteriuria, asymptomatic, in pregnancy, 906*
Benzoic acid, albumin binding, 711, 715, 716
Bicarbonate
and blood coagulation, 75, 76
concentration, 929*, 1238–1242
and alkalosis, 252, 1021
cerebral, 1118–1121
in tubular fluid, 748–750

Bicarbonate (*cont'd*)
and electrolyte excretion, 297–300
excretion
and acetazolamide, 745–748, 929*
and lactic dehydrogenase system, 252
and mercurial diuresis, role of pH in, 1020–1022
plasma concentration. *See* Plasma, concentration
and purine compounds, 944*
reabsorption, 929*, 930
and carbonic anhydrase, 744–750
in respiratory acidosis, 929*, 930*, 1118–1121
serum concentration. *See* Serum, bicarbonate
toxicity, 497–501
Bile
bilirubin, sulfate conjugate, 904*
components, in jaundice, 1124–1129
excretion
after calcium, in gargoylism, 141–143
and glutathione reductase, 217
and hepatic storage, 942*
hemoglobin conversion to pigment, 887*
obstruction and hepatocellular disease, 884*
Bilirubin
excretion in jaundice, 1124–1129
glucuronide formation, 338, 875*, 904*
congenital defect in, 1123–1129
and uridine-diphosphate-glucuronic acid, 334
hemoglobin conversion mechanism, 887*
and isopropyl methyl phosphonofluoridate (sarin), 362
and liver function, 904*, 991
neonatal, 335
serum. *See* Serum, bilirubin
spinal fluid-serum ratio, 1403–1411
in Wernicke's encephalopathy, 1479
Blood
ammonia concentration, 422, 933*, 934*, 990–997
after blood and casein ingestion, 990–997
and cerebrospinal fluid, 933*, 934*
in liver disease, 417–419, 992, 997
and nitrogen ratio, 417–423
and prerenal azotemia, 996
and toxicity, 498–501
amylase concentration, 889*
arterial
composition, 250, 1694–1696
gases, 101–105, 488–494, 1053, 1381–1390
glucose, 525–528, 632–639
ketones, 1381–1390
pressure, 286–292
arteriovenous ammonia differences, 417–423
brain-barrier
and albumin permeability, 1419, 1422
calcium clearance, 146
carbon dioxide, 286–292, 894*
catechols in renal insufficiency, 413
coagulation, 920*, 921*
accelerator activity assays, 70–85
defect in classical hemophilia, 897*
and fibrinolytic enzyme system, 968, 1323–1330
in glass, 911*, 920*, 923*, 924*
grading of clots, factors for, 867
and Hageman factor. *See* Hageman factor
and hyperkalemia, 699–707
and isopropyl methyl phosphonofluoridate (sarin), 362
after methionine and/or vitamin K, 71–85
and phosphatides, 1836–1847
and plasmin, 866–870
in silicone, 911*, 920*
and sodium bicarbonate, 75, 76
and streptokinase lysis, 905*
in thromboplastin antecedent deficiency, 148–152
electrolyte concentration, 756, 1632
and aldosterone, 1551
in respiratory acidosis, 883*
endotoxin, persistence in, 448–450
in shock, 1428
and exercise. *See* Exercise
fatty acids, nonesterified, in chylomicron metabolism, 1333–1341
fetomaternal incompatibility, 1756–1763
flow of brain and anesthesia, 286–292, 901*
flow in patent ductus arteriosus, 210, 211
fructose, 121–125, 754–757, 760, 761
gas in high spinal anesthesia, 286–292
in gastrointestinal tract, 417–421, 996
glucose concentration, 121–125, 930*, 999–1014, 1381–1384, 1389, 1390
and anesthesia, 289–292, 901*
and cortisol, 529
in glucosuria, steroid-induced, 525–528
and glycerol, 625
and insulin, 632–639, 723, 789–792, 1385
and isopropyl methyl phosphonofluoridate (sarin), 362
and protein intake, 1718
and renal phosphate clearance, 369–378, 891*, 892*
after ribose infusion, 654, 724, 725
and starvation, 118–126
synthesis, 999–1014
and tolbutamide, 627–630
glutathione, 1436
reductase activity, 216
glycine concentration in sprue, 25
groups, in antibody-erythrocyte destruction study, 1202–1226
17-hydroxycorticoid concentration after SU-4885, 912*
ketone bodies, 119
in diabetes, 1008, 1009, 1678, 1679
after cortisone, 1384, 1385, 1389–1392
lactate, 244–252, 257, 265, 267, 289–292, 761, 901*
in heart failure, 1579, 1580
and hexose, 757
and pyruvate, in hypoxia, 244–253
lipids, 920*
and dietary fats, 908*
filtration and deposition, 1163, 1164
loss, 232
and antinatriuresis, 240, 241
and lumen of jejunum, water exchange, 1825, 1826
malic acid, 121–125
manganese movement from, 1270–1274
oxygen. *See* Oxygen
pH
and ammonia transfer, 1724–1728
and anesthesia, 286–292
and cerebrospinal fluid, 933*
in metabolic acidosis, 640–644, 760, 761
in pulmonary disease, 1169, 1174
and respiration, 1693–1700
in sleep, 981–989
and toxicity, 498–501
phosphate, 724, 731
phosphocreatine, 901*
placental, protein-bound iodine, 157
platelet, phospholipid fractions, 1836–1847
pooling, in extremities, 41–49
potassium concentration, 699, 702, 706, 707, 910*, 1551
pyruvate, 121–125, 248, 252, 257, 265–267, 724, 731, 1579, 1580
red cell mass in hypertension, 426–429
ribose disappearance from, 720–724, 731
sodium concentration, 1551, 1632
and clearance in joint disease, 392
storage
and Component B, 974–989
and inosine, 978, 980, 1485
sugar in diabetes. *See* Diabetes
temperature and arteriovenous oxygen difference, 1035–1037
transfusions, 151
and chloramphenicol toxicity, 1289–1292
and leukoagglutinins, in pregnancy, 1757–1759
red cell destruction after, 887*
urea nitrogen, 1551
and calciferol, 892*, 893*, 1703
in hypercalcemia, 1703, 1709
and protein intake, 1718
in renal disease, 89, 90, 809
venous
and aldosterone secretion, 232, 240
forearm, pressure-volume curves, 42–49
hepatic, 3–7, 210
and hypothermia, 3–7, 44–46, 48, 49
oxygen, 101, 210, 246–249, 489–491, 542, 555
portal, 3–7

volume, 492–494, 1061–1069, 1693–1700
and acetylcholine, 102–104, 107
after albumin infusion and phlebotomy, 236, 237, 241
forearm, 42–49, 415, 958–961
and levarterenol, 425–429
in Valsalva maneuvers, 1467, 1473
Blood-brain-barrier, ammonia passage across, 1724–1728
Blood flow
and acetylcholine, 99–108
adrenal, after caval constriction, 1784–1789
after dextran, 1786, 1787
and aminophyllin, 884*
and aortic pressure, 36
and arterial occlusion, 1045, 1046, 1080, 1081
and atrial septal defect, 203, 207
capillary, 525–528, 1061–1069
and murine typhus toxin, 899*
and carbon dioxide breathing, 894*
cerebral, 421
and anesthesia, 286–292, 763–770
coronary, 884*, 921*
and aortic insufficiency, 471–475
in fibrillation, 877*
and nitroglycerin, 898*
sex differences, 927*
in tachycardia, 1414–1417
cutaneous, and thermal pain, 33
dynamics, 934*
fibrinolysin activator, in stress, 931*
forearm, 41–49, 421, 838–845, 956–961
and temperature, 44, 1032, 1040–1048
hepatic, 608, 609
and cirrhosis, 925*
and ketone metabolism, 1386, 1387
measurement, comparison of methods, 1848–1856
and octanoate with glucose, 1380, 1381
and oxytetracycline, 910*
in hyperthyroidism, 938*
and hypothermia, 1–7
in hypoxia, 1080, 1081
in mitral stenosis and hexamethonium, 196–200
myocardial, 877*
peripheral, 884*
failure due to infection and cortisol metabolism, 1791–1798
portal, 3–7
pulmonary, 99–108, 935*
collateral, 894*, 1071–1085
and digital clubbing, 894*, 1072, 1084
after exercise, 205, 209, 1693–1700
renal, 289–292
and glomerular filtration rate, 878*
and traumatic shock, 387
shunts, 210
left-to-right, 202–212
peripheral arteriovenous, 493
portacaval, 606–617
splanchnic, and ambient temperatures, 936*
spleno-portal transit times, 1850–1852
and streptokinase clearance, 1314
and thyroidal clearance, 387
and venous congestion in limbs, 46–49
in ventricular septal defect, 203, 207, 935*
Blood pressure. *See* Pressure, arterial
Body
composition, 910*
in cirrhosis of liver, and edema, 687–697
and serum sodium concentration, 1236–1254
lactic dehydrogenase system and muscular work, 1588
lean mass after jejunal perfusion, 1824
manganese, 1275, 1276
pathway, *in vivo*, 1298
potassium stores after loading, 1316–1321
size
and airway resistance, 1279–1285
and hypertension after shunt, 203, 204
and nitrogen displacement by oxygen, 308
and renal clearance, in pregnancy, 1771
water. *See* Water, body
Bone
calcium, 1357–1360
in gargoylism, 139–146
and parathyroid, 95
and desoxycorticosterone, 67
in diabetes, alloxan, 1676–1685
electrolytes, 67
in acidosis, 1676–1685
in hypercalcemia, 95, 96
marrow
in chloramphenicol toxicity, 1290–1292
deoxyribonucleic acid synthesis, 168–171
erythroid, and phlebotomy, 884*
hematopoietic cells, 1564–1575
homografts, after lethal radiation, 935*
injury, and urinary aminolevulinic acid, 936*
megakaryocytes, and hypothermia, 2, 5–7
in myelofibrosis, 580
in pernicious anemia, 166–171
mineral content, 1357–1360
in respiratory acidosis, 1115–1117, 1121
sodium concentration, 1678–1685
after parathyroidectomy, 920*
water content, 67, 1676–1684
Brain
albumin concentration, in vascular disease, 1233
ammonium concentration, 414–423, 933*, 991–997
and blood pH, 1724–1728
arteriosclerosis, 288, 1238
bicarbonate concentration, 1118–1121
bilirubin crystals in jaundice, 1127
blood flow and anesthesia, 285–292, 763–770
cholinesterase activity, 351, 352
chylomicron clearance in, 575–578
fructose catabolism in, 930*
in gargoylism, 141–146
glucose consumption, 286–292
hemodynamics, 286–298
and intracellular osmolarity, 916*
lactate, 289–292
oxygen consumption, 286–292
pulse volume, 767
after stellate ganglion block, 770
pyruvate, 289–292
in respiratory acidosis, 1115, 1118–1121
in thrombocytopenia, 897*
tumor, and spinal fluid protein, 1423
typhoid infection and influenza virus neurotoxicity, 903*
Breast, cancer
adrenal estrogens in, 341–349
seromucoid hexosamines, 53
serum calcium, 88, 89, 95
Bronchiectasis
and collateral circulation, 894*, 1072, 1084, 1085
hematocrit and oxygen capacity, 1167
Bronchitis
hematocrit and oxygen capacity in, 1167
and pulmonary diffusion capacity, 602
Brucellosis, and endotoxin, febrile responses, 219–230
Buffer
cation loss, and acetazolamide, 929*
conservation, and ammonium and titrable acid, 929*
pH, and corticosteroid binding, 520–523
sensitivity to, and vitamin B_{12} binding, 647
Buerger's disease, 941*, 942*
Burn
hypogammaglobulinemia after, 1740–1744
serum protein changes after, 1736–1745
in swine skin, 888*
and urinary cortisol, 818, 819

C

Calciferol
and phenolsulfonephthalein excretion, 892*, 893*
and renal function, 1702–1709
Calcification
in gargoylism, 144
in kidneys after calciferol, 1704–1707
metastatic, 89, 95
uric acid, and electrolyte excretion, 901*
Calcium
balance, 937*
and cortisone, 919*
bone concentration, 891*, 1357–1360
in acidotic diabetes, 1679–1684

Calcium (*cont'd*)
cerebrospinal fluid, 140
concentration and liver vitamin B_{12} uptake, 649
and contractility of actomyosin bands, 465–469
electrolyte excretion after, 294–305
excretion of, 921*, 929*
after jejunal perfusion, 1827
after magnesium loading, 1364, 1367
after neomycin, 893*
gluconate, and renal function, 296–301
and isopropyl methyl phosphonofluoridate (sarin), 362
and metabolism, 913*
in gargoylism, 139–147
nondialyzable, 1660, 1661
and urinary excretion, 317–320
in osteoporosis, 891*
perfusate and plasma concentrations in uremia, 1832
plasma. *See* Plasma, calcium
and renal function, 295, 296, 899*
and parathyroid extract, 907*
serum. *See* Serum, calcium
and trypsin, inhibition of, by soybean, 948
uptake, in osteoporotic acromegaly, 891*
urine flow after, 899*
Cancer
See also specific site
fibrinolytic enzyme system in, 969, 970, 972
mucoprotein fractions in, 129–135
serum properdin concentration in, 933*
Capillary
blood flow
and hexamethonium, 200
and murine typhus toxin, 899*
filtration, and oncotic pressure, 1472, 1473
and glucose, 525–528
protein loss to, in Valsalva maneuvers, 1472, 1473
vascular beds, in cardiac edema, 1472
Carbachol aerosol, lung response to inhalation of, 1746–1754
Carbohydrate
in amyloid composition, 882*
cerebral utilization and high spinal anesthesia, 289–292
intake
and chylomicron, 574–578, 1336–1341
and fructose metabolism, 118–126
and nonesterified fatty acid distribution, 574–578, 1511–1514
and urinary glucose, 1009
metabolism, 252, 758–761, 1000–1014
and fructose, 758–761
and glucose, 528, 758–761, 930*
in pantothenic acid deficiency, 1651
and ribose synthesis, 902*
and serum amylase, 889*
and oxygen consumption in renal failure, 886*
protein-bound, 277, 278
and pyruvate, 252, 261
synthesis from acetate, 1000, 1014
Carbon dioxide
alveolar removal in exercise, 596
blood storage under, 977
cardiac metabolic rate, 890*, 894*
and tachycardia, 1415
and cerebral blood flow, 768–770
concentrations of
in blood after hexose load, 757
in bone, 1357–1360
in metabolic acidosis, 640–644
in respiratory acidosis, 1111–1121
electrolyte response to, 1667–1675
hydration of, and carbonic anhydrase, 1120
and isopropyl methyl phosphonofluoridate (sarin), 362
and nitrogen displacement by oxygen, 306, 312
output, and pulmonary artery occlusion, 1080
palmitate, conversion to, 1337, 1507, 1508
plasma content
in diabetes, 1008, 1009
and exercise, 1694, 1695
and potassium intake, 1318
and pulmonary diffusing capacity, in lung disease, 591–604
retention, in arterial blood, 1057
serum content in renal disease, 90, 96
in squalene conversion to cholesterol, 655–659
tension
and bicarbonate reabsorption, 930*
in hyperthyroidism, 938*
in liver, 1189–1194
in metabolic acidosis recovery, 640–644
in pulmonary disease, 1169, 1174
in sleep, 982–984
in tachycardia, 1414, 1415
transmural central venous pressure affected, 1538
uptake
and aminophyllin, 884*
and blood pH, 249
in congestive failure, 923*
urinary excretion after, 881*
calcium gluconate, 298, 299
Carbon monoxide
pulmonary diffusing capacity, 394–407, 592
and exercise, 594–604, 926*
Carbonic acid
muscle content, 1118, 1119
toxicity, 497–501
Carcinoma. *See* Cancer
Cardiac output
and acetylcholine in hypoxia, 100–107
and aminophyllin, 884*
and anaerobic metabolic rate, 1582
and anesthesia, 899*
and aortic insufficiency, 471–475
in atrioventricular valvular deformities, 1601
and carbon dioxide concentration, 890*, 894*
and carbonic anhydrase, 887*
after electric shock, 885*
and epinephrine, 477
and exercise, 503, 1589, 1695, 1696
in heart failure, 507, 1582–1591, 1601
and hexamethonium, 200
and hyperventilation, 249
in hypothyroidism, 503, 507
and norepinephrine, 477
tetraethylammonium potentiation, 481
and oxygen consumption, 540, 542, 1589, 1590
and pressure, left atrial, 38
Cardiovascular system
and aminophyllin, 884*
and electric shock, 885*
in sickle cell anemia, 486–494
Casein
in amyloidosis, 847–850, 854–857
and renal insufficiency, 856
and trypsin, 948, 954
Castration, estrogen excretion, 341–349
Catechol amines, in renal insufficiency, 409–413
Catheterization
cardiac, 894*
and mitral stenosis, 200
in pulmonary collateral blood flow study, 894*
in right pulmonary artery and brochospirometry tube, 1076
in sickle cell disease, 490–492
coronary sinus, in rubidium uptake study, 921*
hepatic vein, in portacaval shunt, end-to-side, 606–617
and incidence of bacteriuria, 897*
transbronchial, left heart in mitral insufficiency, 35–39
venous and plethysmograph, 42
Cations
See also specific cations
in ash of urinary nondialyzable solids, 1662
renal excretion, and sulfate, 940*
and sodium balances, 1398, 1401
Celiac disease, and sprue, 927*
Cells
See also Erythrocytes; Leucocytes
age and fragility, 899*
brain and plasma pH, 1119
electrolytes in, after DCA, 68
endothelial, 922*
and plasmin therapy for clots, 868
eosinophils, 1567
epithelial, 922*
and calciferol, 1704–1707
giant, in hypersensitive state, 898*
granulocytic, 1571–1575
hematopoietic, 1568
hypoxic, oxidative potential, 244
juxtaglomerular, 660–670
lung, oxygen uptake, 600
lymphocytic, 1567
marrow, 1571–1575
metabolic studies, 166–171
and folic acid, 168
membrane permeability, 261
in respiratory acidosis, 1120
mononuclear, infiltration in kidney, 1690

osmolarity within, 916*
oxygen supply and energy utilization, 264
plasma, of fish, 892*
potassium concentration, 1320
and bicarbonate reabsorption, 750
proliferation of, 887*
serum hexosamine concentrations in, 896*
reticuloendothelial, and fever tolerance, 881*
synthetic processes of
and glucose catabolism, 1194
pyruvate from carbohydrate, 261
water, after DCA, 68

Cephalin
phospholipid separation, 1840
phosphorus content, 1841

Ceruloplasmin
in postmortem synovial fluid, 711
in Wilson's disease, 934*

Cervix, cancer of, fibrinolytic activity in blood, 969–972

Chloramphenicol
ferrokinetic studies, toxicity, 1286–1292
and urinary formiminoglutamic acid, 830

Chloride
absorption from gastrointestinal tract, 1429
and acetazolamide, 929*
and blood pH and convulsion, 499
concentration in bone, 1357–1360, 1679, 1680
concentration in muscle, 66–69, 890*
concentration in plasma
and carbon dioxide, 1114
and hexose infusion, 757
and intestinal transfer, 1827–1829
and intracellular acidosis, 883*
excretion
in alkalosis, 1017, 1018
after jejunal perfusion, 1827–1829
after magnesium loading, 1364, 1368–1371
and plasma calcium, 295, 296, 300, 301
and renal failure, 911*
in respiratory acidosis, 883*
and sodium depletion, 325–328
and spirolactone, 917*
ferrous, failure to displace manganese, 1302
perfusate concentration, and transfer, 1829, 1831, 1833
plasma. *See* Plasma, chloride
serum. *See* Serum, chloride
toxicity, 497–501

Chlorothiazide
antihypertensive agents, 902*
and renal and systemic hemodynamics, 887*

Cholelithiasis
blood ammonium-nitrogen concentrations, 417

Cholesterol
absorption, 884*, 900*, 901*
and atheromas, 161, 1163, 1164
in azotemia, 854
and blood clotting time, 920*
esters, 278
in atheromatous plaques, fatty acids, 1160–1164
in malignancy, 884*
and sarin, 356–362, 365–367
in hyperlipemia, 809
protein-bound, 278, 709, 710, 716
and salicylates, 1135, 1140, 1141
serum. *See* Serum, cholesterol
in synovial fluid, 709, 710, 713, 716
synthesis
in diabetes, 1197, 1198
and glucose oxidation, 1191, 1194
in liver, 1185–1194, 1197, 1198
and squalene, 655–659
in urinary nondialyzable solids, 317, 320

Chondroitin sulfate
acid mucopolysaccharides in, 862
after thyrotropin and TSH, 879*
in amyloidosis, 883*
hexuronic acid-containing polysaccharides, 679
synovial, and aging, 63
and vitamin B_{12} uptake by liver, 649

Christmas factor, 1323–1330

Chromatography
adrenal steroids, 1343, 1344
albumin distribution, 280, 281
in amyloidosis, 846–856
in atheromas
fatty acids of plaques, and plasma, 1155–1164
fluorescence, 160–165
bilirubin conjugates, 332–339, 1124–1127
of 11-desoxycortisol metabolites, 1090
of estrogens, in breast cancer, 341–349
and plasma electrophoretic fractions, 276, 283
in multiple myeloma, 281
plasma phosphatases, acid and alkaline, 279
of platelet phosphatides, 1836–1847
of purines, in gout, 584–589
rheumatoid factor isolation, 913*, 914*
serum proteins, 272–284, 893*
siderophilin location, 279
steroids in congenital adrenal hyperplasia, 890*
thyroxin-binding protein, 279, 280
of urine nondialyzable solids, 318–320
nucleoprotein degradation, 875*

Chromium, radioactive
insulin labeled with, in postoperative sodium study, 1630–1632
in manganese metabolism, 1302–1304
platelet survival, after labeling, 1267

Chylomicron, and fatty acids
distribution, after injection, 574–578
in metabolism study, 1333–1341

Circulation. *See* Blood flow

Cirrhosis, 925, 991
and ammonium metabolism, 416–419, 423
and erythrocyte metabolism, 1478
and isotonic dextrose, 928*
and oxytetracycline metabolism, 910*
and portacaval shunt
fibrinolytic system in, 968
hepatic hemodynamics, 606–617
and serum glutathione reductase, 216–218
and serum seromucoid hexosamines, 53
sodium distribution in, 687–697, 1237, 1238
spleno-portal circulation time in, 1854
and thiamine deficiency, 1480
water distribution, 687–697
and retention, 928*

Citric acid
blood, 121–125
pH, and convulsion, 499
and calcium ultrafiltration, 1516–1522
chromous and ferrous, and radiomanganese, 1303, 1304
cycle precursors, and cortisone, 1392
ferrous, in manganese pathway study, 1302–1304
metabolism, in perfused placenta, 1516–1522
toxicity, 497–501
in tricarboxylic acid cycle, 1002

Citrulline, plasma concentration, 1720

Coagulation of blood. *See* Blood, coagulation

Cobalt
in manganese pathway study, 1302, 1303
vitamin B_{12} labeled, *in vitro* binding study, 556–566

Colitis, ulcerative
hypersensitive granulomatous inflammation, 898*
pain threshold, 31, 32
and pulmonary embolism, 820

Collagen disease
serum hexosamine concentrations in, 896*

Coma
and ammonia concentration, 1726
metabolism, 414–423
hepatic, 414–423
and acidifying agents, 499, 500
thiamine deficiency and erythrocyte metabolism in, 1479
and isopropyl methyl phosphonofluoridate (sarin), 354

Compound F. *See* Cortisol

Connective tissue
destruction, serum hexosamine concentrations in, 896*
ground substance, seromucoid hexosamines, 51–56

Convulsion
after ammonium hydroxide loading, 1726
and blood pH, 499
and glycerol, 625

Convulsion (*cont'd*)
and isopropyl methyl phosphonofluoridate (sarin), 354
Copper
absorption, in Wilson's disease, 934*
in manganese pathway study, 1302
Coronary artery
blood flow, 884*, 898*
and aortic insufficiency, 471–475
and myocardial rubidium uptake, 921*
and oxygen consumption, 473–475
disease incidence, and sex, 927*
hemodynamics, and tachycardia, 1415
Coronary sinus, oxygen content, 884*
Corticosteroids
cortisol displacement by, 514
and endotoxin uptake, 226, 227
excretion
in children, 1091
in hyperthyroidism and myxedema, 737, 738
production of, in perfused placentas, 936*
Corticosterone
binding of, by human plasma, 512–517
excretion in thyroid disease, 737, 738
secretion, after vena cava constriction, 1784–1787
Cortisol
and adrenal activity, 797, 912*, 1527
and albumin, 1233
and ammonium-nitrogen concentrations, 417
and androsterone production, 796
binding of, 512–523
biological half-time, 1795, 1796
and endotoxin reactions, 226, 227
after epinephrine, 879*
excretion, 739
and stress, 813–822
formation
in adrenogenital syndrome, 1342–1346
and diastolic blood pressure, 1528
in hypertension, and ACTH, 1532
and total adrenal steroid output, 1533
and inulin clearance in glucosuria, 528
and lipolytic action of ACTH, 1532, 1561, 1562
metabolism
in hirsute women, 796
in thyroid disease, 738, 741, 742
mobilities and staining reactions, 1343
and placenta, 937*
secretion, 912*
and sodium excretion, 1631, 1638
synthesis of, in congenital adrenal hyperplasia, 890*
in thyroid crisis, treatment, 742
transcortin-bound, 928*
and urinary steroid excretion, 1088–1090
and water excretion in adrenal and pituitary insufficiency, 1799–1808
Cortisone
in Addison's disease, 920*
and adrenal activity, 797
and amyloidosis, 848
and blood glucose, 1384
body electrolytes and water responses, 68
and calcium homeostasis, 919*
and carbohydrate production in liver, 1392
and cortisol binding, 513
and 11-desoxyketosteroids, 796
and etiocholanolone production, 796
and fat metabolism, 1392
in hirsute women, 796
in hypercalcemia, 89, 95
and hypercalciuria, 937*
in hyperthyroidism, 738
and intracellular proteolytic enzyme activity, 926*
and ketone metabolism, 1384, 1385, 1389–1392
for leukemia, and vitamin B_{12} binding, 560
metabolism by prostatic cancer, 933*
in myxedema, 738, 742
in perfusates of placenta, 937*
pressure after
and jejunal perfusion, 1822, 1824, 1832
and sodium removal, 1832
and serum albumin, 1231, 1232
and sodium depletion after adrenalectomy, 1395, 1396
and survival time after trauma, 385–387
Coryza, neutralization by immune globulin, 904*
Creatine
concentrations and anesthesia, 901*
kinase, in muscular dystrophy, 940*
Creatinine
and bicarbonate reabsorption, 745
clearance, 929*
after anesthesia, 188, 901*
and carbon dioxide breathing, 1669
and insulin, 372–374
after jejunal perfusion in uremia, 1824, 1828, 1829
after kidney transplantation, 186, 189
and mercuric-cysteine, 1017
postphlebotomy, 238–241
after potassium sulfate, 325–330
in pregnancy and puerperium, 1766–1770
and tolbutamide, 372–374
and vasopressin dosage, 458–463
and water concentration, 459–461, 878*
and phosphorus clearance after glucose, 891*
postoperative, 1630
Cushing's syndrome. *See* Adrenal hyperfunction
Cyancobalamin
See also vitamin B_{12}
plasma absorption, and intrinsic factor, 888*, 889*
Cyclopropane, water diuresis inhibition, 875*
Cysteine, mercuric, and acid-base balance, 1017–1019
Cystine, intake and plasma concentration, 1712–1717
Cytosine, excretion in leukemia, 875*

D

DCA. *See* Desoxycorticosterone
1,2-Dehydro-9α-fluorohydrocortisone, 921*
Dehydroisoandrosterone
pattern formation, individual differences, 905*
production of, in hirsute women, 797
Desoxycholate
in thromboplastin generation test, 1840
Desoxycorticosterone
electrolytes and water after, 65–69
and hypertension, 660–670, 931*
and arteriosclerosis, 1688–1692
inhibition of corticosterone binding, 514, 517
inhibition of cortisol binding, 513
and juxtaglomerular cell granulation, 660, 667, 669
sodium and water balance studies, 925*
and SU-4885, 912*
trimethylacetate and sodium intake, 666
Desoxycortisol
conversion to cortisol, 1344–1346
inhibition of corticosterone binding, 514, 517
inhibition of cortisol binding, 513
mobilities and staining reaction, 1343
Deuterium oxide, water exchange and clearance by jejunal segment, 1823, 1824
Dextran
and serum protein in nephrotic hyperlipemia, 809
after thoracic inferior vena cava constriction, 1786, 1787
and water clearance, 459–461
Diabetes, alloxan
bone mineral and water content, 1676–1685
lipogenic defect, 1201
Diabetes insipidus
and hypernatremia, 1253
sodium depletion in, and urine osmolality, 1398
Diabetes mellitus
acidosis
and carbon dioxide tension, 640–644
and amino acid penetration, 907*
antibodies in, nonprecipitation, 787–792
blood sugar, 640–644
and renal phosphorus clearance, 891*, 892*
and serum amylase, 889*
during sleep, 925*

and bone crystal sodium, 1680
cholesterol synthesis in, 1198
glucose
production in, 1006–1014
reabsorption, 531
utilization, and fructose, 125
glycolytic pathways in lipogenesis, 1196–1201
and hyperlipemia, 886*
insulin in, 722, 787, 792
dosage and serum binding, 788, 790
juvenile, and insulin, 788
labile, 1007
plasma electrolytes in, 1678
plasma pH and ammonium chloride, 1678
and ribose metabolism, 722, 728–733
seromucoid hexosamines, 53
stable, 1006–1008, 1013, 1014

Diaminopimelic acid, isolated from pine pollen, 888*

Diamox®. *See* Acetazolamide

Diet
caloric intake
and aldosterone, 1549, 1554
mineral and nitrogen balances, 433, 436
and obesity, 1443
carbohydrate-free, and fructose and glucose tolerance, 123
in diabetes, 886*
and electrolyte excretion in man and monkey, 304
folic acid-deficient and formiminoglutamic acid excretion, 827
and hyperlipemia, 886*, 916*
and hypoalbuminemia in children, 685
and hypochloremia, 1667–1674
low magnesium, 430–439
low sodium
and juxtaglomerular granulation, 664
and sodium and potassium balances, 1397
meat and hexose tolerance tests, 120
nonpolar lipids from, in atherosclerotic lesions, 165
pantothenic acid deficiency, 1643
sodium
and DCA effects, 65–69, 925*
and sodium balance after adrenalectomy, 1397–1401
jejunal perfusion, 1822
and seromucoid in nephrotic, 54

Digoxin
and contractility of actomyosin bands, 465–469
renal excretion, 836, 837

Dihydroxyacetone phosphate, in tricarboxylic acid cycle, 1002

3α,11β-Dihydroxyandrostane-17-one, 795–798

2,5-Dihydroxy-benzoate. *See* Gentisate

3α,11β-Dihydroxyetiocholane-17-one, 795–798

3,4-Dihydroxyphenyl acetic acid, 410–413

3,4-Dihydroxyphenyl-β-aminoethane, 410–413

3,4-Dihydroxyphenyl-β-aminopropanoic acid, 410–413

3,4-Dihydroxyphenyl-β-isopropylaminoethanol, 410–413

Diiodotyrosine, 878*

Di-isopropyl fluorophosphate, *in vitro* sensitivity to, 352
and isopropyl methyl phosphonofluoridate (sarin), 350, 362–367

Dimethylbenzimidazole, and vitamin B_{12} binding, 902*
in leukemia serum, 917*, 918*

Dinitrophenol
and liver vitamin B_{12} uptake, 647, 649
metabolism, 1149
and oxygen consumption after trauma, 386, 388
and sodium reabsorption by renal tubule, 932*

Dipeptidase, and proteolytic enzyme, 926*

1,2-Diphenyl-3,5-dioxo-4-(β-phenylsulfoxy ethyl)-pyrazolidine, 909*

Diphosphopyridine nucleotide
in diabetes, and lipogenic defect, 1198
and erythrocyte glucose utilization, 916*
and glucuronide synthesis, 333–339
and liver carbon dioxide production, 1189–1191
oxidation, 244
and serum malic and lactic dehydrogenase, 673

Diuresis
and ACTH, in nephrotic syndrome, 909*
and antidiuretic hormone, 462, 463, 879*, 880*
bicarbonate, and glomerular filtration, 551
after glycerol infusion, 622
and hypotonic urine, 1801–1808
isotonic dextrose, in cirrhosis, 928*
in lipoid nephrosis, reversibility, 922*
mercurial, 902*
and acid-base balance, 1016–1022
and renal artery constriction, 550
and renal hemodynamics after calcium, 899*
water, 879*, 880*, 882*
and anesthetic agents, 875*
and glomerular filtration rate, 548–555, 1800–1808
hydropenia, 879*

DNA. *See* Deoxyribonucleic acid

Dodecabromide, activity as squalene, 656

Dwarfism, pituitary, 923*
and serum sulfation factor activity, 888*

Dyspnea
and antigen-antibody release, 1226
and cardiorespiratory disease, 914*
and isopropyl methyl phosphonofluoridate (sarin), 353, 354

Dystrophy, muscular, and collagen nitrogen, 939*

E

Edema
cardiac, and capillary filtration, 1472, 1473
in cirrhosis of liver, 687
in congestive heart failure, 687
after jejunal perfusion in uremia, 1821
and lung volumes in obesity, 1054
and mitral stenosis, 194–200
ventilatory mechanics, 111–117
periorbital, and aldosterone, 1549, 1550
and portacaval anastomosis, 617
pulmonary
and hexamethonium, 199
and isopropyl methyl phosphonofluoridate (sarin), 354
seromucoid hexosamines, 52
and serum sodium concentration, 1243–1254

EDTA. *See* Ethylenediaminetetraacetic acid

Electrocardiogram
after ammonium loading, 1726
in pantothenic acid deficiency, 1646
after potassium loading, 1318, 1319
and sodium depletion, 330

Electroencephalogram, in sleep, 988

Electrolyte
See also specific electrolyte
balance
in adrenal hyperplasia, 890*
and desoxycorticosterone, 889*
and intake, 1667–1675, 1822
and steroid hormones, 921*
and calcium gluconate, 298, 299
after magnesium, 1368–1371
and renal tubular function, 239
and uric acid stones, 901*
excretion
in adrenal cortical insufficiency, 921*
after fructose infusion, 756
intestinal transfer rates after perfusion, in uremia, 1828–1831
losses and hyponatremia after jejunal perfusion, 1823
postoperative, 1630
plasma. *See* Plasma
in respiratory acidosis, 883*, 1667–1674
serum. *See* Serum

Electronmicroscopy, in lipoid nephrosis, 922*

Electrophoresis
albumin concentrations, 711–717, 1419–1424
antihemophilic factors, 1323–1330
casein, 854–856
cerebrospinal fluid proteins, 1420
Christmas factor, 1323–1330
and chromatographic fractions, 276, 283
in cortisol binding, 519–523
in enzyme, fibrinolytic system, 1323–1330
in erythrocyte hemolysates, 974–979
insulin-gamma globulin complex, 785
lipoproteins, in nephrotic children, 174

Electrophoresis (*cont'd*)
malic and lactic dehydrogenase, 673
myeloma protein patterns, 281
of hemoglobin in pulmonary disease, 1170
of plasma proteins, 174
binding of corticosteroids, 519–523
of postmortem synovial fluid, 708–717
serum, 893*
in amyloidosis, 852, 853, 882*
and corticosterone binding, 519–523
fatty acids in hyperlipemia, 1778
fatty acids in nephrotic syndrome, 1775–1782
in thermal trauma, 1736–1745
thyroxin-binding protein, 279, 280, 1609
vitamin B_{12} binding in, 278, 561–565
of stored blood, 974–989
of tissue acid mucopolysaccarides, 861
Emphysema
hematocrit and oxygen capacity, 1167
and obesity, 1054, 1055
and patient-cycled respirator, 937*
and pulmonary diffusing capacity, 571–573, 597–602
for carbon monoxide, 394–407
and exercise, 602, 914*, 924*
and smoking, 895*
Empyema, properdin concentration in, 877*
Endocarditis, bacterial, properdin concentration in, 877*
Endocrine secretions and renal function in pregnancy, 1772
Endotoxin
absorption in hemorrhagic shock, 1425–1434
brucella
febrile response, 224–230, 881*, 891*
lethal actions, 221, 455
clearance, in fever, 880*
Escherichia coli, hepatic localization, 441–457, 1428
and plasma cortisol metabolism, 1791–1798
and properdin system, 940*
shigella, leukopenic response to, 1100–1104
tolerance development, 225–228, 881*, 891*
and distribution, 442–457
Enzymes
cholinesterase activity, 364, 367
and isopropyl methyl phosphonofluoridate (sarin), 350
fibrinolytic system, 965–972
heredity defect in erythrocyte metabolism, 1176–1183
heterogeneity in serum malic and lactic dehydrogenase, 672–676
intracellular and body fluid, 943*
liver, formation of glucuronides, 333–339
and neoplastic tissue growth, 944*
renal adaptation, and ammonia excretion, 1623
systems, in adrenogenital syndrome, 1342–1347
Epinephrine
and amylase concentration, 889*
and fibrinolytic activity, 931*
and forearm blood flow, 841, 842
glycogenic response to, 1651
in heart block, 879*
and lactate accumulation, 252, 1579
potentiated responses, 478
species difference, 484
in renal insufficiency, 409–413
sensitivity of arterioles and precapillaries to, 899*
and thyroidal hormone, 918*
Erythroblastosis fetalis, serum-spinal bilirubin ratios in, 1404–1408
Erythrocyte
ABO-incompatible, 1203–1209
and acetylcholinesterase, in hemoglobulinemia, 900*
and adenosine triphosphate, 916*
age effects on, 1293–1296, 1542–1547
agglutination, 905*, 1216, 1217, 1225, 1226
of penicillinized, 912*
and albumin, postphlebotomy, 236, 237
in anemia, 916*, 917*
iron deficiency, 833–835
antibody destruction, 1202–1226
and carbon dioxide, 1668
cholinesterase activity, 351, 352
in cord blood, glutathione concentration, 1438
diameters in anoxia, 1172–1174
energy from diphosphopyridine nucleotide reduction, 929*
and fibrin, in clot grading, 867
glucose utilization, 916*, 1439, 1440
glutathione. *See* Glutathione
in gout, 944*
incompatible, 1203–1209
dermal response, 1218
lactic and malic dehydrogenase, 674–676
of marrow, 1564–1575
metabolism, 918*, 1476–1483
and enzyme defect, 916*, 1176–1183
inhibition and palmitate metabolism, 1732
and methylene blue, 1477, 1483
and palmitate, interaction between, 1729–1735
in pantothenic acid deficiency, 1646
6-phosphogluconic dehydrogenase, 1181
plasma separation and blood pressure, 1106–1110
after plasmin therapy, 868
primaquine-sensitive, 928*, 929*
production, and chloramphenicol toxicity, 1289–1291
in pulmonary disease, 1166–1174
purine nucleoside phosphorylase, 1181, 1296
sequestration, 1211–1213, 1222–1224
and acetylphenylhydrazine, 1213, 1220
by filtration at low pressures, 905*
and lecithin, 1213, 1220
in spleen, 899*, 1213
storage, 974–989, 1202–1226
and inosine, 978–980, 1293–1296, 1439, 1440, 1484–1492
survival studies, 918*, 1485–1492
and thiamine deficiency
transketolase reaction, 1480, 1481
in Wernicke's encephalopathy, 1476–1483
thromboplastic substances in, 937*
in uremia, 918*
Erythropoiesis
and chloramphenicol toxicity, 1290–1292
of hereditary spherocytosis, 899*
after phlebotomy, 883*
plasma stimulatory factors, 913*
Erythropoietin, in plasma, 900*
Esophagus
distention, and pain threshold, 29–33
pressure
in hyperventilation, 1538
and phentolamine, 1539–1541
and pulmonary edema, 112
varices, and portacaval anastomosis, 615–617
Estradiol
plasma, binding in, 515–517, 519
urinary excretion, after ACTH, 342–349
Estrogens
adrenal, in breast cancer, 341–349
and alpha globulins, thyroxine-binding capacity, 156
and citrate metabolism in perfused placenta, 1518–1522
excretion, 342
after castration, and ACTH, 346
and hypercalcemia, 89
placental transfer, 1374–1378
and protein bound iodine, 892*, 1377
and sulfonphthalein excretion in hypertension, 1526
and thyroid hormone turnover, 892*
Estrone
plasma, binding in, 515–517, 519
urinary excretion after ACTH, 342–349
Ethanolamine phosphatide, and blood clotting time, 920*
Ether
anesthetic effects, and skeletal muscle metabolism, 901*
and water diuresis inhibition, 875*
Ethionine, and protein synthesis, 84
Ethylenediamine, and fluorescence of phenolic compounds, 410–413
Ethylenediaminetetraacetic acid
decalcification with, and fluorescence, 162
and liver vitamin B_{12} uptake, 648
and platelet survival in thrombocytopenia, 1266
and renal function, 303

and serum
malic and lactic dehydrogenase, 674
trypsin inhibitor, 949–954
Etiocholanolone
in hirsute women, 795–798
pattern formation, individual differences, 905*
Exercise
anerobic metabolism in, 1577–1591
in heart disease, 1601
in aortic stenosis, 944*
and arterial blood, 1580
pH, 544–546, 1693–1700
and blood flow, 839, 844
and arteriovenous oxygen difference, 1579, 1580
pulmonary, 1083, 1085
systemic, 207, 208
and body lactate, 1578, 1580
and bradycardia, 883*
and capillary blood volume, 1061–1069
and carbon dioxide, 593, 596, 1580
and cardiac output, 926*, 1579, 1580
in emphysema, 924*
in heart failure, 1589
and fibrinolytic activity, 931*
and heart, 207, 208, 212, 503–507, 881*, 883*
hemodynamic effects
in heart disease, 881*
in hypothyroidism, 503–509
and left ventricular function, 883*
and oxygen, 210, 1579, 1580, 1589
debt, 255–262
intake, 540–546
and pulmonary diffusing capacity, 1061–1069
for carbon monoxide, 594–604, 926*
and pulmonary hypertension, 203, 204
and pyruvate, 1578–1580
respiration during, 1693–1701
and stroke index, 881*, 883*
in supine position, 202–212, 257
Extremity. *See also* Forearm
arteriovenous ammonium-nitrogen differences in hepatic disease, 417–423
congestion, and vasoconstriction, 46–49

F

Fatty acid, nonesterified
in adipose tissue
and ACTH, 1556–1562
and splanchnic ketone body production, 1388–1391
and adrenocorticotropic hormone, 942*
albumin-bound, 1504
and carbohydrate feeding, 1338–1340
and chylomicrons, 574–578, 1333–1341
and erythrocytes, 1729–1735
and growth hormone, 922*
Fatty acids
in atheromatous plaques, 1153–1164
and blood clotting, 920*, 921*
and cholesterol esters of atheromas, 1160–1164
and cholesterol synthesis, 1192
effect of glycolytic activity, 1198
in hyperlipemia, 915*, 916*, 1776
intestinal mucosa, 919*
after neomycin therapy, 893*
in nephrotic syndrome, 1775–1782
and squalene, 659
synthesis, 658, 1160, 1333–1341
Embden-Meyerhof, and hexosemonophosphate pathways, 1187–1190
and insulin, 943*
in liver, 1185–1194
and reduced triphosphopyridine nucleotide, 1191
urinary, 317, 320
Feces, excretion in
calcium, 913*
in gargoylism, 145, 146
after neomycin, 893*
dipyrrylmethene, 896*
electrolytes, 1551, 1552
fatty acids, 893*
hemoglobin, in alimentary canal lesions, 889*
after magnesium loading, 434
nitrogen, 434, 1551
occult blood, spectrophotometric test, 889*
phosphorus, 1828
potassium, 434, 1551
sodium, 434
and aldosterone, 1551
urobilinogen, in jaundice, 1124, 1129
Fetus
blood flow, and steroid metabolism, 906*
liver, phenolphthalein conjugation, 335, 336
and maternal
estrogen transfer, 1373–1378
leukocyte incompatibility, 1756–1763
thyroid function, 157
plasma proteins, 1093–1099
uridine-diphosphate-glucuronic dehydrogenase activity, 337
Fever
after albumin injection, 894*
and antigen-antibody release, 1226
and erythrocyte destruction, 1210–1213, 1225, 1226
and chloramphenicol, 1287
and endotoxin uptake, 224–230, 442, 881*, 891*
tolerance development, 451, 880*
hypersensitivity associated with, 894*
and insulin binding, 789
after transfusions, 1222
Fibrinogen
concentration
and plasmin clot lysis, 866, 870
transient detection, 965
and diagnostic tests for cancer, 972
and electroshock therapy, 931*
fibrinolytic system activity, 965–972
in abruptio placentae, 967
in blood coagulation, 1323–1330
in cirrhosis, 968, 969
in pregnancy, 966–968
and methionine and/or vitamin K, 71, 82, 84, 85
Fibrosis
carotenoids and/or vitamin A, 164
collagenous, in degenerative joint disease, 392
and grading of clots, 867
and pulmonary diffusing capacity, 603
in Hamman-Rich disease, 598, 600
Fluid
blister, and serum protein concentration, 1742
cerebrospinal, 1405–1407, 1419–1424
acidity gradient, and blood, 933*, 934*
in bacterial meningitis, 218
bilirubin and heme pigment, 1411
in cardiac edema, 1473
in gargoylism, 140, 143
and glutathione reductase activity, 216, 217
and jugular vein occlusion, 764
protein concentration, 1419–1422
elbow joint, 709
extracellular, 916*, 1120
calcium balance, 95–97
and cortisone, 95
and creatinine clearance, 187
electrolyte content after DCA, 67–69
fructose, 14
isotonic expansion of, 188, 923*
in muscle, 68, 69, 1120
pH, and potassium, 1320
and position, 882*
sodium concentration, 189, 190, 241, 920*
space determination, 8-19
interstitial, 13, 18, 241
hypertonic medullary, 911*
intracellular, 644, 879* 898*, 916*, 1120
and body enzymes, 944*
desaturation and oxygen debt, 270
electrolyte response in, to carbon dioxide breathing, 1672
and potassium concentration, 707, 898*
and sodium concentration, 707
knee joint, 716
osmolarity, 898*, 916*
ribose distribution, 723, 724
sequestration, after surgery, 1637
synovial
hyaluronate, 57–63
proteins of postmortem, 708–717
ventricular, 1420, 1421
Fluorohydrocortisone
and chlorothiazide, 902*
inhibition of cortisol binding, 513
in sodium and water balance studies, 925*
Folic acid
in anemia
megaloblastic, 916*, 917*
pernicious, 168, 171
and deoxyribonucleic acid synthesis, 168–171

Folic acid (*cont'd*)
excretion, 915*
and formiminoglutamic acid, 829–831
and glucuronic acid conversion, 1462–1464
and glycine, 20, 21, 25, 26
in sprue, 20, 25
Forearm
blood flow, 41–49
and hemodynamic changes, 838–845
in hyperventilation, 956–961
congestion, 1217
and Valsalva maneuver, 1471–1473
oxygen uptake, 492
after heating and cooling, 1031–1047
Formiminoglutamic acid, in urine
and amethopterin, in leukemia, 829–831
assay method, 824–827
and folic acid deficiency, 827, 915*
Fructose
in amyloidosis, 882*
and blood pH, 757
and glucose metabolism, 125
in infants, 752–761
insulin, and glycosuria, 761
metabolism, 930*
in diabetes, 125
and dietary carbohydrate, 118–126
and urinary concentrations, 14
nondialyzable solids, 318, 320
Fructose-6-phosphate
and glucose hepatic glycolysis, 1185
and primaquine-sensitive erythrocytes, 929*
in ribose synthesis, 653
Furadantin®, 930*
Furazolidone, erythrocyte sensitivity to, 929*

G

Galactosamine-glucosamine ratio, in seromucoid, 51–56
Galactose
in amyloidosis, 882*, 883*
urinary, 318–320
Gargoylism, calcium metabolism in, 139–147
Gas
alveolar diffusing capacity, 894
and nitrogen replacement by oxygen, 312, 313
in obesity, 1052
in pulmonary disease, 592, 594, 598
in sleep, 981–989
and ammonium ion, 498
blood content, 1080
and acetylcholine, 101
and exercise, 542, 544, 594, 1693–1696
and blood pH, 249, 498
exchange, 101
in emphysema, 400, 403, 567–598
and occlusion of pulmonary artery, 1080
lung volume, 597, 601, 602
and compliance, 114–116
after oxygen breathing, 264–271, 308
thoracic volume
after aerosol breathing, 1750, 1751
after charcoal powder breathing, 1750, 1751
Gastrointestinal tract
cholesterol esterification, 884*, 901*
disturbances, and antigen-antibody release, 1226
epigastric burning in pantothenic acid deficiency, 1644–1646
in gargoylism, 143–146
hemorrhage, 889*
and blood ammonium-nitrogen concentrations, 417, 421
after Shigella endotoxin, 1102
iodide space in, 387, 1428
pain, duration and intensity, 28–33
as salt and water source, 68
in sprue
and celiac disease, 927*
glycine absorption from, 25, 26
toxin absorption from, 941*
in irreversible hemorrhagic shock, 1425–1434
vitamin B_{12} absorption from, 889*
Glass factor, 911*, 1323–1330
Globulin
alpha, 278, 279, 709, 717, 848, 852
thyroxine-binding by, 153–159, 1029, 1138
alpha$_1$, 275, 1739, 1742
lactic dehydrogenase, 673
mobility and concentration, 1779
vitamin B_{12} binding, 557–566
alpha$_2$, 1739–1742, 1779
alpha$_3$, 275, 1779
beta, 275, 562–566, 673, 848, 852, 1740, 1742, 1743, 1779
and lipoprotein migration rate, 1778
and synovial fluid, 712
in cerebrospinal fluid, 1419–1424
corticosteroid binding, 516, 519–523
of cortisol, 522
fatty acid, nonesterified, in nephrotic syndrome serum, 1779
gamma, 275–277, 562–566, 1740, 1742, 1743, 1779
antihuman added to human, 783, 784
in Fraction II, 713
and hyaluronidase digestion, 60
of joint fluid and of plasma, 712
and myeloma protein, 282, 283
in postburn septicemia, 1741
precipitable casein-antibody in, 854
production, and plasma cells, 892*
rheumatoid agglutinating factor, 939*
human immune, common cold neutralization by, 904*
iron-binding, 884*
in chloramphenicol toxicity, 1289–1292
and isopropyl methyl phosphonofluoridate (sarin), 362
serum, 1742
in amyloidosis, 846–857
in blister fluid, 1742
Glomerular filtration rate
and acetazolamide response, 551
and bicarbonate reabsorption, 929*
and acetazolamide, 745–748
after calcium infusion, 297, 301, 302, 304
and carbonic anhydrase inhibitors, 887*
and cortisol, 528
in hydropenia, 911*
and hypertonic infusions, 1022
and hyponatremia, 1399–1401
mercurial diuresis, 550
and chloride infusion, 1021
after parathormone, 893*
and Pitressin®, 188
in pituitary and adrenal insufficiency, 1800, 1803–1806
and potassium excretion, 555
and prednisone, 525–528
in pregnancy and in puerperium, 1765–1770
in renal disease, 881*
and renal function, 549, 550, 1366
after calciferol, 1708
magnesium clearance, 1366
phosphorus clearance after glucose, 892*
and salicylates, 804–806
and sodium, 297–304, 548–555, 1399–1401
in shock, 387
in transplanted kidney, 188–193
and tubular transport systems, 881*
and urine concentration
and antidiuretic hormone, 910*, 911*
osmotic, 878
and vasopressin dosage, 458
after water loading, 1802
and water retention, 1399–1401
Glomerulonephritis
aminonucleoside, 924*
galactosamine-glucosamine ratio in, 52–56
membranous, 922*
serum
calcium ultrafiltration, 89
magnesium, 1366–1369
sodium, 1238, 1251–1254
Glomerulosclerosis, diabetic, 1238
Glucosamine
in amyloidosis, 854, 882*
-galactosamine ratio, 854
in seromucoid, 51–56
Glucose
absorption after jejunal perfusion in uremia, 1829
in amyloidosis, 882*
blood concentrations. *See* Blood, glucose
cerebral consumption, 286
conversion to fucose, 930*
in diabetes, 125, 531, 1006–1014, 1198
and epinephrine, 481
and histamine, 477
and norepinephrine, 477
formation, 726
acetate via acetoacetate and acetone, 1011
and fructose, 121–125, 752–761
and glutathione, 1439, 1440

hepatic glycolysis routes, 1185, 1198
infusion
and blood lactate and pyruvate concentrations, 247, 252
and glycosuria, 761
and hyperventilation, 244–252
and insulin, 632–639, 723, 789–792, 1385
and cortisone, 1389, 1390
isotope distribution, 999–1014, 1453
and methylene blue stain, 1483
and ketone body production, 1380
from fatty acids, 1388, 1391
metabolism, 930*, 999–1004, 1185–1194, 1196–1201
and carbohydrates, 118–126, 528, 930*
in stress, 125
oxidation, 943*, 1185–1201
permeability of fetal red cells *in utero*, 1440
and renal phosphorus clearance, 892*
plasma, 121–125
protein-sparing effect of, 943*
and renal phosphate clearance, 369–378
renal tubular reabsorption, 524–532
and cortisol, 528
and prednisone, 525–528
serum concentration, 1238–1242
splanchnic production, 1389, 1390
tolerance, 121–125, 525–528
and ACTH, 1557
in tricarboxylic acid cycle, 1002
uptake, and growth hormone, 943*, 1557
urinary excretion, 1010
and aldosterone, 1550
of nondialyzable solids, 318, 320
utilization, 631–639, 943*
by erythrocytes, 916*, 1439, 1440
by infants, 754

Glucose-6-phosphate
in adipose tissue glucose pathway, 943*
and erythrocytes, heredity deficiency, 929*, 1176–1183
and glutathione, 1439
glycolysis, 1185, 1198
and iodoacetic acid, 916*
liver conversion to carbon dioxide, 1189–1191
and pentose production, 1458
and triphoshopyridine nucleotide, 726, 1189–1191

Glucuronic acid
and bilirubin, 332, 875*
conversion to hexose phosphate, 1462–1464
to ribose, 902*
enzymatic defect, in liver glucuronide synthesis, 1127
excretion of, and aminobenzoic acid, 1125
and 17-ketosteroid excretion, 1089
molar relationship of azo-pigment to, 335
plasma and urine concentration, 801–806
uridine diphosphate, 337
and glucuronide formation, 875*, 876*

Glucuronide
conjugating system, neonatal, 332–339
formation, *in vitro*, 1125
placental transfer, 1378
plasma concentration and renal clearance, 802–806
synthesis, 875*, 876*
and defect in glucuronyl transferase system, 1127–1129
enzyme systems in, 332
and uridine-diphosphate-glucuronic acid, 337

Glutamic acid
intake and plasma concentration, 1712–1717
urinary content, 318, 320

Glutamine
and purine compounds, 944*
and urinary excretion of ammonia, 1618

Glutathione
erythrocyte
and acetylphenylhydrazine, 1181–1183
in cord blood, 1436–1441
and primaquine hemolysis, 929*
reductase
in blood, 214–218
in tumors, 944*
hereditary deficiency, 1176–1183

Glyceraldehyde-phosphate, and glucose hepatic glycolysis, 1185

Glycerol, metabolism, 619–625

Glycine
concentration in amyloidosis, 882*
intake, and plasma concentration, 1712–1717
plasma iron response to, 1812
in sprue, absorption and conversion to serine, 20–26
uric acid from, 579–589
in urinary nondialyzable solids, 318, 320

Glycogen
cardiac, and ACTH, 1557
glucose formation from, 726
in liver, 654

Glycoprotein
in amyloidosis, 883*
mobility, and serum pH after thermal injury, 1740
in pathologic sera, 893*
and serum hexosamine, 856
in synovial fluid, 715

Glycosuria
and phosphorus clearance, 372, 377
in diabetes, 891*, 892*

Goiter
exophthalmic, 879*
nontoxic, and triiodothyronine, 1606
prevention by salicylate, 1147

Gonadotropin, 319
and citric acid metabolism in perfused placenta, 1516–1522

Gout
erythrocytes, 944*
and purine metabolism, 579–589, 909*, 944*
and uric acid, 901*
synthesis, 579–589

Granulopoiesis
control, and batyl alcohol, 913*
plasma granulocytic activity, 878*

Graves' disease, and thyroid function, 1603–1613

Growth hormone. *See* Pituitary growth hormone

Guanine
excretion in leukemia, 875*
7-methylguanine derivation from, 583
and uric acid, 587, 944*

H

Hageman factor
and glass factor, 911*, 923*
in plasma protein fraction, 1323–1330
and plasma thromboplastin antecedent deficiency, 149

Hamman and Rich syndrome, pulmonary diffusing capacity in, 598–603

Hashimoto's struma and mucopolysaccharide, 879*

Heart
action and plasma carbon dioxide, 1541
in tachycardia, 1414–1417
apical systolic murmurs, respiration in, 1596, 1597
availability of blood and hyperventilation, 960, 961
beat, after ammonium hydroxide loading, 1726
block, and epinephrine and levarterenol, 879*
cation exchanges in, 885*
cholinesterase inhibition in, 364
contractility of actomyosin bands from, 465–469
and exercise, 207, 208, 212, 503, 504, 881*, 883*, 1589, 1696
and fatty acid injection, 576–578
and hexamethonium, 195–200
in hypothyroidism, 502–509
and intracellular osmolarity, 916*
and isopropyl methyl phosphonofluoridate (sarin), 354, 355, 364
in left-to-right shunt, 212
magnesium uptake, 880*
muscle, 469, 1317
and potassium concentration, 330, 1317, 1321
and pulmonary artery occlusion, 1085
rate, 1414
resistance, 944*
in mitral stenosis, 195, 196
in sickle cell disease, 492–494
stroke volume, 195, 504, 505, 507, 542, 881*, 883*, 884*
succinoxidase activity, 919*

Heart disease
asymptomatic and anaerobic metabolism, 1593
and edema, 114, 687–697, 1241
pressure-volume loops and compliance, 914*

Heart failure
anaerobic metabolism in, 1577–1591
congestive
and body composition, 687–697, 1251–1254
and exercise, 211, 509, 1581
and mitral valvuloplasty, 1597–1601
and orthopnea, 507
and thiamine deficiency, 1480
ventilatory response to carbon dioxide, 923*
oxygen consumption, 509, 1583, 1589
and plasma oncotic pressure, 1472, 1473
and Valsalva maneuver, 1472, 1473
Helium
and lung diffusing capacity, 597
in emphysema, 397, 398, 402
and nitrogen, intrapulmonary mixing, 568–573
Hematemesis, and portacaval anastomosis, 615–617
Hematocrit
and aldosterone, 1551
in anemia, recovery, 917*
after blood and casein ingestion, 991
after calcium infusion, 91
and chloramphenicol, 1289
after citrate infusion, 93, 94
after hydralazine, 1107–1109
and murine typhus toxin, 899*
and norepinephrine, 1107–1109
in pantothenic acid deficiency, 1646
after phlebotomy, 883*
after phosphorus, 93
and plasma volume, 1468
after plasmin therapy for clots, 868
in pregnancy and puerperium, 1766, 1767
in pulmonary disease, 1166, 1167, 1170
renal intravascular, 1110
after saline infusions, 1467
in sickle cell disease, 488
in Valsalva maneuver, 1468, 1470
Hemochromatosis, and insulin binding, 788, 791
Hemodynamics
cardiac, in sickle cell disease, 492–494
cerebral, and anesthesia, 285–292
changes of, and blood flow in forearm, 838–845
in congestive heart failure, 507
coronary artery, 927*, 1415
hepatic, in portacaval anastomosis, 606–617
hexamethonium effects on, 194–200
in hypothyroidism and exercise, 502–509
and isoproterenol, 881*, 882*
in pulmonary hypertension and left-to-right shunt, 202–212
renal
and diuresis after calcium, 899*
in transplanted kidneys, 186–193
systemic, 927*, 1414
and carbonic anhydrase inhibitors, 887*
in tachycardia, 1414–1417
Hemoglobin
in anemia, 167, 171
naphthalene, 1179
arteriovenous oxygen difference and exercise, 544
and bilirubin, 887*
in infants, 1408
and catalase activity in iron deficiency, 834
conversion to bile pigment, 887*
excretion, 889*, 910*
glomerular clearance, 910*
and glucose-6-phosphate dehydrogenase deficiency, 1178–1181
ionization and carbon dioxide breathing, 1672
in pantothenic acid deficiency, 1646
plasma, 622, 887*, 896*, 910*
after plasmin therapy for clots, 868
postoperative, 1632
and hepatic venous oxygen concentration, 610
renal transport, 909*
sarin, effects on, 361
synthesis
and mesobilifuscin excretion, 896*
and phlebotomy, 883*
and thermolabile factor, 913*
tubular reabsorptive rate, 910*
Hemoglobinemia, and erythrocyte destruction, 1212, 1213, 1222
Hemoglobinuria
causative factors, 910*
and glycerol, 624
paroxysmal nocturnal, 895*, 896*, 900*
Hemophilia, 897*
Hemorrhage
in cirrhosis of liver, 968, 971, 972
diathesis, methionine, vitamin K and vitamin K-S (II), 77–81, 84, 85
gastrointestinal and nonprotein nitrogen, 996
hematocrit after, 1108
in hyperlipemia, 809
intramural, carotenoids and/or vitamin A, 164
and plasma uric acid, 1810
in pregnancy, 965–972
and vitamin K-S (II), 81, 82, 84
and red cell-plasma transit times, 1107–1110
and renal resistance, 1108
shock due to, 1426, 1433
Heparin
in blood coagulation, 1323–1330
and hyaluronidase digestion of synovial fluids and mucins, 60
mucopolysaccharides and, 862
and plasma clearance of hyperlipemia, 886*
and vitamin B_{12} uptake by liver, 649
Hepatitis
brucella endotoxin response in, 223
viral, 216
and glucuronide synthesis, 876*
Heredity
glucose-6-phosphate dehydrogenase deficiency, 1178, 1183
of glutathione instability, 1439
leukocyte antigens, 908*, 1759–1761
of spherocytosis, and cell fragility, 899*
Hexamethonium, hemodynamic effects of, and mitral stenosis, 194–200
Hexosamine
in amyloidosis, 846–857
in breast cancer, 53
in Hodgkin's disease, 131
hyaluronate in synovial fluid, 57–63
in leukemia, 130, 131
mucopolysaccharide content, 862
and nondialyzable solids, 318, 320, 1660, 1661
seromucoid galactosamine-glucosamine ratio, 51–56
serum concentrations, 853–857, 882*, 883*
and immunological reactions, 896*
Hexose
balance studies after infusion, 754–756, 758
concentration
in amyloidosis, 882*
and carbohydrate, 120
in Hodgkin's disease, 131
monophosphate shunt and glucose hepatic glycolysis, 1185
in diabetes, 1198
in postmortem synovial fluid, 711
protein-bound, 131, 277, 278
affecting ribose synthesis, 1453
synthesis, 653
in urinary nondialyzable solids, 318, 320, 1660, 1661
Hexuronic acid
and Cohn fractions, extraction, 679, 680
polysaccharide concentration in plasma in inflammation, 962–964
in synovial fluid, 62
Hirsutism, and adrenocortical hyperfunction, 794–798
Histamine
and erythrocyte destruction by antibodies, 1225, 1226
and gastric secretion, 884*, 885*
and lactic acid after epinephrine, norepinephrine, 477
urinary excretion, 885*
in imidazoleacetic ribose, 1455
Histidine, intake and plasma concentration, 1712–1717
Hodgkin's disease
homografts in, 906*
mucoprotein fractions in, 129, 131, 134, 135
properdin concentration in, 877*
serum protein changes in, 893*
tumor mass, 482
Hormone
See also specific glands; specific hormone
androgenic, and hypertrichosis, 798
antidiuretic
and hyponatremia, 1401
and secretion in adrenal and pituitary insufficiency, 1799, 1801–1803, 1806

and solute excretion, 459, 460, 879*
and water reabsorption, 240, 241
and fatty acid production, adipose tissue *in vitro*, 1560
and intracellular proteolytic enzyme activity, 926*
metabolism, 905*, 906*
thyroid
and testosterone, 892*
transplacental transfer of, 931*
thyroid stimulating, and corticotropin, 1560
Hyaluronic acid
in amyloidosis, 883*
mucopolysaccharides, 860–863, 879*, 880*
synovial fluid, 57–63
Hyaluronidase
and chondroitin sulfate, 859, 880*
synovial fluid hyaluronate content after digestion of, 57–63
Hydralazine, and red cell-plasma transit, 1108, 1109
Hydration
after jejunal perfusion in uremia, 1823, 1825, 1826
and urine osmolality, 462
Hydrocortisone. *See* Cortisol
Hydrogen ion
and potassium
intracellular exchange, 329, 330
plasma concentration, 910*
sensitivity of respiratory center, 644
Hydropenia, solute and water excretion in, 911*
3α-Hydroxyandrostane-17-one. *See* Androsterone
17-Hydroxycorticosteroids in adrenal venous blood, 891*
and conversion of 17-hydroxyprogesterone to cortisol, 1344
and SU-4885, 912*
urinary excretion, 238–241, 1550
and ACTH, 342
postoperative, 1630, 1637
and prolactin, 877*
3α-Hydroxyetiocholane-17-one. *See* Etiocholanolone
17α-Hydroxyprogesterone and adrenal function, 1344–1346
inhibition of cortisol binding, 513
5-Hydroxytryptamine. *See* Serotonin
Hykinone®. *See* Vitamin K
Hyperbilirubinemia, of newborn, 339
Hypercalcemia
calciferol induced, and renal function, 1702–1709
parathormone, 893*
and cortisone lack, 919*
and renal calcium clearance, 907*
phosphorus excretion, 304
and renal concentrating ability, 892*, 893*, 1702–1709
sarcoid with, seromucoid hexosamines, 53
serum calcium, ultrafiltration, 88, 89, 95–97
Hypercalciuria, and cortocoid therapy after prednisone, 937*
Hyperchloremia, and plasma pH, 1677, 1678
Hypercholesterolemia, 901*
in amyloidosis, 855
in nephrotic children, 182, 183
seromucoid hexosamines, 52, 55
Hyperemia
and forearm blood flow, 839, 844, 1039–1048
and isopropyl methyl phosphonofluoridate (sarin), 354
Hyperferremia and xanthine oxidase, 1810–1813
Hypergammaglobulinemia, and amyloid deposits, 855
Hyperglobulinemia, and gout, 580
Hyperglycemia, 886*
in diabetes during sleep, 926*
osmotic diuresis of, and urine formation, 1684
phosphate excretion, 378
Hyperkalemia, after jejunal perfusion, 1823
potassium concentration in, 702–707, 1321
and sodium depletion, 330
and thrombocytosis, 694–707
Hyperlipemia
and diabetes, 886*
nephrotic, 182
hypoalbuminemia in, 808–812
physiologic changes, 915*
postprandial, 921*
serum fatty acids, electrophoretic partition of, 1777, 1778
Hyperparathyroidism
osteoporotic, calcium uptake in, 891*
serum calcium, 92
Hyperphosphatemia, serum calcium content in, 92, 93, 96, 97
Hyperplasia
adrenal, 912*, 1343–1346
and corticoid therapy, 937*
steroid metabolism, 889*
erythroid, delta-aminolevulinic acid excretion in, 935*
Hyperpnea of exercise, 1693
Hyperpotassemia. *See* Hyperkalemia
Hypertension
adrenal steroid synthesis, 1524–1535
blood volume in acute, 426–429
and chlorothiazide therapy, 902*
desoxycorticosterone induced, 660
juxaglomerular cell granulation in, 660–670
levarterenol-induced, 427
and lung volume in obesity, 1054
and magnesium loading, renal effects of, 1364, 1365
portal
in alcoholic cirrhosis, 925*
in portacaval shunt, end-to-side, 606–617
and potassium deficiency, 941*
pulmonary
and acetylcholine, 106, 107
and acute hypoxemia, 1085
and blood flow during exercise, 205, 206
and enlarged cardiac silhouettes, 506
in left-to-right shunt, 203–205
and mitral stenosis, 194–200
and pyelonephritis, 930*
renal, 660, 669, 670, 882*, 903*, 917*
juxtaglomerular indices in, 662
systemic, 206, 1596
and mitral regurgitant flow, 38
tissue electrolytes in, 941*
and vasoconstriction in forearm, 844
Hyperthyroidism
circulation time in, 507
epinephrine test, 919*
intrathyroidal iodine in untreated, 932*
in pregnancy, amelioration of, 156
respiratory adaptations in, 938*
seromucoid hexosamines, 53
and survival time after trauma, 385, 387
and urinary corticoids, 738
Hyperventilation
and atrial pressure, 890*
and blood
availability to heart, 960, 961
oxygen consumption, 244–252
pH, 500
carbon dioxide, 1539
and venous volume change, 958–961
cerebral response, 765–767
and exercise, 1580, 1587
and fructose infusion, 756
intrapleural pressure during, 890*
and phentolamine, 1541
and lactate-pyruvate ratio, 244–252
in metabolic acidosis, 642–644
venous pressure in, transmural central, 1537–1541
Hypoalbuminemia
in children, 682–686
and hypercalcemia, 89
in nephrotic hyperlipemia, 182, 808–812
and renal amyloidosis, 855
urinary excretion of albumin in, 55
Hypocalcemia
and ammonium citrate toxicity, 498
and serum calcium in renal disease, 89, 96
Hypocalciuria, and uric acid stones, 901*
Hypocapnia
and diastolic distensibility of ventricle, 890*
pyruvate change during 251
Hypochloremia, in respiratory acidosis, 1667–1675
Hypogammaglobulinemia
and ABO-incompatible cells, 1220
after thermal injury, 1740–1743
Hypoglycemia
and ACTH, 1557
and cortisone, 1385, 1389–1392
in diabetes, 627–630
during sleep, 925*
and glucose, 726, 930*
and growth hormone, 1557
after insulin, 1385
intraportal secretion, 631–639
ribose concentration, 723, 725

Hypoglycemia (*cont'd*)
and splanchnic ketone metabolism, 1389–1392
phosphate excretion, 378
Hypokalemia, in pantothenic acid deficiency, 1646
Hyponatremia
in adrenal hyperplasia, 889*
in edema, 1251–1254
and electrolyte losses after jejunal perfusion, 1823
and sodium depletion, 1253, 1399–1401
Hypoparathyroidism
glutathione reductase activity, 216
serum calcium ultrafiltration, 88–90, 95
Hypophysectomy
estrogen excretion after, and ACTH, 342–349
sulfation factor activity after, 888*
and urinary nitrogen excretion after prolactin, 877*
Hypoplasia
of bone marrow, 1292
and chloramphenicol toxicity, 1290
erythroid, delta-aminolevulinic acid excretion in, 935*
Hypoproteinuria
seromucoid hexosamines, 52
serum calcium ultrafiltration, 88, 95
Hypoprothrombinemia
and vitamin K, 72, 84
and methionine, 71, 84
Hypotension
and carbonic anhydrase inhibitors, 887*
and endotoxin in irreversible hemorrhagic shock, 1430–1433
of high spinal anesthesia, and blood flow, 289–292
Hypothalamus, irradiation, 878*
Hypothermia
and forearm pressure and volume, 44–46
hematologic changes during, 1–7
and serum potassium concentration, effect of blood cells on, 705–707
Hypothyroidism
hemodynamic studies, 502–509
serum thyroxine-binding capacity in, 892*
Hypoxanthine
concentration and xanthine oxidase acceptors, 1814
conversion of nucleotide, 944*
oxidation to uric acid, 587
plasma iron response to, and to purine, 1811, 1812
and plasma uric acid, 1811
Hypoxia
and acetylcholine effects, 103–106
and pulmonary hypertension, 107
and diffusion gradient for oxygen, 1075
and exercise, 259
and hyperventilation, 249
and lactate-pyruvate ratio, 244–252, 264–271
and pulmonary collateral blood flow, 99–108, 1080–1085

I

Ileum
mineral and water concentration in, 1358
pain, 28–33
rheobase intensity, 31–33
uric acid riboside phosphorylase in, 909*
Imidazoleacetic acid, 902*
and ribose synthesis, 1457–1459
Immune reactions
in amyloidosis, 848
common cold, 904*
and streptokinase clearance, 1314
Infant
bilirubin, 338
in jaundice, 876*
serum-spinal fluid ratios, 1403–1411
congenital adrenal hyperplasia, 889*
cytomegalic inclusion disease of, 927*
erythroblastosis, 1404–1408
and familial leukoagglutinins, 1759
glucose and fructose metabolism, 752–761
glucuronide conjugating ability, 332, 336, 337, 876*
glutathione stability in, 1181–1183
and age, 1438–1440
phenolphthalein conjugation, 335
serum protein, thyroxine-binding, 153–159
Infection
fibrinolytic enzyme system in, 972
and insulin binding, 789
and pantothenic acid deficiency, 1644–1646
properdin systems in, 876*, 877*
renal, and hypertension, 1686–1692
serum hexosamine concentrations in, 896*
urinary and chloramphenicol, 1287
Influenza, Asian virus, 931*
Injury. *See* Trauma
Inosine
and erythrocytes
and glutathione, 1439
osmotic resistance, 1293–1296
storage survival, 978, 980, 1485–1492
plasma iron response to, 1812
synthesis, 944*
and of uric acid, 587
Inositol phosphatide of phospholipid, 1841
Insulin
and amino acid metabolism, 907*
antibodies, nonprecipitating, 783–785, 787–792
and arabinose distribution, 732
binding by human serum, 783–785, 789–791
and blood ribose concentration, 722, 723, 733
and glucose. *See* Glucose
half-life, *in vivo,* 927*
and hypoglycemia, 631–639
and ketone metabolism, 1382, 1383
and lyxose distribution, 724
metabolism of, by placental tissue, 895*
muscle membrane, hyperpolarization of, 944*
and phosphate clearance, 372–374, 376
sequestration of, by peripheral tissue, 922*
and serum amylase, 889*
and D-xylose, 724, 732
Intestine. *See* Gastrointestinal tract
Inulin
clearances, 929*
after calcium infusion, 295, 296
and glomerular filtration, 549–551
in glucosuria, 528
after magnesium loading, 1364–1369
and mercurial diuresis, 550
after parathormone, 893*
and potassium excretion, 553
in pregnancy and puerperium, 1765–1769
and sodium bicarbonate, 551
and vasopressin dosage, 458–463
space, 8–19
after desoxycorticosterone, 66–69
Iron
concentration, after phlebotomy, 883*
deficiency anemia, and catalase in erythrocytes, 833
and endotoxin uptake, 449
metabolism and chloramphenicol, 1286–1292
plasma, in erythropoietic depression, 1290
and radiomanganese turnover, 1302, 1304
tissue release after xanthine oxidase, 1809–1817
in urinary nondialyzable solids, 1662
Irradiation, and thrombocytopenia, 904*
Isoleucine
intake and plasma concentration, 1712–1717
in urinary nondialyzable solids, 318, 320
Isoniazid, and blood ammonium-nitrogen concentrations, 416–418
Isoprenaline, adsorption from plasma by alumina, 410–413
Isopropyl methyl phosphonofluoridate, cholinesterase inhibition, 350–367
Isoproterenol, hemodynamic effects, 881*, 882*

J

Jaundice
bile in, 1126, 1127
bilirubin excretion in, 1124, 1126
congenital, and glucuronide formation defect, 1123–1129
of newborn, 332, 876*
obstructive, sterol metabolism, 884*
Jejunum
calcium content in gargoylism, 141
perfusion of isolated, in uremia, 1818–1835
Joint, disease and sodium clearance, 389–392

K

Keto acid
in placentas, perfused, 1517, 1519
in tricarboxylic acid cycle, 1002
11-Ketoetiocholanolone, excretion, 905*
carcinoma of prostate, 933*
Ketone bodies
blood, in diabetes, 1008, 1009
glycolytic pathways, 1198
metabolism, 1379–1392
Ketosis
and ACTH, 1557
and cortisone, 1392
diabetic, 1201
and fasting, 119
and growth hormone, 1557
glucose formation in, 1006–1008, 1013, 1014
and insulin, 1391, 1392
17-Ketosteroids
and ACTH, 342
and adrenal hyperplasia, 890*
in hyperthyroidism, 737, 738
production in hirsute women, 795–798
urinary excretion, 933*, 1088, 1550
and age, 1089–1091
and aldosterone, 239
in identical triplets, 905*
in myxedema, 737, 738, 741
in pantothenic acid deficiency, 1648, 1656
after prolactin, 877*
in prostatic carcinoma and cortisone, 933*
in thyrotoxicosis, 741
Kidney
aldosterone release, 232
postphlebotomy, 240, 241
ammonia-producing enzyme systems, 1615–1626
amyloid in, 847
arterial constriction, 664
and glomerular filtration rate, 549, 550
bilirubin crystals in, in jaundiced rats, 1126
cholinesterase inhibition, 364
circulation of erythrocytes and plasma, 1106–1110
clearance
of chylomicrons, 575–578
and parathyroid extract, 90–92, 907*
of radioiodine, 382–384
of salicylates, 803–806, 1141
concentrating ability and calciferol, 1702–1709
denervated, 191, 192
disease
and acid-base balance, 640
and blood pH, 1238–1242
and hypocalcemia, 89, 96, 97
magnesium loading in, 1365
plasma catechol concentration in, 409–413
endotoxin uptake in shock, 1428
erythrocyte distribution in, 912*
excretion
phosphate, 369–378
potassium, 548–555
salicylates, 804–806
sodium, 232, 550, 1238
fucose catabolism in, 930*
function
and antigen-antibody release, 1226
in hypertension, 903*, 917*, 930*, 931*
and *Escherichia coli* infection, 1686–1692
and oxygen consumption, 886*
and plasma catechol amine concentration, 409–413
in pregnancy and puerperium, 1764–1774
in respiratory acidosis, 883*
and serum calcium concentration, 141, 294–305, 893*, 1702–1709
after transplant, 185–193, 917*
and glutathione reductase, 215, 216
inulin uptake and destruction, 11–14
ischemic, juxtaglomerular granulation, 663, 669, 670
and osmotic pressure of urine, 878*
plasma albumin, 912*
rates of anaerobic metabolism and anoxia, 903*
reabsorption
of bicarbonate, 883*, 929*, 930*
of water, 893*
stone, and ammonium secretion, 901*
sucrose uptake and destruction, 11–14, 18, 19
transport of hemoglobin, 909*
tubules
after calciferol, 1704–1708
in hypertonic urine, 463
and salicylates, 805, 806
uric acid ribose phosphorylase in, 909*
water, 878*, 893*
activity in, and intracellular osmolarity, 916*
Kwashiorkor, and hypoalbuminemia, 682–686

L

Lactate
concentrations and anesthesia, 901*
and epinephrine infusion and histamine, 477
and malate dehydrogenases of serum, 672–681
metabolism, and fructose versus glucose, 758–761
and norepinephrine, 481
and pyruvate blood ratios
in anaerobic metabolism, 244–271, 1579–1581, 1594
in congestive heart failure, 1578–1580
and exercise, 255–262, 1578–1580
and hyperventilation, 244–252
in hypoxia, 244–252, 255–271
and low-oxygen gas breathing, 264–271
and ribose synthesis, 1458
Lactose
from glucose, 930*
Laennec's cirrhosis. *See* Cirrhosis
Lead, in urinary nondialyzable solids, 1662
Lecithin, isolation, from platelet, 1837–1847
Leucine
intake and plasma concentration, 1712–1717
and proteolytic enzyme activity, 926*
urinary excretion, 318, 320, 1618
Leukemia
cytosine excretion in, 875*
formiminoglutamic acid excretion in, and amethopterin, 829–831
glutathione reductase activity, 216
histiocytic mucoprotein fractions, 128–130, 134, 135
and hyperkalemia, 701
leukocytes, 886*
lymphatic, and vitamin B_{12} binding, 563–565
lymphocytic, 128–130, 134, 135, 560
guanosine and inosine excretion, 875*
plasma granulocytic activity, 878*
monocytic, 560, 563–565
mucoprotein fractions in, 128–130, 134, 135
myeloid, 703, 704, 707
plasmocytic, 132
properdin concentration in, 877*
response to allicin, 941*
serum malic and lactic dehydrogenase, 674–676
urinary cytidylic acid in, 875*
vitamin B_{12} binding, 558
protein fractions of serum, 563–565
Leukocytes
agglutination, in identical twins, 908*
in pregnancy, 1757
antigens, genetics of, 908*
and erythrocytes
antibody destruction, 1204–1226
in blood and marrow, 877*, 1564–1575
fetomaternal incompatibility, 1756–1763
fibrinogen concentration and plasmin, 865, 866
in hypothermia, 3–7
in leukemic sera, 886*
and vitamin B_{12} binding, 560–565
polymorphonuclear and *E. coli* endotoxin, 455
and sarin effects, 361
and serum concentration
of hexosamine, 896*, 897*
in hyperkalemia, 705–707
after Shigella toxin injection, 1101–1104
transfer of sensitivity factor, 1206, 1207, 1212
in vitro effects on, and allicin, 941*
Leukopenia
and ABO-incompatibility, 1203–1209
and chloramphenicol, 1290
and destruction of red cells, 1213, 1220, 1225, 1226
and endotoxin uptake, 1100–1104

Leukopenia (*cont'd*)
and erythropoietic depression of bone marrow, 1292
and immune hemolysis *in vivo*, 1219
after plasmin treatment of clots, 868
and pyrogenic response after transfusion, 1222
and serum hexosamine concentration, 896*, 897*
Levarterenol. *See* Norepinephrine
Linoleic acid
in blood and atheromatous plaques, 1161–1163
plasma turnover, 1509, 1510
Lipid
See also Cholesterol; Fatty acids, nonesterified
in amyloidosis, 882*
and atherosclerotic lesions, 160–165, 1153, 1164
blood concentration
in azotemia, 854
after chylomicron injection, 575–578
and coagulation, 920*
and dietary fats, 908*
in nephrotic hyperlipemia, 809, 916*
in pantothenic acid deficiency, 1650
and lipoproteins in Cohn fractions III and IV-1, 680
synthesis, 1185–1194
in diabetic liver, 1196–1201
pathways, 1185, 1192
urinary excretion, 317, 318, 320
Lipoproteins
alpha, 175–177
peptide moieties, 182–184
in postmortem synovial fluid, 717
beta, 175, 182, 717
and blood clotting time, 920*
post thermal injury, 1740
of Cohn fractions III and IV-1, 679–681
permeability, and edema, 713
serum fractions, 278
in hypoalbuminemia, 55
in nephrotic syndrome, 172–184 1775–1782
Liver
blood flow
collateral, and vascular resistance, 925*
and epinephrine, 840
in portacaval shunt, 606–617
bromsulfalein storage, 942*
in chloramphenicol toxicity, 1288
cholesterol, 364
tritium concentration and squalene, 657
after chylomicron injection, 575–578
cirrhosis. *See* Cirrhosis
in cortisol metabolism, 739–742
diabetic, lipogenic defect, 1196–1201
disease
blood ammonia concentration, 991–997
mesobilifuscin in, 896*
serum calcium ultrafiltration, 88, 90
sodium concentration in, 1237, 1238
endotoxin uptake, 443
in shock, 1428
enlargement, 615–617
and fructose uptake and conversion to glycogen, 760, 930*
and hexose infusion, 756
enzymes and inflammation, 944*
function, in shock due to infection, 1795
glucose-6-phosphate after partial hepatectomy, 1458
glucuronyl transferase activity, 332, 876*
glycogen breakdown, 731–733
and glutathione reductase, 215, 217
and hepatic vein circulation time, 1850–1856
and intracellular osmolarity, 916*
iron release into plasma and xanthine oxidase, 1813
insulin effects, 631–639
in jaundice. *See* Jaundice
lipid, glycolysis and synthesis, 1185–1194
manganese uptake, 1271–1276
intracellular exchange, 1273–1276
neonatal, conjugation of bilirubin, 335
oxytetracycline storage, 910*
platelet counts and hypothermia, 2
as sequestration site, 4, 6
reticuloendothelial system and albumin, 897*
ribose metabolism, 733, 1458, 1459
sequestration of labeled red cells *in vitro*, 1213–1215, 1225, 1226
and serum amylase, 889*
and spleen circulation time, 1851
and uric acid, 909*
in gout, 944*
vitamin B_{12} uptake, intrinsic factor effect on, 646–649
Lung
abscess, properdin concentration in, 877*
blood flow, 99–108
collateral, 894*, 1072
cancer and collateral blood flow, 894*, 1072, 1084
11-ketoetiocholanolone, 933*
capillary pressure and hexamethonium, 199
carbon dioxide tension in, 597–601
in cardiorespiratory diseases, 914*
after chylomicron injection, 575–578
compliance, 112–116, 935*
and charcoal powder breathing, 1748–1754
in sleep, 987
diffusing capacity of
for carbon monoxide, 394–407, 926*, 1065
in disease, 488, 591–604
and exercise, 257, 545, 594, 1061–1069, 1693–1700
measurement of, 394–407, 569, 570, 597, 601
after oxygen breathing, 308–313
and posture, 1061–1069
disease
and alveolar hypoventilation, 1057
and cortisone, 1058
edema, 111–117
in emphysema, 397–404, 570
endotoxin uptake, 1428
fatty acids, nonesterified, uptake, 576–578
glutathione reductase of, 215
nitrogen displacement by oxygen from, 306–313
in obesity, 1049–1060
oxygen uptake, 256, 545, 1074
in Hamman and Rich syndrome, 598, 600, 603
platelet count and hypothermia, 2
resistance, 1747–1755
and "dry" heat exposure, 936*
and hexamethonium, 197–200
in hypothyroidism, 504–507
and isoproterenol, 882*
in left-to-right shunt, 203, 204
and smoking, 356, 895*
tuberculosis, 216
and vitamin B_{12} binding, 560
vasoconstriction in hypoxia, 106
vital capacity, 488, 493, 914*, 935*, 1051
volume, 1693–1696
after aerosol breathing, 1746–1755
and airway conductance, 1279–1285
after aluminum powder breathing, 1750, 1752–1754
after dust particle breathing, 1749–1754
Lupus erythematosis disseminatus, 216
mucoprotein fractions in, 129, 134, 135
seromucoid galactosamine-glucosamine ratio, 53
serum nucleohistone, 876*
serum protein-bound hexoses, 132
Lycine
intake, and plasma concentration, 1712–1717
urinary excretion, 318, 320
Lymph
drainage, in cardiac edema, 1473
hematocrit, and oxygen capacity, 1168
nodes, and allicin, 941*
properdin concentration in, 877*
red blood cells after platelet infusion, 904*
Lymphoblastoma, mucoprotein fractions in, 129, 131
Lymphosarcoma, mucoprotein fractions in, 129, 134, 135
Lyxose, insulin response, 724, 732

M

Macroglobulinemia, multiple serum proteins, 893*
Magnesium
and calcium excretion, 1367
daily requirement of adult, 439
excretion of, 929*
after jejunal perfusion, 1827, 1828

after magnesium loading, 434–439, 1362–1372
tissue uptake, 880*, 1301–1304
tubular reabsorption of, 1366
and urinary nondialyzable solids, 1662

Malabsorption syndrome, formiminoglutamic acid excretion in, 915*

Malic acid
blood concentration, 121–125
in glucose formation from actetate, 1012
and lactic dehydrogenase of serum, 672–681
in tricarboxylic acid cycle, 1002

Manganese
metabolism, 1269–1276, 1298–1304

Mannitol
in amyloidosis, 882*, 883*
urinary excretion, 318, 320
and vasopressin, 458–463

Melena, and portacaval anastomosis, 615–617

Menadione, and blood clotting factors, 76, 77

Meralluride, in alkalosis, 1017, 1018
and water diuresis in adrenal and pituitary insufficiency, 1802–1806

Mercuhydrin®. *See* Meralluride

Mercury, diuretic response, and acid-base balance, 1016–1022

Mesobilifuscin, in liver and biliary disease, 896*

Metaplasia, myeloid
mucoprotein fractions in, 129
and uric acid production, 580, 585, 586
and vitamin B_{12} binding, 560

Methimazole, and thyroid uptake in hyperthyroidism, 932*, 1605

Methionine
blood clotting accelerator activity, 70–85
intake, and plasma concentration, 1712–1717
placental transfer, 1095

Methoxamine, and atrial pressure, 39

2-Methyl-1,2-bis(3-pyridyl)-1-propanone, inhibition of 11β-hydroxylation, 912*

7-Methyl-8-hydroxyguanine, 585

S-(2-Methyl-1,4-naphthoquinonyl-3)-β-mercaptopropionic acid. *See* Vitamin K-S (II)

Mitochondria, in manganese metabolism, 1274, 1276

Mitral valve
insufficiency, 35–39, 891*
and norepinephrine, 37–39
regurgitation and aortic constriction, 36, 38
stenosis of, 35–39, 890*, 891*
and hexamethonium, 194–200

Morphine
lung compliance and resistance changes after, 114
and placebo, postoperative pain relief, 535

Mucin, and synovial fluid hyaluronate, 57–63

Mucopolysaccharides, acid
alkaline fractionation, 56
dermis content, 858, 860
measurement, 858–863
plasma
in Cohn fractions, 678–681
in inflammation, 962–964
after thyrotropin, 878*

Mucoproteins
in hematologic disorders, 127–136
serum, hexosamines of, 51–56

Mumps, 931*

Muscle
in alveolar hypoventilation, 1058
and anesthesia, 901*
ataxia, 354
and thiamine deficiency, 1480, 1482
bicarbonate concentration, 1118–1121
and blood ammonia, 933*
cholinesterase activity, 351, 364
chylomicron uptake, 575–578
electrolytes and water after carbon dioxide, 1114
after desoxycorticosterone, 67–69
facial, and cerebral vasodilatation, 767
fat concentration, 939*
fucose catabolism in, 930*
heart, contractility of actomyosin bands from, 465–469
and insulin, 906*, 907*, 944*
and isopropyl methyl phosphonofluoridate (sarin), 354, 364
and intracellular osmolarity, 916*
lactate accumulation and epinephrine, 252
norepinephrine-induced contractions, 936*
paralysis and ventilatory function, 773–781
phosphorylase, 675
in respiratory acidosis, composition, 1115–1121
skeletal, in muscular dystrophy, 939*
temperature, and oxygen uptake in forearm, 1036

Myalgia and brucella endotoxin, 222–230

Mycolic acid, isolated from pine pollen, 888*

Myeloma
properdin concentration in, 877*
serum proteins, 281, 282, 893*
hexosamine, 896*
mucoprotein fractions, 129, 134, 135

Myleran®, in myelogenous leukemia, 559

Myocardium
blood flow, 877*, 884*
and exercise, 508, 509
oxygen uptake, 884*
and tachycardia, 1415
sex differences, 927*

Myxedema
and alveolar hypoventilation, 1058
insulin binding in, 791
17-ketosteroid excretion, 738
and lung volume in obesity, 1054
and mucopolysaccharide after thyrotropin, 878*
and plasma cortisol, 738, 739, 742
and salicylates, 1134, 1137
seromucoid hexosamines, 52, 53, 55
and thyroid turnover rate, 1350–1355, 1608

N

Naphthalene, hemolytic anemia, 1179, 1183

Necrosis
in atherosclerosis, 162
hepatic, 889*
and carbon tetrachloride, 876*
tubular, persistence of antibiotics in blood, 908*

Neomycin, sprue-like syndrome during therapy, 893*

Neoplasm. *See* Cancer

Neostigmine, sensitivity to, 350, 352

Nephrectomy
intracorpuscular defect following, 918*
obstruction, and albumin catabolism, 897*
sucrose recovery after, space and procedure comparison, 11, 17–19

Nephritis
and amyloidosis, 847
galactosamine-glucosamine ratio, 52, 53
gouty, insulin binding in, 791

Nephrosis
galactosamine-glucosamine ratio, 52–56
hematocrit and oxygen capacity, 1168
and hypoalbuminemia in hyperlipemia, 808–812
lipoid, 922*
lipoproteins in, 172–184
reversibility of, 922*
serum fatty acids, electrophoretic partition, 1775–1782
and steroid therapy, 908*, 909*

Nervous system
central
and alveolar hypoventilation, 1057, 1058
and glycerol, 625
and isopropyl methyl phosphonofluoridate (sarin), 353–355
craniocervical sympathetic cerebral circulation, 771
disorders
and blood or casein ingestion, 992–997
and brucella endotoxin uptake, 223
formiminoglutamic acid excretion, 830
and ketone metabolism, 1389, 1390
and serum sodium concentration, 1239–1242
and thiamine deficiency, 1479, 1480, 1482
and norepinephrine, 484

Nickel
and manganese metabolism, 1302
and urine nondialyzable solid, 1662

Nicotinic acid
and cerebral circulation, 765, 767
and contractility of actomyosin bands, 465–469
Nitrofurantoin, erythrocyte sensitivity to, 929*
Nitrogen
amino acid, plasma concentration in sprue, 21–26
and ammonium uptake, 414–423
antibody in amyloidosis, 853
balance, 937*
and caloric intake, 1400
and carbon dioxide breathing, 1669, 1671
after jejunal perfusion, 1820, 1826, 1827
and Lugol's solution, 1450
and pantothenic acid, 1649, 1655
and protein intake, 1445
and salicylates, 1140
and blood storage, 977
collagen, in muscular dystrophy, 939*
concentration
in amyloidosis, 882*
in bone, 1357–1360
after oxygen breathing, 306–313
displacement by oxygen from normal lungs, 306–313
excretion, 877*
and aldosterone, 1551
and magnesium intake, 434–439
after neomycin, 893*
and helium, intrapulmonary mixing in emphysema, 568–573
and hexosamine ratios in synovial fluid, 59
and jejunal perfusion flow rates in uremia, 1826
loss of, 921*
metabolism and triiodothyronine, 1447
nonprotein, after casein or blood feeding, 997
and isopropyl methyl phosphonofluoridate (sarin), 362
precipitable antibody, 854
in urinary nondialyzable solids, 317, 318, 320, 1660, 1661
Nitroglycerin, and relief of ischemic pain, 898*
Nitrous oxide
absorption, and cerebral blood flow, 770
and water diuresis, inhibition, 875*
of vessel wall, in clot lysis, 867
Nonesterified fatty acids. *See* Fatty acids, nonesterified; and Plasma, fatty acids, nonesterified
Norepinephrine
and acid-base balance, 879*, 936*
adsorption from plasma by alumina, 410–413
and arterial blood pressure, 478
after kidney transplant, 917*
and red cell-plasma transit times, 1108
and atrial pressure, left, 37–39
and cardiac output, 481
and forearm blood flow, 45, 841–844
hemodynamic changes due to, 425–429
in mitral insufficiency, hemodynamic responses, 37–39
plasma concentration in renal insufficiency, 409–413
renal resistance and hematocrit, 1108
and venous pressure, 45
Nucleotides
See also specific nucleotides
binding, in serum, 876*
synthesis, in primary gout, 587–589
Nutrition
glycerol, 625
potassium requirements, 1651
protein intake
and albumin metabolism, 682–686, 1442–1451
and plasma amino acid concentration, 1710–1716
serum calcium ultrafiltration, 88
Nystagmus
and thiamine deficiency, 1480, 1482
in Wernicke's encephalopathy, 1479

O

Obesity
and dietary intake, 1443
hematocrit and oxygen capacity, 1167
and pulmonary function, 206, 1049–1060, 1167, 1643
Oophorectomy, and estrogen excretion in metastatic breast cancer, 341–349
Orcinol, carbazole, uronic acid determination with, 860–863
Orinase®. *See* Tolbutamide
Ornithine, plasma concentration, 1715
Orotic acid, biosynthesis of, 932*, 933*
Osteoporosis
in acromegaly, 891*
senile, and dietary intake, 1443
in thyrotoxicosis, 891*
Oxalacetate
malic and lactic dehydrogenase activity in leukemia, 674–676
in tricarboxylic acid cycle, 1002
Oxygen
arterial, 209, 544, 1694, 1695
and acetylcholine, 100–107
and aminophyllin, 884*
and circulation time, 540
in hyperventilation, 244–252, 960, 961
in obesity, 1050, 1053
and temperature, 1031–1038
arteriovenous difference, 504, 507, 545, 546, 884*, 1580
and anaerobic metabolism, 1582–1591, 1594, 1595
hepatic, 610
in hyperemia, 1040, 1044, 1045
in hypothyroidism, 503–509
in mitral stenosis after hexamethonium, 195
in myxedema, 509
in pulmonary insufficiency, 1167, 1173, 1174
and sex, 927*
in blood storage, 916*, 977
cell deficiency, and lactic dehydrogenase, 244, 252
consumption, 884*, 898*, 916*, 1581
in anemia, 167
and aortic insufficiency, 471–475
and blood pH, 248
and cardiac output, 504, 545, 546
cerebral, 286
and coronary flow, 473–475
and epinephrine, 918*
and gas breathing, 268
in heart disease, 1594, 1595
in heart failure, 507, 1580, 1587, 1590, 1595
in hypertension, 206–208
and hyperventilation, 248
in hypothyroidism, 938*, 507
in hypoxia, 265–267
myocardial, and tachycardia, 1415
in pulmonary disease, 206–208, 1167–1170
and pyruvate, 246, 247
in shunt, 203, 204, 606–617
and radiothyroxine disappearance, 1137, 1141
in renal failure, 886*
and serum salicylate concentration, 1132, 1133
splanchnic, 1382–1387
in Wernicke's encephalopathy, 1479
and exercise, 208, 209, 256–259, 262, 503, 540–546, 598–600, 1580, 1589, 1693–1695
intake
and age, 540, 542, 1167
and blood flow, 609–615, 770, 894*, 1074, 1077, 1080
and blood pH, 542, 545
and cardiac output, 540, 542, 1590
in collateral pulmonary circulation, 894*
and diffusing capacity, 598–600
maximal, 538–546
in reactive hyperemia, 1039–1048
molecular, and xanthine oxidase, 1815
myocardial metabolism of, and tachycardia, 1415
nitrogen displacement from normal lungs, 306–313
in sickle cell anemia, 486–494
tension, 542
alveolar, 988
and erythrocyte formation, 1815
intravascular, 486–494
in pulmonary disease, 1169, 1174
in sleep, 984, 985
transport from lungs to tissues in emphysema, 924*
Oxyhemoglobin, dissociation curve, in sleep, 988
Oxytetracycline, hepatic metabolism of, 910*

P

Pain, threshold studies, 28–33
Palmitic acid
and erythrocyte interaction, 1729–1735
in atheromatous plaques, 1155–1164

metabolism, 1504–1514
triglyceride, in chylomicron, 1333–1341
Pancreas
cancer and serum cholesterol, 884*
and serum amylase, 889*
Panhypopituitarism, body composition in, 688, 1238
and sodium concentration, 1251–1254
Pantothenic acid, deficiency, 1643–1656
Para-aminohippurate clearance
and acetazolamide, 929*
after calcium, 295–296
and glomerular filtration, 551
after kidney transplantation, 186
after magnesium loading, 1364, 1365
in pregnancy and puerperium, 1765–1769
Paralysis
and pulmonary function, 773–781
in Wernicke's encephalopathy, 1479
Parathion, and cholinesterase, 350, 352, 363
Parathyroid
adenoma, seromucoid hexosamine, 52, 53, 56
and bone
calcium, 907*
sodium mobilization from, 920*
in hypercalcemia, 893*
and renal phosphorus clearance, 907*
and serum calcium ultrafiltration, 95–97
Penicillin
and blood ammonium-nitrogen concentrations, 415–418
circulating antibody against, 911*, 912*
erythrocyte reaction to, 1478
persistence in blood, after therapy with, 908*
resistance to, in staphylococcal infections, 914*
Penicillinase, inactivation of penicillin by, 912*
Pentobarbital
after epinephrine, 879*
and excretion rates after kidney transplant, 188
Pentose
accumulation
in erythrocytes, 1478
in Wernicke's encephalopathy, 1479, 1483
and xylulose excretion, 902*, 1464
synthesis from hexose, 1453
and ribose synthesis, 1457–1464
Phenolic steroids. *See* Estrogens
Phenolsulfonephthalein, excretion and vitamin D_2, 892*, 893*
Phentolamine, in hyperventilation, 1539
Phenylalanine
intake and plasma concentration, 1712–1717
in urinary nondialyzable solids, 318, 320
Phenylbutazone, and uric acid riboside phosphorylase, 909*
Phlebotomy
erythropoietic response to, 883*, 884*
for gout, and uric acid excretion, 580
renal electrolyte excretion after, 234–241
Phosphatase
acid, 279
and isopropyl methyl phosphonofluoridate (sarin), 362
alkaline, 362
enzymes from osseous and prostatic tissue, 944*
serum content, and glutathione reductase, 217
Phosphate
and acetazolamide, 929*
and calcium ultrafiltration, 92, 96
clearance
and blood sugar levels, 369, 372, 376–378
and insulin, 373, 376
and ribose, 724, 725
synthesis, 1457–1459
tubular reabsorption defects and glucosuria, 528
in uremia, EDA reaction, 410–413
in urinary nondialyzable solids, 1660, 1661
Phosphatidylethanolamine
clotting activity, 1839–1842
Phosphatidylserine
fraction from platelet lipid, 1839–1843
and prothrombin consumption, 1842
and thromboplastin generation, 937*
6-Phosphogluconate
in adipose tissue, glucose pathway, 943*
erythrocyte, heredity and racial factors, 1176–1183
and pentose production, 1458
3-Phosphoglyceraldehyde
oxidation of, 916*
in tricarboxylic acid cycle, 1002
Phospholipids. *See also* specific compounds
and blood clotting time, 920*
fractions, isolation of, and clotting activities, 1836–1847
serum concentration
chylomicron fraction, 577
in pantothenic acid deficiency, 1650
and thromboplastin formation, 937*
in urinary nondialyzable solids, 318, 320
Phosphoribosylpyrophosphate, and purine synthesis in gout, 944*
Phosphorus
acid-soluble in uremic muscle, 890*
balance, 937*
bone content, 1357–1360
cephalin content of, 1841
concentration
in amyloidosis, 882*
platelet lipids, 1841
and creatine concentration after anesthesia, 901*
excretion
after alkali, 300, 301
after calcium, 295, 296
after calcium gluconate, 298, 299
after carbon dioxide breathing, 1669, 1671
after jejunal perfusion, 1828
and isopropyl methyl phosphonofluoridate (sarin), 362
and nitrogen after prolactin, 877*
renal clearance of
and blood glucose, 891*, 892*
and parathyroid extract, 907*
serum content. *See* Serum, phosphorus
of total ash, of nondialyzable urinary solids, 317, 318, 320
Pickwickian syndrome, 1058, 1059
See also Obesity
Pine pollen, and sarcoidosis, 888*
Pitressin®. *See* Vasopressin
Pituitary glands
anterior
and meralluride, 1802–1804
growth hormone
and adipose tissue, 943*, 1557, 1560
anabolic effect of, 877*
endocrine secretion in pregnancy, 1772
and fat mobilization, 922*, 923*
and sulfation factor, 888*
growth promoting activity and serum sulfation factor activity, 888*
liver, and adrenals in cortisol metabolism, 742
tumors, and 2-methyl-1,2-bis(3-pyridyl)-1-propanone, 912*
Placebo, pharmacology of, 533–537
Placenta
estrogen transfer across, 1373–1378
insulin degradation by, 895*
perfusion
and circulating potassium, 1520
and citrate metabolism, 1516–1522
and corticosteroid production, 936*, 937*
plasma protein transfer across, 1093–1097
thyroid hormones transfer across, 157, 931*, 1354
Plasma
acid mucopolysaccharides, 679–681
in inflammation, 962–964
adrenal vein after vena cava constriction, 1783–1790
albumin, 516, 517
and arterial pressure, 1107
antibodies precipitable by, 896*
distribution in kidney, 912*
metabolism and adrenocortical hormones, 1229–1234
and reticuloendothelial system, 897*
and triiodothyronine, 1448, 1451
amino acid concentration and dietary protein, 1710–1723
arterial
bromsulfalein, in portacaval anastomosis, 608, 609

Plasma (*cont'd*)
barium sulfate-adsorbed and aged serum in accelerator response, 77
bicarbonate
and acetazolamide, 745–748
in alkalosis, 1021
and excretion, 929*
and intracellular acidosis, 883*
in labile diabetes, 1007
and respiratory acidosis, 929*, 1118, 1119
bilirubin concentration, 887*, 1127
calcium concentration, 920*
after alkaline infusion, 300, 301
after calcium infusion, 295, 296
and electrolyte excretion, 294–305
and renal function, 294–305
carbon dioxide
in diabetes, 640–644, 1008, 1009
and serum chloride concentration, 1688
tension, 745–748
cell phylogenesis, and gamma globulins, 892*
chloride, 883*, 1022, 1114
in alloxan diabetes, 1678
after jejunal perfusion, 1823, 1827
after meralluride, and mercuric-cysteine, 1017
and potassium intake, 1318
and sodium sulfate, 940*
transfer to erythrocytes, 1672, 1673
cholesterol esters
and atheromatous plaques, 1163, 1164
and isopropyl methyl phosphonofluoridate, 351, 352, 364, 367
clearance
antigenic proteins, 1306–1314
cortisol, 739, 740
of phosphate, 370–378
radioiron, 1288
salicylates, 1148
of streptokinase, 1306–1314
clot lysis, in cirrhosis of liver, 968, 971
coagulation, glass and Hageman factors, 911*, 924
corticosteroid binding in, 511–519
cortisol, 515–519, 1233
in hyperthyroidism, 737, 738
in shock due to infection, 1798
creatinine
during jejunal perfusion, 1828
in pregnancy, 1766, 1767
creatinine concentration and renal clearance, in pregnancy and puerperium, 1766–1770
cyancobalamin absorption, 888*, 889*
divalent ions, 940*
electrolytes
after desoxycorticosterone, 66–69
and intestinal transfer, 1818–1835
and mercuric-cysteine, 1017
endotoxin clearance from, 443
epinephrine, in renal insufficiency, 411
erythropoietin, 884*, 900*, 1290
estrogen binding, 515–517, 519, 1377
factor V deficiency and methionine, vitamin K, and vitamin K-S (II), 81–85
fatty acids, nonesterified, 575–578, 1339–1341, 1153–1164, 1506
fibrinolytic enzyme activity, 965–972
glycine concentration after glycine administration, oral, 20–26
granulocytic activity, 877*, 878*
hemoglobin, 910*
acidity during sleep, 896*
and bilirubin production, 887*
after glycerol, 622
hemolysis of sensitized red cells, 1221
heparinized
erythrocyte storage in, 916*
glutathione reductase activity, 215
hypertonic, 1022
and antidiuretic hormone, 459
inulin, comparison of procedures for, 8–19
iron, 884*
in chloramphenicol toxicity, 1289–1292
after hemorrhage, 1810–1814
in hepatic vein, 1813
lipids, and dietary fats, 908*
lipoproteins in nephrotic syndrome, 172–184
new bactericidal system in, 940*
new thyroxine-binding protein, 903*
norepinephrine in renal insufficiency, 411
osmolality, 459, 880*, 910*
palmitic acid clearance, 1339–1341, 1505–1510
and atheromatous plaques, 1155–1164
pH, 715, 745–748, 1114
parathyroidectomized animals, 920*
and potassium intake, 1318
in respiratory acidosis, 1119–1121
phenolic compounds adsorption, and alumina, 410–413
phosphatase enzymes from osseous and prostatic tissue, 944*
phosphorus concentration, 121–125
after alkaline infusion, 300, 301
after calcium infusion, 295, 296, 304
after calcium gluconate injection, 298, 299
platelet, 937*
potassium concentration, 699–707
polysaccharides, 962–964
potassium, 67–69, 324–330, 770, 910*, 1317, 1318
and coagulation, 702, 705–707
and electrocardiographic T wave voltage, 1319
and freezing, 702
after jejunal perfusion, 1827
effect of platelets, 699–707
progesterone binding, 515–517, 519
proteins, 511–517, 1323–1330, 1377, 1445
anticoagulant, 1326–1330
Cohn fractions, 677–681, 868
in extravascular system, 717
fetal, 1093–1099
during hemoconcentration, 429
and levarterenol, 425–429
and prednisone, 1233
synthesis of, by guinea pig fetus, 1094
thromboplastin component, 1323
transfer of maternal to fetus, 1093–1099
turnover half-time, 175
in Valsalva maneuver, 1473
recalcification time, 148, 149
in plasma thromboplastin deficiency, 151
renal flow
in cardiac edema, 1473
and filtration fraction in pregnancy, 1765–1769
in puerperium, 1765–1769
after transplantation of kidney, 192
ribose concentration of, 723, 724
salicyl compounds concentrations, 802
serine concentration, 21–26
serine in sprue after glycine, oral, 21–26
silicone and blood clotting, 911*
sodium concentration, 189, 192, 324–330, 761, 920*, 1318, 1823, 1827
sucrose, 8–19
testosterone binding in, 515–519
thromboplastin antecedent deficiency, anticoagulant in, 148–152
urea nitrogen, 1766, 1767, 1770
uric acid, 1828, 1832
and hemorrhage or trauma, 1810
after purine, 1811
volume, 192, 236, 237, 1467
Plasmin, streptokinase - activated, 905*
and dissolution of clots, 864–870
Platelet
agglutination in hemorrhagic diathesis, 81
and antibody destruction of red cells, 1225, 1226
in hypothermia, 2–7
infusions of fresh, hemostatic effect, 904*
lipid fraction of, and red cells, 937*
lyophilized, in thrombocytopenic recipients, 904*
in plasma thromboplastin antecedent deficiency, 149, 150
phosphatides, 1836–1847
potassium, 699–707
survival studies, 1257–1267
specificity of labeling, 1264, 1265
thromboplastic factor, 937*
Pneumonia
pneumococcal, properdin concentration in, 877*
Poliomyelitis
reinfection, 920*
virus studies, 921*, 931*
Polycythemia vera
mucoprotein fractions in, 129

urinary uric acid, 585, 586
and vitamin B_{12} binding, 560
Polysaccharides
hexuronate-containing, 679–681
in inflammation, 962–964
metabolism, in hyperlipemia, 916*
Porphyria, 914*
aminolevulinic acid excretion in, 936*
Posture
and blood flow
capillary, 1061–1069
in forearm, 45–49
and exercise in left-to-right shunt, 202–212
and pulmonary membrane diffusing capacity, 1061–1069
and renal function in pregnancy, 1771
Potassium
balance
and carbon dioxide, 938*, 1114, 1669, 1671, 1672
during hexose infusions, 754–758
in hypercapnia, 938*
and sodium, 330, 1245, 1248, 1249, 1397
blood concentration, 757
pre- and postoperative, 1632
bone content, 1357–1360
cellular concentration, 707, 1320
and changes in bicarbonate reabsorption, 750
deficiency, 898*
lesions of, and after calciferol, 1708
exchangeable
to body water, 910*
in distal tubule, 554, 555
in heart, 885*
in edema, 687–697
in saliva and urine, 238–241
excretion, 325–330, 911*, 929*
after acetazolamide, 552, 555
and adrenal insufficiency, 240
and aldosterone, 918*, 1550, 1551
and alkali, 300, 301
after ascites, 327–330
after calcium, 295–299, 304
after chloride, 325
and glomerular filtration, 548, 549
after inulin, 549, 550
after jejunal perfusion, 1827–1829
after kidney transplantation, 188–193
and magnesium intake, 434–439, 1364, 1368–1371
after neomycin therapy, 893*
in pantothenic acid deficiency, 1652
postoperative, 1630
postphlebotomy, 234–241
in respiratory acidosis, 883*
and sodium depletion, 323–330, 548–555
and spirolactone, 917*
extracellular, 1320
intake, 325–330
and body stores, 1316–1321
and hyponatremia, 1253
lethal limit for rats, 1318
intracellular, and hydrogen exchange, 329, 330
and leukemic white cell, 886*
loss, 921*
and chlorothiazide, 902*
metabolism, 758–761
muscle, 67–69
heart, 941*
in uremia, 890*
and nitrogen, after prolactin, 877*
perfusate concentration, and transfer, 1828–1830
plasma *See* Plasma
platelets, and blood coagulation, 699–707
reabsorption of filtered, 554, 555
requirements, and natural diets, 1651
serum. *See* Serum, potassium
Prednisolone, and cortisol binding, 513
Prednisone
and albumin, distribution and metabolism, 1233
and glucose metabolism, 525–532
in diabetes, 1008, 1013, 1014
and hypercalciuria, 937*
and seromucoid in nephrotic syndrome, 54
and urinary formiminoglutamic acid, 830
Pregnancy
bacteriuria, asymptomatic, 906*
cortisol in, and transcortin, 928*
fibrinolytic enzyme activity in, 966–968, 971, 972
hypertension in, 1366
hypoproconvertinemia and vitamin K-S (II), 77, 85
insulin requirements in diabetes, 895*
leukoagglutinin incidence, 1757
preeclampsia and magnesium loading, 1365
renal function in, 1764–1774
serum protein, thyroxine-binding, 153–159
Pregnanetriol, urinary excretion of, in congenital adrenal hyperplasia, 890*
Δ^4-Pregnene-17α,21-diol,3,20-dione, metabolism, differences in adults and children, 1087–1092
Pressure
See also Hypertension; Hypotension
aortic, 35–39, 471–475
in stenosis, 944*
arterial, 286, 884*
and acetylcholine, 100–108
after adenosine and inosine, 1813
and aldosterone, 1549
and aminophyllin, 884*
and atropine, 482
after caval constriction, 1784–1787
and cerebral circulation, 286, 288, 765, 766
and chlorothiazide, 902*
in coarctation of aorta, 900*
and cortisone, 1822
in electric shock, 885*
and ganglionic blocking drugs, 903*
and glycerol, 621–625
and G-suit inflation, 926*
in hemorrhagic shock, 1427
and hexamethonium, 197–200
and histamine, 477
in hypothyroidism, 503–509
and isopropyl methyl phosphonofluoridate, 355
after jejunal perfusion in uremia, 1824, 1825
and levarterenol, 426–429
and mercurial diuretics, 902*
and norepinephrine, 37–39
after plasmin clot lysis, 868
and renal erythrocyte-plasma transit times, 1106–1110
and renal hematocrit, 1109
sex differences, 927*
and spinal anesthesia, 289–292
and sodium balance, 1822, 1825
and transplanted kidney function, 917*
and venous congestion in limbs, 46–49
atrial, 35–39, 503–509, 890*
and heart size, 505, 506
and hyperventilation, 890*
cerebrospinal, 767
cuff, 764
and venous pressure and volume, 42
diastolic, 102, 108, 196, 474, 1528, 1549
and epinephrine, 918*
esophageal, in pulmonary disease, 112, 935*
and exercise. *See* Exercise
forearm venous, 42–49, 956–960
hepatic vein, in cirrhotic liver and portacaval shunt, 606–618
hydrostatic capillary, and plasma volume, 428
intestinal wall, and visceral pain, 28–33
intradural, and jugular vein occlusion, 764
intrapleural, 116, 890*, 935*, 1541
oncotic, after albumin infusion, 241
pulmonary artery, 112, 198, 199, 506, 507, 914*, 927*, 935*, 1414
and acetylcholine, in hypoxia, 100–107
and carbon dioxide breathing, 894*
and carbonic anhydrase inhibitors, 887*
in left-to-right shunt, 203, 204
in mitral stenosis, 196, 1595
in sickle cell disease, 492–494
and tachycardia, 1415
pulse, 35–39, 46–49, 286, 477, 756, 765, 918
and fructose, 756, 760
in hypoxia, and acetylcholine, 103
and inflation of occluding pulmonary balloon, 1077
and oxygen intake, 542
after thyroxin treatment, 385, 388

Pressure (*cont'd*)
systolic, 37–39, 102, 108, 196, 205
and pyelonephritis, 1688–1690
thoracic, 1784–1786
transmural, 114
in hyperventilation, 1537–1541
venous
in hyperventilation, 956–960
in omental vein, 616
portal, in cirrhosis or portocaval shunt, 613–617
after psychic stimulation, 879*
and temperature, 1031–1038
ventricular, 37–39, 196, 504, 934*, 935*, 944*
volume, 46–49
wedge, 102–107, 492–494
hepatic, 606, 607, 610, 925*
during Valsalva maneuvers, 1466, 1467
Primaquine, erythrocyte sensitivity to, 929*
Priscoline®. *See* Tolazoline
Probenecid
salicylates, and renal clearance, 804
and uric acid
in gout, 580
riboside phosphorylase, 909*
Proconvertin, and blood coagulation, 1323–1330
Progesterone, protein binding, 512–523
Proline
concentration in amyloidosis, 882*
intake and plasma concentration, 1712–1717
and urinary ammonia excretion, 1619
Properdin system
in acute infections, 876*, 877*
in cancer, 933*
Propylthiouracil
and Graves' disease, 1605
and uric acid riboside phosphorylase in, 909*
Prostate
cancer
and cortisone metabolism, 933*
serum protein-bound hexoses, 133
hypertrophy, fibrinolytic enzyme system, 969, 970, 972
Protein
in amyloidosis, 882*
antigenic, plasma clearance of radiolabeled, 1306–1314
antigens, delayed hypersensitive state, 938*
and blood ammonia concentration, 991
blood coagulation and fibrinolytic enzyme system, 1323–1330
casein precipitable, 854
in cerebrospinal fluid, 1419–1428
concentration site and membrane permeability, 1422, 1423
contractile, of muscle in dystrophy, 940*
deprivation in children and in lower animals, 685
flavo-, and cellular oxidation, 244
fractions
binding specificities, 514, 515
cholesterol distribution between, 710, 713, 716
in nephrotic serum after albumin, 1779
hexoses bound to, 130, 131
in hypertension, 426–429
in infant, kernicterus, 1406
intake, 684
and albumin metabolism, 682–686, 1442–1451
and nitrogen removal after perfusion, 1826
and plasma amino acids, 1710–1723
loss to capillary filtrate, 1472, 1473
metabolism, and serum calcium content, 90
placental transfer, 1095–1098
plasma. *See* Plasma
serum. *See* Serum
sparing effect of glucose on, 943*
spinal fluid, 1404–1408
and age of infant, 1410
synovial fluids, 62, 708–717
synthesis, 906*, 943*
thyroxine-binding, 279, 280, 1353
electrophoresis, 903*
and testosterone, 1026–1029
vitamin B_{12} binding, 278, 279
Proteinuria
and epithelial cell healing, 922*
seromucoid hexosamines, 52, 54–56
Prothrombin
activity, after vitamin K-S (II), 76, 77, 84, 85
balance, and streptokinase, 905*
and blood coagulation, 1323–1330
in cholecystnephrostomized dogs, 72, 73, 84
consumption in phospholipid fractions, 1842
in hepatectomized rats, 76, 77, 84
utilization of thrombocytopenic plasma, 897*
Pulmonary artery
and amyloidosis, 847
blood flow. *See* Blood flow, pulmonary
congenital atresia, 1072, 1083
edema, and hexamethonium, 199
hemodynamics, in tachycardia, 1414–1417
hypertension, 106, 107, 194–200, 203–208, 506, 1085
infarct, 223, 415, 1054
insufficiency, and red cell changes, 1166–1174
media of small branches and acetylcholine, 106
occlusion of, 894*, 1079
pressure. *See* Pressure, pulmonary
Purine
and hypoxanthine effects on plasma iron, 1811
metabolism in gout, 579–590, 909*
nucleoside phosphorylase, erythrocyte, 1296
heredity and racial factors, 1176–1183
uric acid from, 944*
Purpura, thrombocytopenic
and hyperkalemia, 701
mucoprotein fractions in, 129, 134, 135
Pyelonephritis
and amyloidosis, 847
and hypertension, 930*, 931*, 1686–1692
of pregnancy, asymptomatic, 906*
Pyrimidine, metabolism, 932*, 933*
Pyrogallol, adsorption from plasma by alumina, 410–413
Pyrogen
and fibrinolytic activity, 931*
release, and destruction of red cells by antibodies, 1225, 1226
Pyruvic acid
blood
and carbohydrate deprivation, 121–125
and hexose infusion, 757
after ribose infusion, 724–726
concentration, 260, 261
after anesthesia, 289–292
and diphosphopyridine, 244
and glucose, 121–125
formation, 1011, 1012
and fructose, 758–761
hepatic glycolysis, 1185
and lactate ratios. *See* Lactate, and pyruvate
malic and lactic dehydrogenase activity in myocardial infarction, 674–676
and oxygen consumption, 246, 257, 261, 264–271
in tricarboxylic acid cycle, 1002

R

Red cell. *See* Erythrocyte
Reichstein's substance S, metabolism, in adults and children, 1087–1092
Respiration
adaptation, in hyperthyroidism, 938*
after aerosol or dust particle breathing, 1746–1755
center sensitivity, and potassium, 644
Cheyne-Stokes, 354
in sleep, 986, 988, 989
exertional breathlessness and fatigue, 507
and glycerol, 621–625
and heavy exercise, 1693–1700
in hypoxia, 264–271
and isopropyl methyl phosphonofluoridate, 354
in lung disease, diffusing capacity measurement, 591–604
malfunction of muscles and alveolar hypoventilation, 1058
in obesity, 1052
and hypoxemia, 1055
in paraplegics, 773–781
pulmonary mechanics, 111–116
volume, 115, 116
and tachycardia, 1414
Reticulocytes
circulating, in blood and marrow, 1573
concentration, and chloramphenicol, 1289
sequestration, by filtration at low pressures, 905*
Rhenium and manganese metabolism, 1302–1304

Rheumatoid factor, isolation, 913*
Ribose
and glucose, 654
conversion, 651–654, 720, 723–733, 1457–1459
metabolism, 719–733
synthesis, 1453–1464
hexose pathway, 653, 902*, 1457
urinary excretion, 722, 724
and expired carbon dioxide radioactivity, 727, 728
Ribose-5-phosphate
conversion to xylulose-5-phosphate, 1459
inhibition of incorporation to inosinic acid by purine compounds, 944*
isomerization, 732
and phosphoglucomutase activity, 726, 733
in ribose conversion to glucose, 652–654
Riboside
synthesis, 902*, 1459
uric acid phosphorylase, and colchicine, 909*
Ribulose-5-phosphate
erythrocyte, heredity and racial factors in metabolism, 1176–1183
phosphorylation, 732, 733
in ribose conversion to glucose, 652–654
Rubidium, coronary blood flow measurement with, 921*

S

Salicylates
and acetazolamide, 929*
and salicyl conjugates, 800–806
and thyroid function, 1131–1151
and oxygen consumption, 1133, 1140, 1141
in rheumatoid arthritis, 1135–1137
and thyroxine half-life, 1149
tubular secretion of, and probenecid, 804–806
Salyrgan®, and potassium, 550–553
Sarcoidosis
Boeck's, and serum calcium, ultrafiltration, 88, 89, 95
and pollen of pine trees, 888*
Sarcomas
glutathione reductase activity, 216
inhibition of growth and allicin, 941*
properdin concentration in, 877*
reticulum cell, mucoprotein fractions in, 129, 134
Sarin. *See* Isopropyl methyl phosphonofluoridate
Sedoheptulose-7-phosphate
and erythrocyte, 1477
in ribose conversion to glucose, 652–654
Septicemia
proteins, of postmortem synovial fluids, 709, 710
Serine
glycine conversion to, in sprue, 20–26
plasma concentration, 1712–1717
after glycine ingestion, 21–26
in urine nondialyzable solids, 318, 320
Serotonin
and potassium concentration in hyperkalemia, 706
release and destruction of red cells by antibodies, 1225, 1226
in renal insufficiency, 410–413
Serum
albumin, 275–280, 283, 684
in amyloidosis, 848–856, 883*
in glomerulonephritis, 55
in infants with communicating hydrocephalus, 1419–1424
metabolism and adrenocortical hormones, 1229–1234
palmitate binding by, 1731
in protein malnutrition, 683–686
after thermal injury, 1739, 1742, 1743
and triiodothyronine, 1442–1451
vitamin B_{12} binding by, 562–566
alkaline phosphatase, 279
antibodies, 455–457, 854–857
bicarbonate, 252, 1238–1242
lactate replacement, 252
bilirubin, 217
in alcoholism, 876*
and ammonium uptake in extremities and brain, 415, 416
in jaundice, 1128, 1129
and liver function, 991
in malignancy, 884*
spinal fluid ratio, 1403–1411
calcium concentration, 142
after calciferol, 1702, 1704, 1709
and cortisone, 919*
and mannitol diuresis, 893*
and radiostrontium clearance, 913*
ultrafiltrable, 87–97
chloride concentration, 1238–1242, 1823
and isopropyl methyl phosphonofluoridate, 362
cholesterol
in azotemia, 854
and blood coagulation, 921*
and exercise, 504
in hemoglobulinuria, 900*
in nephrosis, 175, 809
in pantothenic acid deficiency, 1649
and testosterone, 1025, 1029
electrolytes, 238
after adrenalectomy, 1395–1401
and aldosterone release, 238–241
glucose concentration, 1238–1242
glutathione reductase, 215–218
hexosamine, 853, 856, 882*, 883*, 896*
of mucoprotein, 51–56
magnesium, 1364–1369
malic and lactic dehydrogenase, 672–676
nephrotic, fatty acid partition in, 1775–1782
new bactericidal system in, 940*
and carbon dioxide breathing, 1668
nucleohistone binding phenomenon, 876*
osmolality, 1238–1244
after meralluride, 1804
phosphorus
after calcium, 92, 93, 96
after glucose, 891*, 892*, 901*
and growth hormone, 923*
in renal disease, 89, 90
potassium concentration, 1823
and calciferol, 1703
and cortisone, 890*
in disease states, 1238–1242
and freezing, 702
after phlebotomy, 238–241
in thrombocytosis, 707
precipitin titers, and endotoxin radioactivity, 443–457
properdin, in cancer, 933*
proteins, 846
and alkali, 52, 53
after calcium, 91
after citrate infusion, 93, 94
components of, 272–283, 893*
and estrogen, 892*
in hypocalcemia, 89, 90
after parathyroid extract, 91, 95
and portacaval anastomosis, 615–617
and salicylates, 1135, 1140, 1141
and testosterone, 892*
after thermal trauma, 1736–1745
and thyrotropin, 1145
thyroxine-binding, 153–159, 279, 280
in Valsalva maneuver, 1468–1473
prothrombin times
effects of phospholipids, 1842
and plasma thromboplastin antecedent deficiency, 149–151
sodium concentration, 238
and body composition, 1236–1254
and cortisone, 890*
and jejunal transfer after perfusion, in uremia, 1830
sulfation factor and somatotropin activity, 888*
trypsin inhibition, reversibility of, 947–954
uric acid, 854
in gout, 580
and stones; 901*
vitamin B_{12} binding, in leukemia, 556–566, 917*, 918*
Sheehan's syndrome, and sulfation factor, 888*
Shock
and bacteremia, 940*
due to infection, cortisol metabolism in, 1791–1798
hemorrhagic
and endotoxin absorption, 1425–1434
and plasma iron content, 1813
traumatic
and plasma uric acid, 1810
and thyroid gland, 380–388
Sialic acid
in amyloidosis, 882*, 883*
in urinary nondialyzable solids, 318, 320, 1660, 1661
Skeleton
See also Bone
formation measurement with nonradioactive strontium, 891*
fucose catabolism in, 930*
mineral and water concentration in, 1357–1360

Skin
acid mucopolysaccharides, 858–860
and endotoxin uptake, 226–229
and erythrocyte incompatibility, 1218–1224
homografts, in Hodgkin's disease, 906*
pallor, and norepinephrine, 478
reactions of isohemolysins, 1219
resistance, and isopropyl methyl phosphonofluoridate, 355
temperature, and oxygen uptake in forearm, 1036
in thyroid diseases, 879*
Sleep
hemoglobinemia, and respiratory acidosis, 896*
respiration in, 981–989
secretion in, and histamine, 884*, 885*
vasodilation in, 770
Smoking
and gastrointestinal system, 356
and pulmonary function, 895*
Sodium
balance, 241
and cortisone, 1822
and electrolyte excretion, 325–330
and hexose, 754–756, 758
bicarbonate, 551, 552
and clotting factors, 76
blood concentration, 392, 1551
pre- and postoperative, 1632
body, exchangeable pool of, 934*
bone
in diabetic acidosis, 1676–1685
and parathyroidectomy, 920*
chloride, 550, 551, 622
in acidosis, 643
and creatinine clearance, after kidney transplant, 187
and extracellular volume, 192
and hypertension, 941*
and meralluride, 1020, 1021
citrate, and manganese metabolism, 1302–1304
concentration, 1357–1360
and glomerular filtration rate, 911*
and osmolarity, 1254
in red blood cell, 707
conservation after blood loss, 241
depletion
after adrenalectomy, 1394–1401
and potassium excretion, 323, 327–330
and desoxycorticosterone, 66–69, 666–670
dietary intake, 1397
and chlorothiazide, 902*
and exchangeable pool, 934*
and juxtaglomerular granulation, 664–670
postoperative urinary excretion, 1631
restriction, 67–69, 241
diuresis
and anesthesia, 189
and renal potassium excretion, 548–555
and spirolactone, 917*
exchange
and body water, 1247
in edema, 687–697
excretion, 761, 929*
after acetazolamide, 555
and adrenal insufficiency, 240
after albumin, 236, 237
and aldosterone, 1550, 1551
after alkaline infusion, 300, 301
and antidiuretic hormone, 459
in ascites, 327–330
after calcium, 295–304
after chloride infusion, 549, 550
after inulin, 549, 550
after jejunal perfusion, 1827, 1828
and kidney function, 188–193, 549, 550
and magnesium intake, 434–439, 1364, 1368–1371
after mannitol infusion, 549, 550
after mercurial diuretics, 550, 555
after neomycin therapy, 893*
after phlebotomy, 234–241
and position, 882*
postoperatively, 923*, 1628–1638
after potassium, 325–330
in respiratory acidosis, 883*
after sodium sulfate, 555
and spirolactone, 917*
after vasopressin infusion, 549, 550
and glomerular filtration, 297, 301–304, 548–555, 1399–1401
hydroxide, and chondroitin, 859
and hypertension, 1822, 1825
interstitial and osmolalities, 911*
intracellular, and carbon dioxide breathing, 1672
loss, 921*
and chlorothiazide, 902*
in sweat, 1400
metabolism, 758–761
octanoate, conversion to ketones, 1381–1390
perfusate concentration, and transfer, 1828
plasma, 189, 192, 324–330, 761, 920*, 1318
of platelets, in hyperkalemia, 707
potassium ratio, 885*
and salivary secretion and aldosterone, 238–241
reabsorption, 190, 192, 329
renal tubule, 932*
and renal failure, 911*
retention, 918*, 921*, 923*, 1550
after ACTH, 342
and blood volume, 240, 241
after sodium diuresis, 919*
serum. *See* Serum, sodium
sulfate, infusion, 552, 553, 940*
transport, 192
and water reabsorption, 932*
in uremia, muscle, 890*
Somatotropin. *See* Pituitary, growth hormone
Spherocytosis, 129, 936*
splenic conditioning in, 899*
Sphingomyelin
isolation of, from platelet, 1839–1847
Spirolactone, 917*
Spleen
amyloid in, 847
cholinesterase inhibition, 364
chylomicron uptake, 575–578
endotoxin uptake in shock, 1428
enlargement, 614, 616
erythrocyte conditioning by, 899
and sequestration in leukopenia, 1213–1215, 1224, 1225
and liver, circulation time, 1850–1856
in myelogenous leukemia, 559
platelet sequestration, 2, 6, 7
reticulocyte sequestration, 905*
uric acid riboside phosphorylase in, 909*
Sprue
and celiac disease, intestinal similarities, 927*
formiminoglutamic acid excretion in, 915*
and glycine absorption, 20–26
Squalene, metabolic role in cholesterol biosynthesis, 655–659
Staphylococcus, and penicillin, 914*
Stein-Leventhal syndrome, and hirsutism, 794–798
Steroids. *See* also specific compounds
adrenal cortical, 912*
degradation to 17-ketosteroids, 1087
in hirsutism, 794–798
in hypertension, 1524–1535
and urinary formiminoglutamic acid, 830
formaldehydogenic, 1088–1090
hydroxylation of substrates *in vitro,* 1342–1346
in nephrotic syndrome and seromucoid hexosamines, 53, 54
Porter-Silber output after caval constriction, 1784–1787
synthesis of, and ACTH, 1532
"Stiff man syndrome," seromucoid hexosamines, 53
Stomach
See also Gastrointestinal tract
cancer, 133
and glycerol, intravenous, 623–625
uric acid riboside phosphorylase, 909*
Stool. *See* Feces
Streptokinase
lysis of intravascular clots, 905*
plasma clearance, 1306–1315
Stress
circulating fibrinolytic activity, 931*
osmotic, of erythrocytes, 1296
postoperative, and placebo and morphine, 537
and urinary cortisol metabolites, 813–822
and utilization of fructose versus glucose, 125
Strontium
dynamics of, 913*
and liver vitamin B_{12} uptake, 648, 649
nonradioactive, rates of osteogenesis measured by, 891*

in vivo displacement by calcium, 1304
Strophanthidin
in aortic stenosis, 944*
SU-4885, 912*
Substance S. *See* Δ^4-Pregnene-17α,21-diol,3,20-dione
Succinic acid
in glucose formation from acetate, 1012
inhibitory effect in intestinal mucosa, 919*
in tricarboxylic acid cycle, 1002
Sucrose
clearance, 8–19
and plasma levels, 11, 12
hydrolysis after jejunal perfusion in uremia, 1829
Sulfate
divalent cations and renal excretion of, 940*
and mercurial diuresis, role of pH in, 1020–1022
Sulfuric acid
concentration in amyloidosis, 882*
chromogens, mobilities and staining reactions, 1343
Surgery
postoperative pain relief with morphine or placebo, 535
and sodium excretion, 1628–1638
and urinary cortisol metabolites, 815–822

T

Tachycardia
and atropine, 481
and epinephrine infusion, 478
and fructose infusion, 756
hemodynamics in, 1413–1417
and isoproterenol, 882*
and pantothenic acid deficiency, 1644–1646
Taurine, plasma concentration, 1712–1717
Temperature
See also Fever; Hypothermia
blood storage and inosine, 978
and glycerol, intravenous, 623–625
and isoantibody hemolysis, 1222
and forearm, 1031–1038
pressure and volume, 44–46
intra-articular, in osteoarthritis, 391
and musculo-cutaneous vasodilatation, 936*
and oxygen uptake in hyperemia, 1039–1048
and serum agglutinating factor and penicillin, 912*
and vitamin B_{12} uptake in liver slices, 648
Testosterone
and iodine metabolism, 1027
plasma, binding in, 515–517, 519
production in hirsutism, 797
and protein bound iodine, 892*
and serum cholesterol concentration, 1029
and thyroid function, 1024–1029
Tetany
and calcium, 89, 500
and magnesium, 940*
susceptibility, and sodium depletion, 920*
Tetracycline
concentration in liver, 910*
half-life in serum, 908*
Tetraethylammonium chloride, pressor action, 482
and norepinephrine infusion, 479, 484
Tetraethyl pyrophosphate, *in vitro* sensitivity to, 352, 363
and isopropyl methyl phosphonofluoridate, 350
Tetrahydrocortisol
and placenta, 937*
in stress, responses, 813–822
Tetrahydrocortisone, 937*
urinary excretion of, 813–822
in congenital adrenal hyperplasia, 890*
Thiamine, deficiency
and ribose synthesis from hexose, 1459
and transketolase reaction, 1477
Thiopental
absorption, and cerebral blood flow, 770
water diuresis, and vasopressin, 875*
Thorax
capillary beds in cardiac edema, 1472
caval constriction and aldosterone secretion, 1784–1788
Threonine
intake, and plasma concentration, 1712–1717
in urinary nondialyzable solids, 318, 320
Thrombin, coagulation and potassium concentration, 702, 706, 707
Thrombocytopenia
and cephalin fraction of bovine brain, 897*
and chloramphenicol toxicity, 1290
coagulation defect in, 897*, 904*
and destruction of red cells by antibodies, 1225, 1226
and erythropoietic depression of bone marrow, 1292
formiminoglutamic acid excretion in, 830
of hypothermia, 1–7
after hepatectomy and/or splenectomy, 6, 7
Thrombophlebitis
brucella endotoxin response in, 223
and pulmonary embolism, 615–617
Thromboplastin
generation, 149–151
and red cell lipid fraction, 937*
and phospholipid concentration, 1842
plasma antecedent deficiency, anticoagulant in, 148
Thymidine, in proliferating cell study, 887*
Thyroid gland
acid mucopolysaccharide content, 858, 861
after thyrotropin, 878*
adenoma, colloidal, acid mucopolysaccharide in, 861
and adrenal function, 736–742
and estrogen-effect on protein bound iodine, 892*
function, 895*, 1131–1151
in traumatic shock, 380–388
and glutathione reductase, 215
Hurthle cell adenoma and thyrotropin, 879
in hyperthyroidism, 932*
and pituitary interrelation, 1144–1151
in pregnancy, 156
radioiodine uptake and clearance, 382–384
and salicylates, 1138–1147
and thyrotropin, 1145
and thyroxine, 1348–1355
in treated Graves' disease, 1603–1613
and testosterone, 1024–1029
thiocyanate-dischargeable iodide in, 926*
Thyrotoxicosis
and epinephrine, 918*
and erythrocyte metabolism, 1478
osteoporotic, calcium uptake in, 891*
radiothyroxine turnover study in, 1348–1355, 1609, 1613
steroid metabolism in, 739–742
Thyrotropin
acid mucopolysaccharide, 878*
and thyroid function after salicylates, 1144–1151
Thyroxine
degradation
and methimazole, 932*
in myxedema, 932*, 1355
peripheral, 1606
in thyrotoxicosis, 1351–1355
metabolism, 1348–1355
and testosterone, 1025, 1028
serum protein binding in pregnancy, 153–159, 279, 280, 1355
synthesis of, and hypothalamus irradiation, 878*
transplacental transfer of, 931*
in treated Graves' disease, 1605–1607
triiodothyronine and iodide, separation of, 931*
versus 2,4-dinitrophenol in traumatic shock, 388
Tissue
adipose
fatty acids, 1512
glucose utilization, 943*
and lipolytic action of ACTH, 1556–1562
elasticity in cardiac edema, 1473
glycogen, and growth hormone, 1557
granulation in interstitial stroma after calciferol, 1705
subcutaneous
acid mucopolysaccharide content, 858, 860

Tissue (*cont'd*)
temperature and oxygen uptake in forearm, 1039–1048
visceral, and pain rheobase values, 33
Tolazoline, and blood flow, 840
and cerebral blood flow, 763–771
and osteoarthritic knee joint, sodium clearance after, 389–392
Tolbutamide
blood glucose response in mild diabetes, 627–630
and phosphate clearance, 372–374
Toxemia, rickettsial, cardiovascular dysfunction during, 898*
Toxicity
of ammonium salts, 497–500
and blood-brain-barrier, 1724–1728
and pH, 498, 1725
cardiac, and mercuric chloride, 1022
chloramphenicol, ferrokinetics in, 1286–1292
of endotoxin, 230, 1430–1433
epinephrine and hyperthyroidism, 918*, 919*
of glycerol, 619
of imidazoleacetic acid, 1463
vitamin D and renal function, 1707, 1708
of vitamin K-S (II), 77
Transcortin, avidity for cortisol and corticosterone, 928*
Transplant
homografts in Hodgkin's disease, 906*
kidney function after, 185–193
Trauma
infected wounds and chloramphenicol, 1287
and reformation of clot after plasmin, 870
thermal
serum protein changes, 1736–1745
of swine skin, 888*
urinary cortisol metabolites in, 818, 819
and thyroidal radioiodide content, 386, 388
Tricarboxylic acid cycle, and glycolytic pathway, 1002–1004
Triglyceride. *See* Lipids
Trihydroxyindole, versus ethylenediamine in blood of uremic patients, 412, 413
Triiodothyronine
and albumin catabolism, 1447–1449, 1451
degradation, 932*
in hyperthyroidism, 738, 1606, 1609
and lipolytic action of ACTH, 1561, 1562
and nitrogen metabolism, 1447–1449, 1451
and thyroxine, 1354, 1609
transplacental transfer of, 931*
Triphosphopyridine nucleotide
in diabetic lipogenesis, 1197–1201
erythrocyte
heredity and racial factors, 1176–1183
utilization, 916*
and glucose 6-phosphate formation, 726
and liver
carbon dioxide, 1189–1191
glycolysis and lipid synthesis, 1185–1194
in protein synthesis, 1458
Trypsin
digestion of casein, 948
inhibitor in serum, 947–954
standardization with soybean, 952–954
Tryptophan
intake, and plasma concentration, 1712–1717
urinary nondialyzable solids, 318, 320
Tuberculin
allergic response, 939*
clearance and febrile tolerance, 880*
pine pollen fractionation, 888*
Tuberculosis
miliary, and blood ammonium-nitrogen concentrations, 416
mycobacteriophage propagation and inhibition, 942*
pep and appetite ratings after placebo, 534
pulmonary
body composition in, 688, 1238–1242
glutathione reductase activity, 216
Tumor
ascites, and ribose synthesis, 1458, 1459
atropine, in pheochromocytoma test, 484
and glutathione reductase, 944*
pituitary, 912*
and serum sulfation factor activity, 888*
protein concentration, 1420
Typhoid, infection, resistance to, 903*
Tyrosine
intake, and plasma concentration, 1712–1717
in urinary nondialyzable solids, 318, 320

U

Unesterified fatty acids. *See* Fatty acids, nonesterified; and Blood, fatty acids, nonesterified
Urea
clearance
and glomerular filtration, 911*
in hypercalcemia, 1703, 1704
and magnesium, 1366
and vitamin D_2, 892*, 893*, 1703, 1709
in uremia
after jejunal perfusion, 1820, 1826
Uremia
acidosis and carbon dioxide tension, 640–644
catechol amines in, in renal insufficiency, 409–413
and chloramphenicol, 1287
insulin binding after therapy, 788
jejunal segment perfusion in management, 1818–1835
persistence of antibiotics in blood, 908*
prevention of intracorpuscular defect by renal tissue, 918*
and protein binding, 940*
seromucoid galactosamine-glucosamine ratio, 53, 54
urine urea and solute concentration, 911*
Uric acid
concentration after jejunal perfusion, 1828
excretion, 875*, 944*
and purine metabolism in, 932*
after transfusion, 1492
in gout, 579–589, 944*
isopropyl methyl phosphonofluoridate, 362
plasma, and hemorrhage or trauma, 1810
purine oxidation, 587
renal stone formation, 901*
riboside metabolism in tissues, 909*
in uremia, ethylene diamine reaction, 410–413
Uridine, excretion, in leukemia, 875*
Uridine-diphosphate-glucose
and glucuronide synthesis, 332–339
oxidation, 332
Uridine-diphosphate-glucuronic acid
and glucuronide synthesis, 332–339
in newborn, 337
specific enzymatic function, 332, 1125
Uridine triphosphate, in glucuronide formation, 875*
Urine
in adrenal and pituitary insufficiency, 1799
albumin in hypoalbuminemia, 685
aldosterone, 238–241
postphlebotomy, 235, 236
and potassium, 918*
alkaline, 929*
mechanisms in, 881*
and salicylate clearance, 804
after aminophyllin, 1802
ammonia in respiratory acidosis, 883*
calcium output in gargoylism, 145, 146
carbon dioxide pressure, 881*
concentration, 899*, 940*
in bacteriuria, 906*
after calciferol, 1703
and glutathione reductase, 217
and hexose infusion, 754–756, 758
in congenital adrenal hyperplasia, 890*
cortisol metabolites, 739
mechanisms for changes, 821, 822
distal tubular, potassium exchange, 329
endotoxin radioactivity in shock, 1428
excretion in
bicarbonate, 745–748
bilirubin, 896*, 1129
chloride, 295–301

corticoids, 1090
electrolytes, 883*, 901*, 1550
estrogen, 347
etiocholanolone, 1092
formiminoglutamic acid, 824–827, 830, 915*
17-ketosteroids, 238–241, 342, 737, 738, 890, 912*, 933*, 1089
and mercuric cysteine and mercuric chloride, 1022
nitrogen, 434
and plasma glycine concentration, 24, 25
of purines, 875*
ribose, 722, 724
sodium, 192, 235–238, 326–330, 434, 761
uric acid, 580
and uric acid stones, 901*
flow, 899*, 1617–1626
after alkaline infusion, 300, 301
after calcium infusion, 295–299
and glomerular filtration rate, 549, 550, 911*, 1800, 1802
and jejunal perfusate composition, 1822
and jejunal perfusion, 1820
after magnesium loading, 1364, 1365
and mercurial diuresis, 550
postoperative, 1630
postphlebotomy, albumin and saline infusion, 237, 238
and sodium bicarbonate, 551
and solute excretion, 1802
and vasopressin, 458–463
and water clearance, 882*
glucosamine loss in glomerulonephritis, 53, 54
glucose clearance, 14
in hemochromatosis, 915*
17-hydroxycorticosteroids, 238–241
hypertonic, 459–463, 916*
inlying catheters, bacteriological studies from, 897*
ketone bodies, and fasting, 119
ketosteroid metabolites and hair growth, 794–798
loss of sugar, 761
magnesium concentrations, 434
after loading, 1362–1371
after meralluride, 1802
mucoprotein, 319
nondialyzable solids, 315–320
separation into three reproducible fractions, 1658–1665
osmolality, 459–463, 880*, 916*
and position, 882*
during sodium depletion, 1398
after vasopressin, and calciferol, 1702
after water ingestion, 1801, 1802, 1805
pH
and acetazolamide, 929*
after alkaline infusion, 300, 301
and ammonia excretion after amino acid loads, 1621
after calcium gluconate injection, 298, 299
after carbonic anhydrase inhibitors, 887*
and salicylate clearance, 805
and spirolactone, 917*
potassium, 434
and desoxycorticosterone, 69
postphlebotomy, albumin and saline infusion, 237, 238
after potassium sulfate infusion, 326–330
pregnanetriol, 890*
pyrimidine, in leukemia, 875*
tetrahydrocortisone, 890*
Urobilinogen, excretion
in jaundice, 1124, 1129
mesobilifuscin ratio, 896*
Uronic acid
in acid mucopolysaccharide carbazole and orcinol determinations, 860, 861
serum in amyloidosis, 854, 855, 882*

V

Vaccines, antituberculosis, 939*
Valine
intake, and plasma concentration, 1712–1717
of urinary nondialyzable solids, 318, 320
Valsalva maneuvers, and venous pressure, 879*, 1465–1475
Vanadium sulfate, and manganese metabolism, 1302, 1304
Vascular system
and murine typhus toxin, 898*
peripheral venous tone and psychic stimulation, 879*
portal versus peripheral vein insulin administration, 631–639
pulmonary, changes in dynamics, 210, 211
resistance
cerebral, 286–292
hepatic postsinusoidal, 608, 609
in hypothyroidism and exercise, 504
in left-to-right shunt and exercise, 206–208
pulmonary, 200, 492, 935*
peripheral, 484, 1414
splanchnic, 289–292
Vasoconstriction
cerebral, 765
and cold pressor test, 767
and stimulation of ganglia, 770
digital, 765, 770
and electrical stimulation of stellate ganglion, 768
in forearm, 844
and congestion in legs, 46–49
and intradural volume and blood flow, 767
and norepinephrine, 484
Vasodilatation
and ambient temperatures, 936*
of cerebral vessels, 765, 766, 770
and hypotension, 289–292
and coronary circulation, 898*
and epinephrine, 484, 843, 844
pulmonary vessels and acetylcholine, 105, 107
tolazoline, and sodium clearance rate, 392
Vasopressin
action in renal tubule and frog skin, 461, 462
in Addison's disease, 920*
circulating, and calcium, 899*
graded doses of, and water excretion, 458–463, 875*
and membrane permeability of kidney, 463
and renal failure, 911*
sodium and water balance studies, 925*
and urine flows, 899*
and solute excretion, 460
urinary osmolality after, and calciferol, 1702
Vena cava
blood counts and hypothermia, 3–7
inferior
constriction of, 1783–1790
Venous pressure-volume curve, in forearm, 42–49
Ventilation
and acetylcholine, 103, 105
alveolar, 313, 985, 1052
and nitrogen concentration, 309, 310, 312
and aminophyllin, 884*
and characteristics of slow space, 571–573
and heavy exercise, 1693–1700
and occlusion of pulmonary artery, 1080
in bronchiectasis, 1077
in pulmonary disease, 111–117
and diffusing capacity, 591–604
in sickle cell disease, 486–494
in sleep, 981–989
Ventricle
function
in aortic insufficiency, 473, 944*
and hexamethonium, 197–200
and sex, 927*
magnesium concentration in, 880*
oxygen consumption and nitroglycerin, 898*
pressure, 196–200
in left-to-right shunt, 203, 204
and mitral regurgitant flow, 38
septal defects, 203, 204
and circulatory dynamics, 934*
stroke work, 884*
and bradycardia after norepinephrine, 37
Virus
ECHO-9, or exanthema, 928*
"hemadsorption" in diagnosis and study of infections, 931*
infection, lower economic group, 927*
inhibition, and properdin system, 940*
non-neurotropic influenza, 903*
salivary gland, in children, 927*
toxicity, resistance to, 903*
Viscera, tension, intramural, and pain, onset and rheobase, 28–32
Vitamin
A, and atheroma extract, 163
B_{12}
binding, 893*, 902*
in leukemic sera, 278, 556–566, 917*, 918*

Vitamin (*cont'd*)
and DNA synthesis, 168–171
and hog intrinsic factor concentrate, 646–649
and pernicious anemia bone marrow, 166–168
plasma absorption, 889*
D
toxicity, 88, 89, 95, 1707–1709
D_2. *See* Calciferol
K, accelerator response to, 70–85
K-S (II)
in hemorrhagic diathesis, 77–81
in pregnancy, 77, 85

W

Water
balance study during hexose infusions, 754–758
blood, excess lactate concentration in, 261
body
in acidosis and alkalosis, 1250
in cirrhosis, and edema, 687–697
and edema, 1823
postburn shifts, 1742
ratio of sodium and potassium, 1249, 1250, 1254
in uremia, 1823, 1824
bone content, 67, 1357–1360
in diabetes, 1679–1685
bound, in urinary nondialyzable solids, 1660, 1661
cerebral concentration after carbon dioxide exposure, 1114
clearance
and hyponatremia of cirrhotics, 928*
and isotonic expansion of extracellular fluid, 188
after meralluride, 1802
and solute excretion, 458–463
concentration
and desoxycorticosterone, 67–69
and dinitrophenol, 932*
deprivation, and hypernatremia, 1253
diuresis, 882*
and anesthetic agents, 875*
and cortisol, 1799–1808
in hydropenia, 879*
and osmolal clearance, 882*
and sodium excretion, 882*
and vasopressin, 459, 879*, 880*
and erythrocytes in pulmonary disease, 1170, 1171
exchange between blood and lumen of jejunal segment, 1825, 1826
excretion
in adrenal insufficiency, 1799–1808
in pituitary insufficiency, 1799–1808
renal, 234–241
and vasopressin dosage, 458–463
and exercise, 257, 258
extracellular, 890*
in respiratory acidosis, 1116, 1117
intake and urine osmolality, 1801
intracellular, 1118, 1119
in uremia, 890*
metabolism, 758–761
in hyperlipemia, 916*
muscle concentration, 67
after carbon dioxide exposure, 1114
plasma
in acidosis and diabetes, 1676–1685
after carbon dioxide exposure, 1114
of platelets in hyperkalemia, 707
production, in renal failure, 886*
reabsorption
after calciferol, 1708
renal tubule, 932*
retention, 1246
hyponatremia, 1399–1401
susceptibility to intoxication and thiopental, 875*
transfer, and perfusate osmolality, 1825
Watson-Schwartz test, false-positive, 915*
Weight
birth
and serum and spinal fluid bilirubin, 1405–1407
and spinal fluid and heme in newborn infants, 1409
and caloric intake, low-magnesium diet, 437
and capillary blood volume, 1064–1069
and exercise, 257, 258
heart, and tachycardia, 1415
and inulin space after desoxycorticosterone, 66
after jejunal perfusion, 1820
loss
after calciferol, 1702
and caloric intake, 1400
and meat diet, 119
in obesity, 1050–1053
and salicylates, 1140
after thyroxin treatment, 385, 388
and membrane diffusing capacity, 1064–1069
and nitrogen balance, 387, 1820
and pantothenic acid deficiency, 1643
and pulmonary function, 1048–1059
and renal excretion of digoxin, 837
and serum sodium, 1251–1254
in Valsalva maneuvers, 1467
and water balance, postphlebotomy, 239
Wernicke's encephalopathy, erythrocytes of, 1476–1483
Wilson's disease
plasma copper-protein ceruloplasmin, 934*
serum protein fractionation in, 893*

X

Xanthine
after chromatographic separation of urinary purines, 582, 583
and ferritin iron release *in vivo*, 1809–1817
oxidation to uric acid, 587
Xanthomatosis, 886*
Xylitol and glucuronic acid conversion to hexose phosphate, 1462–1464
Xylulose
and glucuronic acid conversion to hexose phosphate, 1462–1464
in pentosuria, 902*, 1464
Xylulose-5-Phosphate
and glucuronic acid conversion to hexose phosphate, 1462–1464
in ribose conversion to glucose, 652–654
ribulose 5-phosphate, 732

Z

Zinc
and manganese metabolism, 1302–1304
and urine nondialyzable solids, 1662